Enzymes of cyclic AMP metabolism in hepatocytes by Zeng, Li
 
 
 
 
 
 
 
https://theses.gla.ac.uk/ 
 
 
 
 
Theses Digitisation: 
https://www.gla.ac.uk/myglasgow/research/enlighten/theses/digitisation/ 
This is a digitised version of the original print thesis. 
 
 
 
 
 
 
 
 
Copyright and moral rights for this work are retained by the author 
 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge 
 
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author 
 
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten: Theses 
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
ENZYMES OF CYCLIC AMP METABOLISM IN 
HEPATOCYTES
LI ZENG, B.Sc.
This thesis is presented for the degree of Doctor of Philosophy.
Division of Biochemistry and Molecular Biology, 
Institute of Biomedical and Life Science, 
University of Glasgow.
June, 1996.
#
ProQuest Number: 10391482
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 10391482
Published by ProQuest LLO (2017). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLO.
ProQuest LLO.
789 East Eisenhower Parkway 
P.Q. Box 1346 
Ann Arbor, Ml 48106- 1346
GLASGOWUNIVTïRSnYowTl
Dedicated to my Mum 
and
ail the people I love
Acknowledgements
Here, my sincere thanks go to my supervisor, Professor Miles Houslay 
for his help, understanding, patience, enthusiasm and guidance throughout my 
PhD project and thesis. I would also like to thank the Division of Biochemistry 
and Molecular Biology, IBLS, University of Glasgow for the use of their 
facilities throughout my period of study.
I would like to thank John Brown Engineering Ltd and the University of 
Glasgow for their financial support during rny studies.
My enormous thanks go to everyone in 'Lab A3' who have helped me 
in any way during my PhD. I enjoyed working in this lab and it was always 
fun! ! ! Also, I would like to thank eveiyone I know in the Department for their 
consideration, laughter and chatter.
However, I wish to tenderly acknowledge the following individuals for 
their love, support, and encouragement over the years of my PhD studies: My 
first special thanks go to Sandra, for her friendship and support over the years, 
for helping me out whether in academic or social life and for her patient help 
with ray thesis. A special thanks also for Moira, who besides all of the above, 
also lent me the computer to make this thesis possible.
I will remember all these good and memorable times I had in Scotland.
My heartfelt thanks to my best Chinese friends An-xin (Cindy), Tu- 
yong (Esther) and MeiNa, for the excitement, enjoyment and happiness I shared 
with them as well as the hardships.
Tremendous thanks to everyone in my family, whose love, support, 
encouragement, understanding and belief in me has made all the difference. I 
know that I own you all a lot, but I'd still like to take this opportunity to say, 
don’t woriy about me, I will be fine! ! ! Last, thanks to God, for his blessing.
_____________
Abbreviations
AP-1
ATF
ATP
BSA
CaM
cAMP
cDNA
cGMP
Cilostimide
CRE
CREB
DAG
DMSO
DPD
DTP
EDTA
EGTA
EHNA
GDP
Gi
Gs
G protein 
GTP 
Hepes 
IBMX
A-kinase anchoring protein 
Activation transcription factor 
Adenosine trisphosphate 
Bovine serum albumin 
Calmodulin
Adenosine-3', 5'-cycHc monophosphate 
Complementary deoxyribonucleic acid 
Guanosiiie-3', 5'-cyclic monophosphate 
[4,5-dihydro-6[4-( IH-imadazol-1 -yl)phenyl} -5-methyl- 
3(2H)-pyrazone]
Cyclic AMP responsive element
Cyclic AMP responsive element-binding
Diacylglycerol
Dimethyl sulphoxide
Dunce-like phosphodiesterase (PDE4B)
Dithiothreitol
Ethylenediaminetetraacetic acid
Ethylene glycol-bis (P-aminoethyl ether) N, N, N', N'- 
teüaacetic acid
Erythro-9-(2-hydroxy-3-nonyl)-adenine 
Guanosine diphosphate
Inhibitoiy G protein to adenylyl cyclase activity 
Stimulatoiy G protein to adenylyl cyclase activity 
GTP binding protein 
Guanine trisphosphate
N-2-Hydroxyethylpiperazine-N'-2-ethane-sulphonic acid 
1-isobutylmethy 1-3-xanthine
u
K1 The dissociation constant for the enzyme-inhibitor
complex
Km Michaelis constant, equal to the substi ate concenti ation at
which the reaction rate is half the maximum value 
PBS Phosphate buffered saline
PDE Phosphodiesterase
PI-3 kinase Phosphatidylinositol-3-kinase
PIP2 Phosphatidylinositol-4,5-bisphosphate
PKA Cyclic AMP-dependent protein kinase
PKC Protein kinase C
PLC Phospholipase C
PMA Phorbol- 12-myristate, 13-acetate
PMSF Phenylmethylsulphonylfluoride
RDI Rat dunce-like 1 (PDE4A)
Rolipram [4- {3 - (cy clopentoxyl) -4-methoxy phenyl }-2-pyiTolidone]
SDS-PAGE Sodium dodecyl sdphate-polyaciylamide gel
electrophoresis 
TEA Tiiethanolamine
TEMED N, N, N', N’-Tetramethylethylene diamine
TP A 12-O-tetradecanoylphorbol 13-acetate (PMA)
Adendda
p-ARK p adreneric receptor kinase
CAT Chloramphenicol acetyltransierase
CREM C yclic AMP responsive element modulator
DEPC Diethyl pyrocarbonate
ICER Inducible cAM P early repressor
IP 3  Inositol 1,4,5-trisphosphate
KLH K eyhole lim pet haem ocyanin
LDH Lactate dehydrogenase
PCA Perchloric acid
PIP2  Phosphatidyl inositol 4,5-bisphosphate
PtdSer Phosphatidylserine
UCR Up stream conserved region
iii
__________._________  ..'I
Contents.
Title.
Acknowledgements.
Abbreviations.
Contents.
List of figures.
List of tables. 
Summary.
Page
1
ii
iv
xi
xvii
xix
Chapter 1: Introduction.
1.1 cAMP signalling
1.1.1 Cyclic AMP as a second messenger
1.1.2 Termination of the cyclic AMP signal by
phosphodiesterases (PDEs)
1.2 G-protein dependent signal transduction systems
1.2.1 G-proteins subtypes
1.2.2 G-protein coupled receptors
1.2.3 Characterisation of G-proteins
1.2.4 Regulation of G-proteins
1.2.4.1 Gs, the stimulatory regulatory 
component of adenylyl cyclase
1.2.4.2 Pertussis toxin substrates: Gi
and Go
1.2.4.3 Hormonal regulation of G-proteins
1.2.4.4 G-protein phosphorylation
1.2.4.5 Bacterial toxins
1.3 Adenylyl cyclase signalling
1.3.1 Divergent structure
1.3.1.1 Structure 
iv
1
1
4
5 
5 
8 
10 
11
11
12
12
13
13
15
17
17
1.3.1.2 Structural correlation with activity
1.3.2 Molecular diversity in the adenylyl cyclase family
1.3.3 Tissue distribution of adenylyl cyclases
1.3.4 Diverse regulatory properties
1.3.4.1 Regulation by G-protein subunits
1.3.4.2 Regulation by Ca^ "^
1.3.4.3 Regulation by phosphorylation
1.3.5 Forskolin: A potent activator of adenylyl cyclases
1.3.6 Adenylyl cyclase signalling in P9 cells
1.3.6.1 SV40-immortalised hepatocytes
1.3.6.2 Analysis of the signalling system in
an immortalized hepatocyte cell line
1.4 Cyclic AMP-specific Nucleotide Phosphodiesterases
1.4.1 Multiple families of PDEs
1.4.2 Stracture of cyclic nucleotide PDEs
1.4.2.1 Catalytic domain of cyclic 
nucleotide PDEs
1.4.2.2 Regulatory domains of cyclic
nucleotide PDEs
1.4.3 Cyclic AMP specific PDE4
1.4.3.1 Structural features and tissue
expression of PDE4
1.4.3.2 Cellular Regulation of cyclic AMP
specific PDE4
1.4.3.3 Inhibition of cyclic AMP specific
PDE4
1.5 Cyclic AMP dependent protein kinase (PKA)
1.5.1 Structure and tissue distribution of PKA 
isoforms
17
19
20 
22 
23
25
26 
27 
29
29
30
31 
31 
34
34
36
37
37
44
49
50
50
1.5.2 Phosphorylation of target proteins by PKA
1.5.3 Modulation of transcription factors by PKA
1.6 Perspectives concerning the protein kinase C family in 
cell regulation
1.6.1 Classification of PKC isoenzymes
1.6.2 Activation of PKC
1.6.3 Stmcture of PKC isoenzymes
1.6.4 Tissue expression
1.6.5 Regulation of PKC isoenzymes
1.6.5.1 Inhibitors of PKC
1.6.5.2 Proteolytic regulation of PKC
1.6.5.3 Down-regulation of PKC
1.6.6 Phosphorylation of substrates
1.7 Diabetes induced alterations in hepatocyte signalling 
pathways
1.7.1 Defects in hepatocyte adenylyl cyclase
signalling in diabetes
1.7.2 Diabetes induced alterations in PKC
expression in hepatocytes
1.7.3 Diabetes induced changes in cAMP
phosphodiesterase activity
Chapter 2 : Materials and Methods.
2.1 Materials
2.1.1 Tissue culture plastic ware
2.1.2 Tissue culture medium
2.1.3 Radio chemicals
2.1.4 General reagents
2.1.4.1 Chemical compounds 
vi
52
53
55
55
55
58
61
62
62
65
65
66
68
69
71
72
74
74
74
74
75 
75
2,1.4.2 Biochemical reagents
2.1.5 Molecular biology reagents
2.1.6 Equipment
2.1.7 Animal resources
2.1.8 Cell lines
2.2 Media, buffers and standard solutions
2.3 Methods
2.3.1 Hepatocyte preparation
2.3.1.1 Hepatocyte isolation
2.3.1.2 Hepatocyte disruption by pressure
2.3.1.3 Preparation of a hepatocyte (crude) 
membrane fraction
2.3.1.4 Fractionation of hepatocytes
2.3.2 Attachment of hepatocytes to collagen plates
2.3.3 Assessing desensitization in immobilized cells
2.3.4 Determination of ATP content of hepatocytes
2.3.5 Treatment of hepatocytes
2.3.5.1 Incubation of hepatocytes with ligands
2.3.5.2 Treatment of hepatocyte membranes 
with alkaline phosphatase
2.3.6 Cell culture
2.3.6.1 Culture of P9 cells
2.3.6.2 Culture of CHO cells
2.3.6.3 Culture of NIH-3T3 cells
2.3.7 Treatment of P9 cells
2.3.7.1 Preparation of P9 membrane and 
soluble fractions
23.1.2 Actinomycin D treatment of cells
2.3.7.3 Bacterial toxin treatment of cells
vii
2.3.7.4 Longteim hoimone treatment of 
P9 cells
2.3.8 Thennal dénaturation of adenylyl cyclase
2.3.9 Cyclic AMP binding assay
2.3.9.1 Assay principle
2.3.9.2 Preparation of cyclic AMP binding 
protein.
2.3.9.3 Assessing intracellular cAMP 
concentrations
2.3.9.4 Assay procedure
2.3.10 Adenylyl cyclase assay
2.3.11 Cyclic AMP phosphodiesterase assay
2.3.11.1 Assay principle
2.3.11.2 Preparation of Dowex-Cl
2.3.11.3 Assay procedure
2.3.12 Bradford assay
2.3.13 Lactate dehydrogenase (LDH) assay
2.3.14 Inducing diabetes in rats
2.3.15 Dissection of the rat brain
2.3.16 RNA extraction
2.3.16.1 RNA extraction by Tri-reagent
2.3.16.2 DeteiTnining RNA concentration
2.3.17 First strand cDNA synthesis
2.3.18 PCR (polymerase chain reaction)
2.3.19 Purification of oligonucleotides
2.3.19.1 Precipitation of oligonucleotides
2.3.19.2 Quantitation of oligonucleotides
2.3.20 DNA purification
2.3.21 Antibody preparation
viü
90
91 
91
91
92
92 '•il
93
94
94
94
96
96
97
■ 197
97
98
98
98
99
100
101 1101
101
101
101 i
102
Chapter 3: Insulin and vasopressin elicit inhibition of
cholera toxin-stim ulated adenylyl cyclase activity in 
both hepatocytes and the P9 immortalized hepatocyte 
cell line through an action involving protein kinase C.
Introduction 108
Results 111
Discussion 143
Chapter 4: Induction  of specific cyclic AMP
phosphodiesterase PDE4 splice variants by forskolin and 
cholera tox in -treatm en t of the P9 im m ortalised  
hepatocyte cell line.
2.3.21.1 Antibody production 102
2.3.21.2 Preparation of anti-serum 103
2.3.21.3 ELISA 103 1
2.3.22 Gel electrophoresis 104
2.3.22 1 Resolving gel preparation 104
2.3.22.2 Stacking gel preparation 104
2.3.23 Western blotting 104
2.3.24 COS cell transfection 105 ■i
2.3.24.1 DEAE Dextran transfection 105
2.3.24.2 Preparation of cell extracts 106 i
2.3.25 Immunoprécipitation of PDE activity 106 1
Introduction 152
Results 155
Discussion 185
IX
Chapter 5: Cyclic AM P-Phosphodiesterase expression
in normal and diabetic hepatocytes.
Introduction 109
Results 193
Discussion 216
Chapter 6: General Discussion. 220
References 224
Appendix: A role for protein kinase C-mediated
phosphorylation in eliciting glucagon desensitization in 
rat hepatocytes.
Introduction 
Results and Discussion
262
268
X
List of Figures
Figure 1.1 Diagram showing the action of adenylyl cyclase
and cyclic AMP phosphodiesterase on ATP and 
cyclic AMP respectively 2
Figure 1.2 Flow of information through G protein-dependent
signal transduction systems 6
Figure 1.3 The G-protein Cycle 9
Figure 1.4 Structure of adenylyl cyclase 18
Figure 1.5 Comparison of the amino acid sequences from a
region conserved among members of the 
adenylyl cyclase family 21
Figure 1.6 Schematic repiesentation of the catalytic and
regulatoiy domains of cyclic nucleotide 
phosphodiesterases 35
Figure 1.7 Comparison of primary amino acid sequences
.ofratP D E 4A ,B ,C andD  38
Figure 1.8 Compar ison of piimaiy amino acid sequences
of rat PDE4A splice variants 41
Figure 1.9 Diagrammatic representation of protein kinase A 51
Figure 1.10 Phylogenetic relationships between
mammalian PKC isotypes 56
Figure 1.11 Domain structure of PKC isoenzymes 59
Figure 1.12 Stnrcture of the serine/threonine protein
kinase inhibitors chelerythrine and
staurosporine 64
Figure 2.1 The principle of the cyclic AMP PDE assay 95
Figure 3.1 Dose dependence of cholera toxin-stimulated
cAMP response in hepatocytes 116
xr
 : '   - . ____
Figure 3.2 Time dependence of cholera toxin-stimulated
cAMP response in hepatocytes 
Figure 3.3 The presence of insulin and glucagon
attenuates the ability of cholera toxin to 
activate adenylyl cyclase in intact hepatocytes 
Figure 3.4 PKC inhibitors can blocked the vasopressin
and insulin mediated attenuation of cholera 
toxin stimulated adenylyl cyclase activity in 
hepatocytes
Figure 3.5 Okadaic acid mimics PKC's ability to
attenuate cholera toxin stimulated adenylyl 
cyclase activity in hepatocytes 
Figure 3.6 Alkaline phosphatase reversed the PKC
attenuation of cholera toxin stimulated 
adenylyl cyclase activity in hepatocytes 
Figure 3.7 Insulin, PMA and vasopressin were not
additive in their ability to inhibit cholera toxin 
stimulated adenylyl cyclase activity in 
hepatocytes
Figure 3,8 (a) PMA treatment of hepatocytes did not affect 
the catalytic unit of adenylyl cyclase 
Figure 3.8 (b) PMA treatment of hepatocytes did not affect 
Gs-stimulated adenylyl cyclase activity 
Figure 3.9 Time dependence of cholera toxin-stimulated
cAMP response in immortalized hepatocyte P9 cells 
Figure 3.10 Inhibition of cholera toxin stimulated
adenylyl cyclase activity by insulin and PMA 
in P9 cells
117
118
119
120
121
122
123
124
125
126
xu
Figure 3.11 Time dependence of the cholera toxin-
stimulated intracellular c AMP response in 
CHO-HIR cells 
Figure 3.12 Time dependence of the cholera toxin-
stimulated intmcellular cAMP response in 
NIH-3T3 cells 
Figure 3.13 Cholera toxin actived adenylyl cyclase
activity in CHO cells in a manner which is 
resistant to inhibition by PMA 
Figure 3.14 PMA enhanced cholera toxin-stimulated 
adenylyl cyclase in NIH-3T3 cells 
Figure 3.15 Thennal dénaturation of adenylyl cyclase 
activities in CHO cells and hepatocytes 
Figure 3.16 Thennostability of adenylyl cyclase activities 
in CHO cells and hepatocytes 
Figure 3.17 Thennostability of adenylyl cyclase activities 
in P9 cells
Figure 3.18 (a) RT-PCR analyses of type-I adenylyl cyclase 
transcripts in different cells 
Figure 3.18 (b) RT-PCR analyses of type-II adenylyl 
cyclase transcripts in different cells 
Figure 3.18 (c) RT-PCR analyses of type-IV adenylyl
cyclase transcripts in different cells and type 
V adenylyl cyclase transcripts in hepatocytes 
and P9 cells
Figure 3.18 (d) RT-PCR analyses of type-V adenylyl 
cyclase transcripts in CHO and NIH-3T3 
cells
127
128
129
130
131
132
133
134
135
136
137
Xlll
Figure 3.18 (e) RT-PCR analyses of type-VI adenylyl 
cyclase transcripts in different cells 
Figure 4.1 Time course of forskolin activated total PDE
and PDE4 activity 
Figure 4.2 Time course of cholera toxin activated total
PDE and PDE4 activity 
Figure 4.3 Time course of forskolin elevated intiacellular
cAMP in P9 cells 
Figure 4.4 Time course of cholera toxin elevated
intracellular cAMP in P9 cells 
Figure 4.5 (a) Design of primers for RT-PCR detection of 
PDE4A
Figure 4.5 (b) Design of primers for RT-PCR detection of 
PDE4B
Figure 4.5 (c) Design of primers for RT-PCR detection of 
PDE4C
Figure 4.5 (d) Design of primers for RT-PCR detection of 
PDE4D
Figure 4.6 RT-PCR analyses of hormone effects on
PDE4A 'generic' transcripts in P9 cells 
Figure 4.7 RT-PCR analyses of hormone effects on
PDE4D 'generic' transcripts in P9 cells 
Figure 4.8 RT-PCR analyses of hormone effects on
PDE4B 'generic' transcripts in P9 cells 
Figure 4.9 RT-PCR analyses of hormone effects on
PDE4C 'generic' transcripts in P9 cells 
Figure 4.10 Im mu noblot analysis of rPDE39 in P9 cells
Figure 4.11 RT-PCR analyses of hormone effects on
PDE4D3 ti'anscripts in P9 cells 
xiv
163
164
166
167
168
169
170
171
172
173
176
  ■  .
Figure 4.12 RT-PCR analyses of hormone effects on
PDE4D1 transcripts in P9 ceUs 
Figure 4.13 RT-PCR analyses of hormone effects on
PDE4B1 transcripts in P9 cells 
Figure 4.14 RT-PCR analyses of hormone effects on 
PDE4B2 transcripts in P9 cells 
Figure 4.15 Immunoblot analysis of hormone effects on 
PDE4D3 in P9 cells 
Figure 5.1a Design of degererate primers for RT-PCR 
detection of PDEl transcripts 
Figure 5.1b RT-PCR analyses of PDE 1 transcripts in
normal and diabetic hepatocytes and P9 cells 
Figure 5.2 RT-PCR analyses of PDE4A 'generic' transcripts in
normal and diabetic hepatocytes 
Figure 5.3 RT-PCR analyses of PDE4B 'generic'
transcripts in normal and diabetic hepatocytes 
Figure 5.4 RT-PCR analyses of PDE4D 'generic'
transcripts in nonnal and diabetic hepatocytes 
Figure 5.5 RT-PCR analyses of PDE4C 'generic'
transcripts in normal and diabetic hepatocytes 
Figure 5.6 RT-PCR analyses of RDI transcripts in
normal hepatocytes 
Figure 5.7 RT-PCR analyses of rPDE6 transcripts in
normal and diabetic hepatocytes 
Figure 5.8 RT-PCR analyses of rPDE39 transcripts in
normal and diabetic hepatocytes 
Figure 5.9 RT-PCR analyses of PDE4B1 transcripts in
normal and diabetic hepatocytes
177
178
179
180
197
198
199
200
201
202
203
204
205
206
XV
__________  :   : :  - -.......
Figure 5.10 RT-PCR analyses of PDE4B2 transcripts in 
noiTnal and diabetic hepatocytes 
Figure 5.11 RT-PCR analyses of PDE4D1 transcripts in 
normal and diabetic hepatocytes 
Figure 5.12 RT-PCR analyses of PDE4D3 transcripts in
nonnal and diabetic hepatocytes 
Figure A .l Desensitization of glucagon-stimulated cyclic 
AMP accumulation in intact hepatocytes 
Figure A. 2 Desensitization of glucagon-stimulated
adenylyl cyclase in hepatocyte membranes
207
208
209
273
274
XVI
   : :  %______________
List of tables
Table 1.1 Properties and regulation of adenylyl cyclase 
subtypes
Table 1.2 Summaiy of cyclic nucleotide
phosphodiesterase isoforms 
Table 3.1 Cholera toxin-stimulated adenylyl cycylase
activity in hepatocyte membranes 
Table 3.2 Cholera toxin-stimulated adenylyl cyclase
activity in P9 cells 
Table 3.3 Cholera toxin-stimulated adenylyl cyclase
activity in CHO and NIH-3T3 cells 
Table 3.4 Summary of adenylyl cyclase expression in
different cell lines 
Table 4.1 Assessment of cAMP phosphodiesterase
activities in P9 cells and hepatocytes 
Table 4.2 Sub-cellular distribution of PDE4 in P9 cells
Table 4.3 Attenuation by actinomycin D of forskolin
and cholera toxin stimulated induction of 
PDE4 activity in P9 cells 
Summary of hormone mediated induction of 
PDE4 splice variants 
Summary of the effects of insulin on 
components of the cAMP signalling pathway 
in normal and diabetic states 
Table 5.2 Assessment of cAMP phosphodiesterase
activity in hepatocytes from normal and 
diabetic animals 
Table 5.3 Assessment of PDEl activity in hepatocytes
and P9 cells
xvii
Table 4.4
Table 5.1
16
32
139
140
141
142
181
182
183
184
210
211
212
Table 5,4 Sub-cellular distribution of PDE4 activity in
noiTnal and diabetic hepatocytes 
Table 5.5 Immunoprécipitation of PDE4 activity in
hepatocytes
Table 5.6. Summary of PDE4 splice variant expression
in normal and diabetic hepatocytes 
Table A. 1 Protein kinase C involvement in the
desensitization of glucagon-stimulated cyclic 
AMP accumulation in intact hepatocytes
213
214
215
275
X V lll
Summary
Incubation of hepatocytes or the SV40-DNA immortalised hepatocyte P9 
cell line witli cholera toxin led to a time-dependent activation of adenylyl cyclase 
activity which occurred after a defined lag period. When added together with 
cholera toxin, each of the hormones insulin and vasopressin was capable of 
attenuating the maximum stimulatory effect achieved by cholera toxin over a 
period of 60rain through a process which could be blocked by the compounds 
staurosporine and chelerythrine. Attenuating effects upon cholera toxin- 
stimulated adenylyl cyclase activity could also be elicited using either tlie protein 
kinase C stimulating phorbol ester PMA (12-O-tetradecanoyl phorbol-13- 
acetate) or the protein phosphatase inhibitor okadaic acid. Alkaline phosphatase 
treatment of membranes reversed the inhibitory effect of P M A . Cholera toxin 
also stimulated the adenylyl cyclase activity of intact CHO and NIH-3T3 cells 
but this activity was insensitive to the addition of PMA. Overexpression of 
various protein kinase C isoforms in CHO cell lines did not confer sensitivity to 
inhibition by PMA upon cholera toxin stimulated adenylyl cyclase activity. It is 
suggested that the protein kinase C mediated phosphorylation of a membrane 
protein attenuates cholera toxin-stimulated adenylyl cyclase activity in 
hepatocytes and P9 cells. The cellular selectivity of such an action may be due 
to the target for this inhibitory action of protein kinase C being a particular 
isoform of adenylyl cyclase. This is believed to be type V adenylyl cyclase 
which provides the major activity in hepatocytes and P9 cells but is absent from 
both CHO and NIH-3T3 cells.
Multiple families of phosphodiesterase are differential^ expressed and 
regulated in a cell-specific fashion. The work here focuses on identifying 
which members of the multigene PDE4 isoenzyme family are expressed in 
hepatocytes and P9 cells. This was done by RT-PCR transcript analysis and 
immunoblotting, showing that only the PDE4A and PDE4D families are 
represented. The effect of elevated cAMP on low Km cAMP-specific PDE
xix
'--a
7 %
expression in P9 cells was determined. Chronic treatment of P9 cells with the 
adenylyl cyclase stimulators forskolin and cholera toxin led to a profound 
increase in PDE4 activity. This was prevented by actinomycin D, an inhibitor 
of RNA synthesis. PDE4 up-regulation was due to an increased level of 
PDE4D3, a subtype product of the PDE4D gene, as determined by both 
transcript analysis and immunoblotting which detected an ~93kDa species, 
reflecting PDE4D3 protein. Although novel transcripts for PDE4B (PDE4B2) 
were detected associated with this PDE4 up-regulation, the protein product of 
this gene could not be detected in the P9 cells.
Hepatocytes from streptozotocin-induced diabetic rats showed decreased 
high affinity PDE activities, namely PDE2, PDE3 and PDE4 activities compai'ed 
to normal animals. This was associated with changes in the PDE4 transcript 
profile noted for PDE4B2 and PDE4D3 forms.
XX
Chapter 1 
Introduction
 ^   :   :_________
1.1 cAMP signalling
The inti'acellular signal triggers a cascade of molecular reactions 
the result of which culminates in the biochemical response. One such 
intracellular signal, or second messenger, is cyclic adenosine 3*, 5'- 
monophosphate (cyclic AMP). Cyclic AMP has been shown to bind with high 
affinity to the regulatory subunits of a protein kinase, thereby activating the 
enzyme (Taylor, 1989). This enzyme has since been named cyclic AMP- 
dependent protein kinase (PKA). Cellular cyclic AMP homeostasis is 
maintained not only by regulating its synthesis by adenylyl cyclase (Cooper et 
a i ,  1994; Taussig and Gilman, 1995), but also by control of its degradation, 
through the action of the cyclic nucleotide phosphodiesterases (PDEs) (Beavo et 
aL, 1994; Conti et a l ,  1995b) (Figure 1.1). Since the discovery of cyclic 
nucleotides, their synthesis and its modulation by hormones, neurotransmitters 
and pharmacological agents are mechanisms which are now among the most 
well established in cellular signalling.
f t
1.1.1 Cyclic AMP as a second messenger
The second messenger cyclic AMP has shown to be central in the 
functioning of a diverse range of biological systems. Of great importance is the 
role of cyclic AMP in the hormonal control of blood glucose and fatty acid 
levels. Cyclic AMP has a dual effect in the hormonal control of lipolysis in 
adipocytes. On the one hand, cyclic AMP mediates the lipolytic action of 
hoiTnones such as catecholamines, corticotrophin and glucagon (Steinberg et al 
1975). The cAMP promotes lipolysis through the activation of cyclic AMP- 
dependent protein kinase, which phosphorylates and activates hormone 
sensitive lipase resulting in hydrolysis of stored triglyceride to liberate glycerol 
and free fatty acids (Strâfors et aL, 1984). Conversely, the degradation of 
cyclic AMP and the subsequent reduction in cyclic AMP-dependent protein 
kinase activity has been shown to be of functional importance in the antilipolytic
1
Figure 1.1 Diagram showing the action of adenylyl cyclase and 
cyclic AMP phosphodiesterase on ATP and cyclic AMP 
respectively.
•■■ . ...... -________________
NH:
OH OH OH
HO—P CH:
ATP OH OH
adenylylcyclases NH-
Cyclic AMP
0 = P
OH
cyclic AMP 
phosphodiesterases NH'
OHIHO—P -0- CHz o
5'AMP OH OH
.action of insulin (Smith and Manganiello, 1988, Vasta et aL, 1992 and 
Anderson etaL, 1989),
In liver, cAMP exerts its influence at two levels. Firstly, it acutely 
regulates the activity of the key enzymes involved in glycolysis, 
gluconeogenesis and fatty acid metabolism (Strafors et aL, 1984). Secondly, it 
regulates gene transcription. Homeostatic control of blood glucose levels has 
been shown to be a cyclic AMP mediated event. Glucagon, the hormone 
produced by the alpha cells of the pancreas, is involved in the promotion of 
glycogenolysis, gluconeogenesis and the release of free fatty acids. The 
receptor for glucagon is coupled to the cyclic AMP synthesising enzyme 
adenylyl cyclase through the stimulatory G-protein Gg (Houslay, 1991b). In
the liver, elevation of the intracellular levels of cyclic AMP, via activation of the 
glucagon receptor, triggers an enzymatic cascade initiated by PKA mediated 
phosphorylation (Cohen, 1985). Primarily this is the phosphorylation of 
glycogen phosphorylase, leading to the breakdown of glycogen and glucose 
release, and of glycogen synthase which results in the inactivation of the 
glycolytic enzyme pyruvate kinase (Johnson and Venezialek, 1980). This 
cyclic AMP signal in response to glucagon in hepatocytes has been shown to be 
transient (Heyworth et al ., 1983). Following the initial increase in cyclic 
AMP, a rapid desensitisation, which is a cAMP independent process, occurs 
(Heyworth and Houslay, 1983), in which the glucagon receptor is uncoupled 
from Gs stimulation. Several reports have also shown that this desensitisation 
of glucagon stimulated adenylyl cyclase is due to a protein kinase C mediated 
phosphorylation of the receptor (Murphy et aL, 1987, Murphy and Houslay, 
1988; Savage etaL, 1995).
In liver, insulin opposes the action of glucagon and catecholamines on 
these processes. By restraining the level of cAMP it opposes PKA-mediated 
phosphorylation and gene transcription and has cAMP-independent effects on 
gene expression which favour the anabolic pathways. It enhances pyruvate
kinase levels and restores glucokinase levels which have been lowered by 
diabetes mellitus (Spence, 1983). In addition to its effects on carbohydrate 
metabolism, insulin has long been known to oppose the lipolytic action of 
cAMP both in liver and adipose tissue (Iliano and Cuatrecasas, 1972).
It is remarkable that the elevation of intracellular cAMP levels can also 
result in either stimulation or repression of specific gene expression (BOnelli g/ 
aL, 1992; Montminy et aL, 1986; Comb etaL, 1986) where cAMP abolishes 
tlie induction of pyruvate kinase (Munnich et aL, 1984) and impairs glucokinase 
expression (Pilkis, 1970), suggesting that complex, cell-specific molecular 
mechanisms must operate in the nucleus. cAMP is the major stimulus for the 
increased synthesis and impaired degradation of mRNA for the gluconeogenic 
enzyme phosphoenolpyruvate carboxykinase (PEPCK) (Hod et aL, 1986). 
cAMP-induced gene expression is important in many cellular responses, 
including the establishment of long-term memory (Borrelli et aL, 1992; 
Montminy et aL, 1986). cAMP inducible transcription factors (ICERs) have 
now also been identified, which are involved in the repression of transcription 
(Molina et al., 1993). The kinetic expression of these transcription factors is 
characteristic of an early response gene, such as c~fos, c~jun and o-rel (Verma 
and Sassone-Corsi, 1987), with induction being rapid and transient. These are 
the first transcriptional repressor in the cyclic AMP signalling pathway whose 
functions are regulated by the modulation of its own intracellular levels and not 
by phosphorylation. It is thought to be important in the phenomenon of down- 
regulation of gene activity after a first burst of activation by cyclic AMP.
1.1.2 T erm ination  of the cyclic  AMP signal by 
phosphodiesterases (PDEs)
Another vital aspect of the cyclic AMP signalling pathway is its means 
of degradation. The only way in which the cells of eukaryotic organisms can 
terminate the cyclic AMP signal is through its hydrolysis catalysed by a
-/y
heterologous family of enzymes known as the cyclic nucleotide 
phosphodiesterases (PDEs) (Beavo et al., 1994; Conti et a l ,  1991). The 
degradation of cAMP through the action of PDEs presents a physiological 
function, the modulation of which may usefully be manipulated in the control of 
disease states such as depression and inflammation where changes in 
intracellular cAMP levels/PDE activity are known to occur.
However, some organisms such as Dictyostelium (^iti e ta l ,  1992) can 
also extrude cyclic AMP from the cell, and this must occur in certain cells of the 
body as cAMP occurs in plasma and urine.
1,2 G-protein dependent signal transduction systems
G proteins regulate the activity of effector enzymes in response to the 
interaction of specific ligands with appropriate receptors. Each G protein 
contains a guanine nucleotide-binding a  subunit and a complex of tightly 
associated p and y subunits. Upon activation of a G protein by an agonist- 
bound receptor, GDP is released from the a  subunit in exchange for GTP. 
This binding of GTP causes conformational changes that result in dissociation 
of GTP-a from p y, liberating two species which are capable of the regulation 
of downstream effectors (Figure 1,2).
1.2.1 G-protein subtypes:
Although G proteins consist of three distinct subunits, a , P and y, they 
are generally defined by the nature of their a  subunits (Gilman, 1987; Kaziro et 
<3/., 1991). a  is the guanine nucleotide binding component whilst py subunits 
form a tightly, although non-covalently, associated complex. In the inactive 
state, heterotrimeric G proteins are bound to the inner leaflet of the plasma 
membrane via fatty acid modifications such as palmitoylation and myiistylation 
(Spiegel e ta l ,  1991; Thissen and Casey, 1994).
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Figure 1.2 Flow of information through G protein-dependent 
signal transduction systems
Adapted from Bimbaumer et al, 1990
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1The heterotrimeric G-protein a  subunits, of Mr between 39,000 and 
50,000, bind and hydrolyze GTP and define the receptor and effector specificity 
of a G protein. To date, about twenty subtypes of a  subunits, five p subunits 
and seven y subunits have been isolated (Milligan, 1995). They aie recognised 
to play a central role in signal transduction, as they couple a diverse array of 
receptors to intracellular effectors.
All a  subunits contain sets of sequences highly homologous to 
sequences which in bacterial elongation factor TU are known to be involved in 
GTP binding and hydrolysis. The a  subunits of all G proteins are substrates of 
one or both of two ADP-ribosyltransferases, the toxin of Vibrio cholera 
(cholera toxin) (Johnson e ta l ,  1978, Northup et a l ,  1980) which depends on 
GTP for its activity (Kahn and Gilman, 1986) and the toxin of Bordetella 
pertussis (pertussis toxin) (Hildebrandt et a i ,  1983; Bokoch et aL, 1983; 
Codina et al., 1983) which depends on ATP for its action (Mattera et a i,  1986).
a  subunits do not interact with receptors unless they first combine with 
py dimers (Florio and Sternweis, 1989; Navon and Fung, 1987). The overall 
import of free Py dimers appears to be to promote interaction of the a  subunits 
with receptors so that receptors may cause their activation by GTP. In addition, 
by dissociating from the activated a  subunit, py dimers have the all-important 
role of facilitating the stabilization of the activated form of the G protein, 
allowing receptors to act catalytically and suppressing non-specific noise 
originating from the activity of unoccupied receptors (Milligan, 1996). 
However, it is becoming clear that py components may activate effectors system 
in their own right. They have been suggested to regulate potassium channels 
(Logothetis et at., 1987), phospholipase A2 (Bourne, 1989), phospholipase C 
(Katz et al., 1992), calmodulin (Katada et a l ,  1987) and adenylyl cyclase 
(Codina et a l ,  1988; Goldsmith et a l ,  1988; Fdedrman et at., 1992). 
Recently, Thomason et at., (1994) also showed that platelet cytosol contains 
PI3-kinase activity that is sensitive to py subunit complexes. The
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demonstration (Goldsmith et ah, 19%%\ a/., 1992) that p y
signalling can be hoimone-specific, implies an important role in this field.
1.2.2 G-protein coupled receptors
Characterization of individual G protein-coupled receptor linked 
signalling pathways is one of the central issues in receptor research. All G 
protein-coupled receptors consist of a single polypeptide chain with seven 
putative transmembrane domains. Upon agonist binding to the receptor 
(Figure 1.3), it is thought that the conformation of the receptor changes, 
allowing the association of the G protein with cytoplasmic regions of the 
receptor. Receptor activation and subsequent binding of the G protein, 
promotes the exchange of GTP for GDP. Upon binding GTP, Py subunits are 
released as a heterodimer, leaving the a  subunit to interact with and modulate 
the activity of effectors such as adenylyl cyclase (Gilman, 1984). It has become 
increasingly evident that py subunits also have the ability to modulate the 
activity of certain classes of adenylyl cyclase (see below) (Tang and Gilman, 
1991; Tang et a l ,  1991), PLC (Camps et a l ,  1992) and ion channels. The a  
subunitieffector interaction is teiminated by an intrinsic GTPase activity which 
hydrolyses thé terminal phosphate of GTP, returning the a  subunit in its 
inactive GDP-bound state. In this state, it re-associates with the py complex, 
forming the heterotrimeric conformation once more, which is required for 
receptor interaction (Figure 1.3).
Given the numerous possible combinations of currently identified a , p 
and y subunits, a wide diversity of receptor-G protein signalling pathways 
could be anticipated. Many receptors apparently interact with only one type of 
G protein, e.g. either Gs, Gj/Go, or Gq/Gn (Ross and Gilman, 1977; Johnson 
et a l ,  1978; Kuhn, 1980), although receptors apparently interacting with more 
than one G protein have been found. For example, glucagon receptors can 
mediate both stimulation of adenylyl cyclase, via Gg, and activation of
8
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Figure 1,3 The G-protein Cycle
(a) G-protein in the basal state is holomeric and has GDP bound to the a  
subunit.
(b) Activated receptor (R) catalyses exchange of GDP for GTP; a  subunit 
dissociates from the py component.
(c) In this example, GTP-bound a  subunit interacts with the effector, although 
free py subunits can also modulate the activity of effector molecules.
(d) Intrinisic GTPase activity of the a  subunit hydrolyses GTP and the trimer 
re-associates.
(Adapted from Spiegel, 1992)
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phospholipase G, presumably via Gq (Bitensky etal., 1981; Northup etal., 
1980); TSH-induced activation of adenylyl cyclase and phospholipase C is 
mediated by Gs and G q /G n  (Allgeier et al., 1994). Receptors coupled to 
pertussis toxin-sensitive Gi/Gq proteins can interact with more than one member 
of this G protein class (Bimbaumer et al., 1990).
1.2.3 Characterisation of G-proteins
Gs is expressed ubiquitously in mammalian cells. It is essential for 
stimulatory regulation of adenylyl cyclase by hormones. GTP at micromolar 
levels is required for efficient coupling. G$a is encoded by a single gene, but 
differential splicing can produce up to four different polypeptides (Bray et al., 
1986) which have a tissue specific distribution (Mumbey et «/., 1986). One 
finding that two forms of Gsa (43kDa and 45kDa) could reconstitute fluoride 
and guanine nucleotide regulatoiy activity in the Gg-lacking mutant S49 cyc- 
cells with equal efficacy, led Graziano et al. (1987) to propose that there is no 
functional difference between the different forms. However, evidence has also 
been presented that the shorter form may have a greater ability to activate 
adenylyl cyclase (Walseth et at., 1989).
Complementary DNA cloning of Gia has revealed three different Gia 
cDNAs: G ial, Gia2 and Gia3 (Kaziro et al., 1991). All of which are encoded 
by distinct genes. All three polypeptides have been purified from tissue sources 
and their distribution characterised. They show 85% amino acid sequence 
identity. Gia2 (40KDa) and Gia3 (41KDa) are ubiquitous but their relative 
amounts vary between tissues (Milligan, 1990). Gia2 is generally thought to 
be the form responsible for inhibition of adenylyl cyclase (Bushfield et a l ,  
1990b; McKenzie and Milligan, 1990), although there is evidence both for 
(Pobiner et a l,  1991) and against (McClue e ta l,  1992) Gia3 also having such 
a role. Gia3 has been proposed to regulate sodium channels (Cantiello er a l ,  
1990), potassium channels (Mattera e ta l ,  1989) and Golgi trafficking (Stow et
1 0
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aL, 1991). G ial (41kDa) has a more limited tissue distribution, notably 
present in cerebral cortex, adipocytes and neural tissue-derived cell lines. It 
may seiwe to couple opiate receptors to inhibition of adenylyl cyclase (Attali and 
Vogel, 1989).
Go, another pertussis toxin substrate, is expressed predominantly in 
neural tissues where it is thought to regulate calcium channels (McFadzean et 
a l ,  1989). The pertussis toxin-insensitive Gq is a member of a group of a  
subunits thought to couple receptor activation of phospholipid hydrolysis by 
activating the P-isoform of phospholipase C (Simon et a i,  1991).
There is very strong conservation of a  subunit structure between 
species, e.g. only one residue out of 394 differs between rat and human Gsa- 
The amino acid sequences of Gi(%2, Gia3 and Goa are 98% identical between 
mammalian species. This demonstrates that there is strong evolutionary 
pressure to maintain G-protein function.
1.2.4 Regulation of G-proteins
1.2.4.1 G^. the stimulatorv regulatorv component of adenvlvl cvclase
Gs constitutes a potential mixture of up to 16 proteins which have been 
unequivocally established as providing the stimulatory regulatory component of 
adenylyl cyclase. This was demonstrated by showing that it could reconstitute 
hormonal, NaF and guanine nucleotide regulation of adenylyl cyclase and 
confer cholera toxin sensitivity to the «g-deficient adenylyl cyclase system of 
cyc-S49 cells (Codina et al., 1984; Northup et al., 1980). Gg has also been 
established as the component responsible for high-affinity binding of hormones 
to adenylyl cyclase stimulatory receptors as demonstrated by reconstitution of 
high-affinity binding to p-adrenergic receptors in cyc-membranes and its ability 
to confer high-affinity binding characteristics to fully purified p-adrenergic 
receptors after co-incorporation into phospholipid vesicles (Cerione et a i,
1 1
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1984). Gg intriguingly, also seems to stimulate a class of Ca^+ channels 
(Yatani ar a/., 1987).
L2.4.2 . Peitu^^is lQxin substrates: Gr and Gn
Pertussis toxin has played a key role in defining our understanding of 
the involvement of G proteins in signal transduction through its ability to block 
inhibition of adenylyl cyclase systems (Ui, 1984). The first new G protein it 
helped to define was Gi which, by definition, mediates inhibition of adenylyl 
cyclase (Hildebrandt e ta l ,  1983). Inhibition of adenylyl cyclase by low 
concentrations of GTP had been shown as early as 1973 (Bimbaumer, 1973) 
and has since been studied extensively in the context of the mediation of the 
action if various inhibitory hormones. In GH4C1 pituitary cells, an excellent 
model to study the specificity of pertussis toxin-sensitive G proteins in coupling 
of receptors to effectors, all known three a i subunits are expressed as well as 
the two types of ao- These cells also express a range of effectors. However, 
Lui et al,  (1994) showed the specificity of the a  subunits of Gi2 and Go in the 
coupling of specific receptors to inhibition of cAMP synthesis and calcium 
entiy, respectively, in these cells.
1.2.4.3 Hormonal regulation of G-proteins
Down-regulation of plasma membrane receptors on prolonged exposure 
to agonist is responsible for reducing responses to specific hormones ie. 
homologous desensitisation. Altered expression of G-proteins may play a role, 
however, in heterologous desensitisation, i.e. desensitisation to multiple 
hormonal stimuli (Milligan and Green, 1991). (For more detail about 
desensitisation see the appendix). In this regard, Gga has been found to be 
down-regulated by stimulatory signals (McKenzie and Miligan, 1990). 
Similarly, exposure to inhibitory agonists can cause down regulation of Gi 
(Green and Johnson, 1989). However both the mechanisms by which receptor 
sequestration and altered G-protein expression are deteimined remain unknown.
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1.2.4.4 G-protein phosphorylation
Phosphorylation, a major control mechanism in metabolic regulation has 
been implicated in the regulation of G-protein function (Houslay, 1991a). 
Phosphorylation of GDP-bound Gi and Goa subunits by the purified insulin 
receptor tyrosine kinase (O'Brien et al., 1987) and phosphorylation of Gia2 
(Krupinski et al,  1988) have been recorded, but not the phosphorylation of 
Gsa- Insulin, however, does not appear to elicit Gi phosphorylation in intact 
cells (Pyne et al., 1989a), raising the possibility that the action of the insulin 
receptor is only an in vitro phenomenon. Phosphorylation of G |a2 has been 
detected in response to the phorbol ester TP A and calcium-mobilising 
hormones, which cause the production of diacylglycerol, suggesting that PKC 
might elicit such phosphorylation (Bushfield et al, 1991). Indeed, it appears 
that PKC can phosphorylate the a-subunit of Gi2 on a specific serine residue, 
leading to changes in GTP-dependent inhibition of adenylyl cyclase (Monis et 
al, 1994; Murphy et al,  1989; Bushfield er u/., 1991).
1.2.4.5 Bacterial toxins 
(a) Cholera toxin
Cholera toxin from Vibrio cholerae is the causative agent of the 
diarrheal disease cholera, and mediates its effects by increasing cAMP 
concentrations (Finkelstin, 1973). Although the human small intestinal mucosal 
cell is the normal target of the toxin, cholera toxin is an ubiquitious activator of 
adenylyl cyclase in most vertebrate cells (van Heyningen, 1983; Fishman, 
1990). The structure of the homologous Escherichia coli heat-labile enterotoxin 
has been published (Sixma et al., 1991). Cholera toxin is composed of an A 
subunit and a homopentameric B subunit (Fishman, 1990). Each subunit has a 
different function, the B subunit recognizes and binds to specific receptors on 
the cell surface which have been identified as the ganglioside Gmi (Fishman, 
1990). The A subunit, which consists of two peptides, Ai and A% linked by a
1 3
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disulphide bond, activates adenylyl cyclase. The Ai peptide transfers ADP- 
rib ose from NAD+ to the a  subunit of the stimulatory G protein, Gg, 
obliterating the GTPase activity normally associated with this subunit. In the 
presence of GTP which causes the dissociation of Gg to release a free Gga- 
subunit, this ADP-ribosylation traps Gga in its active GTP-bound form. This 
species causes the constitutive activation of adenylyl cyclase (Van Heyningen, 
1977; Gilman, 1984; Bimbaumer et a l,  1985; Northup, 1985). The site of 
ADP-ribosylation is an arginine residue present in all variants of Gga; residue 
201/202 in the long foims and 187/188 in the short forms (Northup, 1985).
The intervening steps between binding and activation are less well 
understood. There is a characteristic lag period after cholera toxin bind to the 
cell surface and before an increase in adenylyl cyclase activity is observed in 
hepatocytes (Houslay and Elliott, 1979 and 1981). At the end of the lag period, 
small amounts of Ai peptide begin to be formed and their concentration 
increases in parallel with the increase in adenylyl cyclase activity (Kassis et al, 
1982). The site where Ai is generated and the mechanism(s) involved are not 
known. How A% reaches Gga which is located on the cytoplasmic face of the 
plasma membrane is also unclear. The molecular basis of this lag period 
remains to be defined, although it can be altered by changing temperature, 
cholera-toxin concentration and membrane fluidity (Houslay and Elliott, 1979). 
Two major models have been proposed. The first, based on photoabelling 
studies (Wisnieski and Bramhall, 1981; Tomasi and Montecucco, 1981), 
suggested that the cholera toxin A subunit may penetrate the membrane bilayer, 
undergoing reduction and releasing A% at the cytoplasmic face of the membrane 
where it can activate Gg (Fishman, 1990). In the other model, the lag time is in 
part, connected with a requirement for cholera toxin to undergo endocytosis 
before it can be processed and recycled back to the plasma membrane in order 
to act on Gg at the cytosolic surface of the plasma membrane (Houslay and 
Elliott, 1981; Janicot and Desbuquois, 1987; Janicotar al, 1988 and 1991).
1 4
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(b) Pertussis toxin
Pertussis toxin from Bordetella pertussis, the causative organism of 
whooping cough, ADP-ribosylates and inactivates the GDP-bound (trimeric) 
form of Gi(x preventing its dissociation and abolishing both receptor-mediated
and tonic inhibition of adenylyl cyclase. The site of action of the toxin is a 
cysteine residue located four residues from the C teitninus within the receptor 
binding domain (Morgan, 1989). The a  subunits of at least six G-proteins can 
be modified by pertussis toxin-catalysed ADP-ribosylation (Freissmuth et al, 
1989). Pertussis toxin has proven a particularly useful tool in identifying Gi- 
mediated events and substrates involved in signal transduction. Pertussis toxin 
treatment of cells, by removing inhibitory Gi input to the catalytic subunit, can 
enhance responses to stimulatory hormones (Heyworth et a l ,  1984). 
Hormonal activity not mediated by G-proteins is not influenced by pertussis 
toxin treatment.
1.3 Adenylyl cyclase signalling
Adenylyl cyclase, the enzyme which catalyzes the conversion of 
intracellular ATP to cyclic AMP, is controlled dynamically by a variety of 
hormones, neurotransmitters and other regulatory molecules. The hormone- 
sensitive adenylyl cyclase system is comprised of three types of plasma 
membrane-associated components: heptahelical, G protein-coupled receptors for 
a variety of hormones, neurotransmitters and autocoids; stimulatory and 
inhibitory heterotrimeric G proteins and the catalytic entity itself (Taussig and 
Gilman 1995), So far, ten isofonns of adenylyl cyclase have been identified 
(Tang and Gilman, 1992; Taussig and Gilman 1995). These can be classified 
into three groups, with distinct structural and diverse regulatory properties 
(Krupinski et a l ,  1992; Kawabe et a l, 1994; Yoshimura and Cooper, 1993; 
Jacobowitz et al,  1993) (Table 1.1).
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Table 1.1 Properties and regulation of adenylyl cyclase subtypes
Abbreviations used;
PKC, protein kinase C; CaM, calmodulin; AC, adenylyl cyclase.
References;
1. Jacobowitz e ta l ,  1993
2. Yoshimura and Copper, 1993
3. Tang and Gilman, 1991
4. Gao and Gilman, 1991
5. Pieroni et al, 1993
6. Chen and Iyengar, 1993
7. Kawabe et a l ,  1994
8. Ishikawa e ta l ,  1992
9. Krupinski et al,  1992
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T yp e E xp ression E ffect o f  G -protein Ca2+/C aM PK C
o f  A C G s a Py e ffe c t e ffec t
I Braih^ 4- «3 4- ml
II Brain, lung 4" 4-3 0 4-^
III O lfactory 4- 0 + 4- b y  a  and
IV Brain, others 4- 4 .4,5 0 4-2
V Heart, others 4- 0 - 4- by a  and
VI H eart 4- 0 m8 n.d.
VII K idney 4- 4-9 - n.d.
VIII N ervou s
system
4- n.d. 4- 0
N.B. + stands for stimulated; - stands for inhibited; 0 stands for no effect; nid. 
stands for not determined.
1.3.1 Divergent structure
1.3.1.1 Structure
Adenylyl cyclases have molecular weights of around 120kDa and are 
associated with the plasma membrane (Tang and Gilman, 1992) (Figure 1.4). 
A short cytoplasmic amino terminus is followed by six transmembrane spans 
(M l), a large (40kDa) cytoplasmic domain (C l), a second set of six 
transmembrane spans (M2) and a second cytoplasmic domain (C2) (Tang and 
Gilman, 1992). It is members of this complex and widely distributed group of 
adenylyl cyclases that are subject to stimulatory and inhibitory regulation by 
hormones and neurotransmitters, acting via the intermediacy of both receptors 
and heterotrimeric guanine nuceotide-binding regulator proteins (G proteins) 
(Gilman, 1987).
Among the different isoforms of adenylyl cyclase, the amino acid 
sequence is 50% homologous (Tang and Gilman, 1992). However, the two Cl 
and C2 domains (C la and C lb) are more highly conserved (up to 93% 
sequence identity) and this relationship extends to corresponding domains of 
topographically similar adenylyl cyclases from hoih drosophila (Levin et al,
1992) and Dictyostelium (Pitt et al, 1992). The C la  and C2a domains are 
highly homologous to each other as well as to the catalytic domains of 
membrane-bound guanylyl cyclases and domains that are found in each of the 
subunits of cytosolic heterodimeric guanylyl cyclases. Based on these 
relationships, it is predicted that one or both of these domains of mammalian 
adenylyl cyclases is the site for catalysis of cyclic AMP synthesis (Taussig and 
Gilman, 1995).
1.3.1.2 Structural coiTelation with activity
Expression of constructs encoding M lC l and M2C2 in Sf9 cells, 
showed the enzymes to be regulated in characteristic, type-specific fashions by 
G protein subunits or calmodulin (Tang et al, 1991). It is thus assumed that
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Figure 1.4 Structure of adenylyl cyclase
The predicted topology of membrane-bound adenylyl cyclase is shown. 
Cylinders represent membrane-spanning regions; N, amino-teiTuinal domain; 
M l, first set of membrane spanning regions; C la  and C lb , the first large 
intracellular cytoplasmic domain; M2, second set of transmembrane spanning 
regions; and C2a and C2b, second large intracellular' domain.
Adapted from Taussig and Gilman, 1995.
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the interaction between the C l and C2 domains is essential for catalysis. It is 
also notable that point mutations, in either the C la  and C2a domains of the 
adenylyl cyclases, can impair enzymatic activity severely and that mutations in 
either domain can elevate the Km for substrate. It has thus been speculated that 
both domains can bind ATP (Tang et al, 1991).
The duplicated motif prompted the motion that adenylyl cyclase is 
composed of two "half-sites" that interact to provide catalytic activity (Taussig 
and Gilman, 1995). Expression of a "front half" constmct of type I adenylyl 
cyclase, tmncated to remove domain C lb, with the back half of type II adenylyl 
cyclase, which largely lacks C2b permits assembly of a functional adenylyl 
cyclase that responds very well to both forskolin and activated Gga- The 
variable C lb  and C2b domains are thus not necessary for responses to these 
regulators. Gga interacts with C la/C2a and perhaps regulates interactions 
between these domains. C lb  domain is likely to be a site of interaction of 
calmodulin with type I adenylyl cyclase (Vorherr et al, 1993).
1.3.2 Molecular diversity in the adenylyl cyclase family
Molecular cloning studies have indicated that the diversity within the 
adenylyl cyclase family is greater than initially anticipated. Analysis of sequence 
relationships among the adenylyl cyclases permits some grouping (Krupinski et 
al,  1992). Type II, IV, VII and IX are clearly more related to each other than 
to the others ; a similar relationship exists between type V and type VI (Table 
1.1). The regulatory properties of these isoforms appear to reflect their 
evolutionary relationships (Taussig and Gilman, 1995). Types I, III, VIII are 
equally dissimilar from the others (Cali et a l,  1994; Tang and Gilman, 1992; 
Iyengar, 1993). Type V and VI possess long N-terminal domains (149-163 
amino acids) compared to other types (about 70 amino acids). This disparity in 
N-terminal lengths between different cyclase types has prompted exploration of 
N-terminal function. Truncation of the first 52 amino acid residues of type I
1 9
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adenylyl cyclase was shown to decrease activity to 10% of that seen in wild- 
type adenylyl cyclase (Tang et a l ,  1991), suggesting an important role in 
secondaiy stmcture or membrane orientation.
Application of low stringency hybridization and polymerase chain 
reaction techniques has now permitted isolation of six additional full-length 
clones (types II-VI and VIII) (Krupinski e ta l,  1989; Bakalyar and Reed, 1990; 
Ishikawa et a l,  1992). The dendrogram of the alignment gives a qualitative 
indication of the amino acid similarity among the various products (Figure 1. 
5). Relationships among these 57 amino acid fragments are qualitatively similar 
to what is observed if the complete protein sequences of types I-VI are aligned. 
The dendrogram indicates the existence of at least five different subfamilies 
amongst the adenylyl cyclases (Figure 1.5). Types I, III and VIII define their 
own branches of the family, while types V and VI (only one amino acid 
difference in this region, but only 83% nucleotide identity) are the most closely 
related of any two sequences (Krupinski et al, 1992). The type VII peptide is 
84% identical with that of type II, and together with type IV enzymes, these 
three proteins probably fonii a distinct subfamily. Once the type VII cDNA has 
been expressed, it will be of interest to note if it also can be activated 
synergistically by G protein py subunits in the presence of an active Gg^, a 
distinguishing property of the type II and IV isoforms (Feinstein et a l,  1991; 
Gao and Gilman, 1991; Tang and Gilman, 1991).
However, definition of the extent of molecular diversity in this family is 
probably not yet complete with alternatively spliced transcripts of adenylyl 
cyclases having also been suggested (Wallach e ta l,  1994).
1.3.3 Tissue distribution of adenylyl cyclases
Documentation of the cellular and subcellular localization of the different 
isoforms of adenylyl cyclase in mammalian tissues has been hindered by the 
low levels of expression (generally 0.01-0.001% of membrane protein) and
2 0
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Figure 1.5 Comparison of the amino acid sequences from a 
region conserved among members of the adenylyl cyclase family.
All of the amino acid sequences presented were obtained by translating 
nucleotide sequences derived from rat cDNA templates. The alignment of the 
rat sequences and the corresponding dendrogram of the alignment is from the 
program Clustal in the Intelligenetics PC/Gene sequence analysis package.
The dendrogram indicates the existence of at least five different subfamilies 
among the adenylyl cyclases. Types I,III and V m  define their own branches of 
the family, while types V and VI (only one amino acid difference in this region, 
but only 83% nucleotide identity) are most closely related of any two 
sequences. The type VII peptide is 84% identical with that of type II and 
together with type IV these three proteins probably fomi a distinct subfamily.
Adapted from Krupinski et al, 1992.
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'limited availability of high affinity, isoform-specific antibodies (Cooper et a l,  
1994). Most information thus comes from analysis of patterns of mRNA 
expression (Krupinski e ta l ,  1992). On such a basis, all isoforms of adenylyl 
cyclase appear to be expressed in the brain, apparently in region-specific 
patterns (Table 1.1).
The type I enzyme is largely restricted to the nervous system and 
regulated by Ca^+/camodulin (Xia et a l,  1993); the type II enzyme appears to 
be restricted to the hippocampus and cerebellum (Fumyama etal,. 1993); the 
type III is found predominantly in olfactory neuroepithelium (Bakalyar and 
Reed, 1990), whereas the types IV, V, VI and VII are differentially expressed 
primarily in peripheral tissues, such as heart, kidney, liver, lung and skeletal 
muscle (Gao and Gilman, 1991; Krupinski et a l,  1992). Evidence indicates 
that type VIII adenylyl cyclase is specifically expressed in the brain but not in 
other tissues such as heart or liver (Cali et a l,  1994). Northern analysis of 
brain regions indicates that human type IX is also restricted to the CNS, being 
most abundant in the caudate, cerebellum and hippocampus (Helluvo et a l, 
1993).
1.3.4 Diverse regulatory properties
Studies on the regulation of the isoforms of mammalian adenylyl 
cyclases reveal a wealth of common and disparate features (Kawabe et al, 
1994; Jacobowitz et al, 1993; Yoshimura and Cooper, 1993). All isoforms are 
activated by both forskolin and the GTP-bound a  subunit of the stimulatory G 
protein Gg. All are inhibited by certain adenosine analogues termed P-site 
inhibitors. However, all of the isoforms of adenylyl cyclase are further 
regulated in type-specific patterns by other inputs, partularly including those 
that are dependent on Ca^+ or that arise from other G protein subunits (Table 
1 . 1 ).
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1.3.4.1 Regulation by G-protein subunits
G-proteins consist of a , (3 and y subunits. Activation of heterotrimeric 
G proteins results in the dissociation of two regulatory moieties, the GTP- 
bound a  subunit and a dimer of the p and y subunits. The adenylyl cyclases 
from murine S49 cells and platelets, that were originally characterized with 
regard to the effects of G proteins, are activated by Gsa and are largely 
insensitive to the G protein Py subunit complex. Regulation of adenylyl 
cyclases by Gsa has been appreciated for some time and was the basis for 
discovery of this G protein (Cooper et al, 1994). However, knowledge of 
direct interactions of other G protein subunits with specific isoforms of adenylyl 
cyclase is more recent.
(a) Gsa-
All of the cloned adenylyl cyclase species appear to be equally well- 
regulated by Gsa, either when reconstituted with activated Gsa or when 
expressed in Sf9 cells and stimulated with GTP-Y-S (Tang, 1992; Iyengar,
1993). However, in intact HEK 293 cells, the Ca^+-actived types I and VIII 
were not readily stimulated by PGEl and the endogenous Gs (Yoshimura and 
Cooper, 1992; Cali e ta l ,  1994). Under similar circumstances, however, other 
adenylyl cyclases such as the II, V or VI foims were well stimulated. This may 
have resulted from high endogenous levels of Py subunits of G-proteins, 
exerting inhibitory effects on type I and VIII.
(p) py:
Smigel (1986) and Katada etal., (1987) first noted inhibition of type I 
adenylyl cyclase activity by the G protein py subunit complex, but in neither
case was it clear that the effect was exerted directly. Only recently was it noted 
that prominent inhibition by Py of type I adenylyl cyclase expressed in Sf9 cells
occurred with the purification of the expressed protein permitting the
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demonstration of the direct interaction of adenylyl cyclase with this subunit 
complex (Taussig et ai,  1993). Notably, however, when the effects of py on 
other isoforms were tested, smpiising stimulatory effects were obseiwed with 
type II (Tang and Gilman, 1991) and type IV adenylyl cyclase (Gao and 
Gilman, 1991). More interestingly, stimulation of these enzymes by Py is 
highly conditional in that whilst it was detectable, tlie magnitude of stimulation 
by py was enhanced in the presence of Gga* Stimulation of type II adenylyl 
cyclase by Py required significantly higher concentration of Py than of Gsa, and 
the source of the py was presumed to be contributed by G proteins such as Gi 
or Go oligomers, which are far more abundant than Gs, at least in brain 
(Taussig and Gilman, 1995). This provides a clear mechanism for cross-talk 
between signalling pathways.
(c) Gi:
Gi proteins (G ial, Gia2 and Gia3) were discovered as substrates for 
pertussis toxin and as the G protein oligomers responsible for inhibitory 
regulation of adenylyl cyclase activity. The three Gia proteins can inhibit type I 
adenylyl cyclase (Taussig et al,  1993) but the effect is not as prominent as that 
observed with py. Furthermore, inhibition of type I adenylyl cyclase activity by 
Gi is largely absent when the Gga-stimulated activity was examined (Taussig 
and Gilman, 1995). Indeed inhibition was largely confined to an action 
observed in the presence of calmodulin or forskolin. Type I adenylyl cyclase 
can also seemingly be inhibited by Goa (Cooper et al, 1994). Types II, III and 
VI were all well inhibited by Gja2 (Chen and Iyengar, 1993) when expressed 
in HEK 293 cells. However, the inhibition of type II could be offset by 
pretreating transfected cells with phorbol ester (Jacobowitz et al, 1993). Thus, 
there appears to be a type-specific potential for modulation of G^o^-mediated 
inhibition. This finding may also have some bearing on the ability of protein 
kinase C to stimulate selectively type II adenylyl cyclase (Yoshimura and
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■Cooper, 1993); i.e. whether PKC directly effects type II adenylyl cyclase or 
indirectly modifies interactions with adenylyl cyclase, remains to be 
deteimined (Kawabe et al, 1994). Type V and VI adenylyl cyclases expressed 
in Sf9 were inhibited by Gia subunits, with no apparent difference in potency 
between GiaC Gia2 and Gia3.
1.3.4.2 Regulation by Ca^+:
Changes in intracellular Ca^+ can have profound effects on cellular 
concentrations of cyclic AMP if appropriate isoforms of adenylyl cyclase are 
present (Cooper, 1991).
Types I and VIII adenylyl cyclase, and type III to a lesser extent, were 
markedly stimulated by nanomolar concentrations of Ca^+ (Cooper et al,
1994). In the presence of calmodulin, intracellular cyclic AMP concentrations 
rose dramatically when transfected cells expressing these isoforms were 
exposed to agonists that elevate intracellular Ca^+ (Caldwell et a l,  1992). 
Progress has been made in determining the sequences responsible for Ca^+ 
regulation, via calmodulin, of type I adenylyl cyclase. Vorherr et al, (1993) 
identified two potential calmodulin binding domains in the sequence of bovine 
type I adenylyl cyclase. A peptide corresponding to one of these domains 
(amino acids 495-522), which is equivalent to the cytosolic region just prior to 
the seventh transmembrane-spanning domain, could totally preclude the 
activation by Ca^+/calmodulin of bovine brain adenylyl cyclase. Further 
support that the amino acid sequence 495-522 in type I adenylyl cyclase is a 
calmodulin binding site came from site-directed mutagenesis (Bakalyai* and 
Reed, 1990). Unlike type I adenylyl cyclase, stimulation of type III adenylyl 
cyclase by Ca^+/calmodulin required concomitant stimulation by other factors, 
such as forskolin or Gpp[NH]p (Choi et al, 1992). This might suggest that the 
calmodulin binding site is inaccessible in the basal state and only becomes 
accessible upon activation. In addition, the type III adenylyl cyclase is also 100
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times less sensitive to Ca^+ than the type I enzyme (Choi ef al, 1992) indicating 
structural differences. Of the remaining adenylyl cyclase subtypes, both forms 
V and VI are inhibited by Ca^+, independent of the addition of exogenous 
calmodulin, and three forms, II, IV and IX are insensitive to Ca^+ as 
determined in various types of expression assays (Cooper et al, 1994).
1.3.4.3 Regulation by phosphorylation
The intracellular cyclic AMP concentrations achieved in response to 
exogenous regulators are highly dependent on the state of phosphorylation of 
components of hormone-sensitive adenylyl cyclase systems. This is 
particularly obvious in the case of the receptors for stimulatory and inhibitory 
ligands, which are desensitized and down-regulated following phosphoiylation 
by various kinases such as cyclic AMP dependent protein kinase, protein kinase 
C and a variety of receptor-specific kinases that view the agonist-bound 
receptors as preferential substrates (Dohlman et al, 1991). Only a few reports 
of phosphorylation of G protein subunits exist like Gia2 (Bushfield er a/., 
1990, Murphy et al, 1989; Morris cf al,  1994), however more studies are 
available to investigate phosphoiylation of adenylyl cyclase itself.
Feedback inhibition of adenylyl cyclase in response to phosphorylation 
by cyclic AMP-depen dent protein kinase was detected in chick hepatocytes and 
the S49 lymphoma cell line (Premont et al, 1992). These cells share the type 
VI enzyme that contains two consensus sites for phosphorylation by cyclic 
AMP-dependent protein kinase, one on which is also conserved in the closely 
related type V isoform (Premont e ta l ,  1992).
Recent exploration of the regulation of adenylyl cyclase by protein 
kinase C was extensively prompted by the use of the PKC activator-phorbol 
esters. Reports indicated that the activity of type II adenylyl cyclase, expressed 
by transfection, could be augmented substantially by stimulation of protein 
kinase C (Jacobowitz et al, 1993; Yoshimura and Cooper, 1993; Lustig et al,
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-1993). Kawabe and co-workers (1994) have demonstrated the phosphotylation 
of type V adenylyl cyclase in viti'o by PKC and this effect was specific for the a  
and Ô isoforms of PKC, suggesting cross-talk between this adenylyl cyclase 
and both Gq-mediated phosphalipid pathways (for PKC-a) and growth factor 
tyrosine kinase-mediated pathways (for PKC-ô).
The actual site of phosphorylation has proved difficult to determine 
because of the numerous potential PKC phosphorylation sites in many of the 
adenylyl cyclases. Nevertheless, type II adenylyl cyclase contains a unique, 
putative PKC phosphorylation site at serine 871, which is located in the second 
cytoplasmic loop (Yoshimura and Cooper, 1993).
There is less consensus with regard to effects of protein kinase C on 
type I adenylyl cyclase, this Ca^+Zcalmodulin stimulated enzyme would seem a 
logical candidate for feedback regulation by a Ca^+-activated kinase (Cooper et 
al,  1994).
__
1.3.5 Forskolin; A potent activator of adenylyl cyclase
The diteipene forskolin (Lindner, et al., 1978) from the roots of Coleus 
forskolhlii (Bhat et a l ,  1977) is a unique and potent activator of adenylyl 
cyclase. Its ability to reversibly activate cAMP-generating systems in intact 
cells clearly distinguishes it from other stimulating agents such as (a) cholera 
toxin, which activates cAMP-generating systems in intact cells in an ineversible 
fashion by covalently modifying the guanyl nucleotide-binding subunit and (b) 
fluoride, which is ineffective in activating the enzyme in intact cells as like 
guanyl nucleotides and divalent cations it requires access to intracellular sites. 
Thus, forskolin represents an invaluable agent for the general activation of 
adenylyl cyclase in intact cells and, hence, for the investigation of the 
relationship of cAMP levels to physiological functions in a variety of systems. 
The stimulation of adenylyl cyclase is rapid and potent, with lOflM forskolin 
generally giving half maximal activation. Maximal stimulation by lOOjaM
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forskolin is generally greater than that achieved with fluoride or non- 
hydroysable GTP analogues and there is little variation in the kinetics of its 
action between cell types. Forskolin stimulated intracellular cAMP in the intact 
cells usually reaches a maximum level after 5-10 minutes. Thereafter, any fall 
in cAMP level can usually be attributed to cAMP phosphodiesterase activity or 
cAMP extrusion, as homologous desensitisation to forskolin has not been 
observed.
Forskolin can act synergistically with both weak and strong agonists in 
elevating cAMP (Seamon and Daly, 1983) and can reveal responses to 
hormones which are too low to observe in the absence of forskolin (Darfler et 
al ,  1982). This synergistic action is more easily observed in intact cells than in 
plasma membranes. These obseiwations led to the suggestion that forskolin has 
two sites of action (Barovsky et al ,  1984) viz. A low affinity site for its action 
on the catalytic subunit of adenylyl cyclase and a high affinity site responsible 
for its potentiation of hormone action. However the high affinity response 
requires functional Gs (Darfler et a l ,  1982), suggesting that forskolin 
potentiates other hormones by an action on G$. Brooker et a l ,  (1983) 
suggested that forskolin, in exerting its low affinity effect on the catalytic 
subunit, may act on a distinct protein susceptible to inhibition of protein 
synthesis.
The majority of forskolin's phannacological actions can be attributed to 
cAMP elevation and protein kinase A activation (Seamon and Daly, 1986) and 
indeed, all, adenylyl cyclase isoforms discovered to date can be activated by this 
diteipene (Seamon and Daly, 1983). However, a number of cAMP- 
independent actions of forskolin have also been reported, for example an 
inhibitory effect on glucose transport (Klip e ta l ,  1988).
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1.3.6 Adenylyl cyclase signalling in P9 cells
1.3.6.1 SV40-immortaIised hepatocytes
Immortalisation means acquisition of an unlimited proliferative potential. 
The SV40 vims can be used to immortalise and transfonn various cell types by 
transfection, using genetic material prepared from virions. This leads to the 
establishment of a stable cell line (Chou, 1989). Woodworth et ai,  (1986) 
generated such a cell line by transfection of rat hepatocytes with SV40, The 
large T antigen induces changes in the host cell, bringing about immortalisation 
and eventually transforming them to tumorigenicity. A high concentration of T 
antigen is thought to be required for immortalisation and expression above a 
certain level is necessaiy for tumorigenicity (Efrat and Hanahan, 1989). These 
transfected rat hepatocyte cells did not initially show a fully transformed 
morphology, but developed this after a time in culture. Such cell lines, at least 
at low passage, have been suggested as beings more useful than hepatoma cells 
as a model system for the study of drug metabolism (Nairn et al ,  1990). 
Indeed, for up to 22 passages after transfection, gene products were expressed 
in SV40“immortalised cells at similar levels to those in native hepatocytes 
(Nairn et al,  1990). Chromosomal damage and cytogenetic abnormalities 
obseiwed in SV40-immortalized cells, as compaied to native rat hepatocytes, are 
lower than in other established cell lines (MacDonald et al,. 1991). This closer 
genotypic relation to native cells has caused workers to consider the value of 
SV40-immortalised cells as model systems. Interestingly, the immortalised cell 
line was found to retain the pathway for glutathione synthesis and possessed 
glutathione S-transferase activity comparable to rat hepatocytes (Nairn et al,  
1990). As cell lines differ phenotypically from their native cell types, some 
have been subjected to agents and conditions which promote differentiation in 
order to produce cells with more native characteristics.
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1.3.6.2 Analysis of the signalling system in an immortalized hepatocyte cell line 
P9 cells transformed by SV40 retain a variety of differentiated enzyme 
activities characteristic of hepatocytes, namely glucose-6-phosphatase, glycogen 
phosphorylase & bilirubin in glucuronyltransferase. Both glucagon and 
prostaglandin E l (PGEl)-stimulated adenylyl cyclase activities are also 
retained, albeit at decreased levels compared with native hepatocytes 
(Livingston et al ,  1995), The loss of responsiveness appears to be due to the 
low level of glucagon receptors in the plasma membrane. Meanwhile, the levels 
of the G-protein subunits Gi^z.,. Gii^a, Gp and the "long" form of : Ggt^ t^  
(45kDa) were shown to be 4-fold higher relative to native hepatocytes, whereas 
those of the "short" form of - (42kDa) were lower by 40%. Associated
with this were marked alterations in the guanine nucleotide regulation of 
adenylyl cyclase. Receptor-mediated stimulation, achieved by either PGEl or 
glucagon, was apparent in P9 cells, although the latter was only evident upon 
amplification with forskolin. Glucagon-stimulated cyclic AMP accumulation in 
P9 cells did not exhibit desensitisation in contrast to hepatocytes, nor was the 
phosphorylation of Gjotz evident. This cell line was used to show that 
signalling through high-affinity insulin receptors can attenuate the Gg-coupled- 
receptor stimulation of adenylyl cyclase activity and increase the expression of 
the inhibitory G-protein. Gi%2 and Gi@t3
P9 cells thus appear to provide the first example of an immortalized 
hepatocyte cell line which exhibits a G-protein-regulated adenylyl cyclase 
activity and a functional, high-affinity insulin-signalling system (Livingston et 
a l ,  1995). Culture of P9 cells with low, physiological, concentrations of 
insulin increases the expression of both Gi and " Gi , suggesting that the 
expression of these two inhibitory G-proteins may be directly regulated by 
insulin action in both hepatocytes and P9 cells (Livingston et al ,  1995). 
Adenylyl cyclase signalling in the P9 cell line, unlike marker protein 
expression, is considerably divergent from that of native rat hepatocytes.
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However, the cell line may still be useful at low passage for studying aspects of 
cyclase signalling, insulin action and the activities of other second messenger 
systems.
Indirect evidence has been provided for differences in cAMP 
phosphodiesterase activity between P9 cells and their native rat hepatocyte 
counterpai'ts. The nature of the cAMP degradation pathway depends on the cell 
phenotype and evidence has previously been presented that the complexity of 
this process may be greater in differentiated cells (Conti et al ,  1991). As P9 
cells are rapidly dividing and cAMP is inextricably involved in growth control 
(Roesler et a l ,  1988), there is good reason to expect differences in its 
regulation between the two cell types. The phosphodiesterases expressed in P9 
cells would merit fonnal investigation.
1.4 Cyclic AMP-specific Nucleotide Phosphodiesterases
The enzyme activity that catalyzes the hydrolysis and inactivation of 
cAMP and cGMP second messengers in cells is contributed by a family of 
cyclic nucleotide phosphodiesterases (PDEs). These elicit the hydrolysis of the 
3 ’ phosphate ester bond to give the corresponding 5’ nucleoside 
monophosphate, thus rendering the signal inactive (Butcher and Sutherland, 
1962). These isozymes are differentially expressed in individual cell types and 
are differentially regulated. Currently more than 30 different isozymes have 
been identified due to the presence of both multiple genes together with 
alternative splicing (Beavo et a l ,  1994; Bolger, 1994; Conti et a l ,  1995b; 
Houslay and Kilgour, 1990; Reeves and England, 1990).
1.4.1 Mutiple families of PDEs
Cyclic nucleotide hydrolysing PDEs exhibit distinct biochemical 
characteristics and can be divided into at least seven functional classes (Beavo et 
al,  1994; Conti et al,  1991) (Table 1.2).
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Table 1.2 Summary of cyclic nucleotide phosphodiesterase 
isoform s. »
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■Isoenzyme Type Effectors Substrate Specificity Selective Inhibitor
PDEl
formerly Type-I, 
Ga2+/CaM- 
stimulated PDE
Stimulated by 
calcinm/calmodulin
Differing Km for 
cAMP andcGMP 
depends on the 
tissue
vinpocetine
PDE2
formerly Type-II, 
cGMP-sîimulated 
PDE
cAMP activity is 
stimulated by low 
(pM) [cGMP]
riigh Km for both 
cAMP and cGMP
EHNA
PDE3
formerly Type-HI,
cGMP-inhibitied
PDE
cAMP activity is 
inhibited by low 
(pM)[cGMP]
Low Km for both 
cAMP and cGMP
miiiinone
cilostamide
amrinone
PDE4
formerly Type-IV, 
cAMP- 
specific PDE
: Specific for cAMP Low Km for cAMP 
only
rolipram
Ro20-1724
PDE5
formerly Type-V, 
cGMP-binding 
cGMP^speciflc PDE
Specific for cGMP 
located in the 
periphery eg. heart 
or lung
Isoforms with high 
and low Km for 
cGMP only
zaprinast
dipyridamole
PDE6
formerly Type-V,
Photoreceptor
PDE
Specific for cGMP 
Located in rods and 
cones of visual 
system
Micromolar Km for 
gGMP
dipyridamole
PDE7
formerly Type-VII, 
cAMP-specific 
rolipram-insensitive 
PDE
Specific for cAMP Very low Km for 
cAMP only
None reported 
Insensitive to 
rolipram and IB MX
'  : : :   : .____
(i) PDEl, which can hydrolyse both cyclic GMP and cyclic AMP and 
whose activity is stimulated by calcium/calmodulin (Ca^'^/GaM); (ii) PDE2 
hydrolyses cyclic AMP and cyclic GMP, with the activity being stimulated by 
micromolar concentrations of cyclic GMP; (iii) PDE3 specifically hydrolyses 
cyclic AMP in a manner which is inhibited by micromolar concentrations of 
cyclic GMP; (iv) PDE4 enzymes are cyclic AMP specific PDEs which are 
insensitive to cyclic GMP, and whose activity is attenuated by the selective 
inhibitor rolipram; (v and vi) PDE5 and PDE6 enzymes specifically hydrolyse 
cyclic GMP, but differ in their structure and tissue distribution; (vii) PDE7 
specifically hydrolyses cyclic AMP and is insensitive not only to cyclic GMP 
but also to the non-selective PDE inhibitor isobutylmethylxanthine (IBMX) and 
tlie PDE4 selective inhibitor rolipram.
The PDE enzyme family shows a diverse range of properties that are 
exemplified by their differential sensitivity such as responsiveness to 
phosphorylation i.e. can regulate PDEs by various kinases (Beltman et a l ,  
1993; Degerman e ta l ,  1990; Houslay and Kilgour, 1990; Kilgour e ta l ,  1989; 
Manganiello et al., 1990a; Pyne et a l ,  1989; Swinnen et a l ,  1989b); their 
inhibitor specificities and cofactor requirements (Degerman et a l ,  1990; Hall 
and Hill, 1992; Houslay and Kilgour, 1990; Moore et a l ,  1991; Reeves and 
England, 1990; Swinnen e ta l ,  1989b); their hormonal regulation (Conti e ta l ,  
1995b; Sette e t a l ,  1994b; Swinnen e t a l ,  1991); their differential expression 
patterns (Engels et al ,  1995; Engels et al ,  1994; Lobban et a l ,  1994) and their 
intracellular localisation (Lobban et a l ,  1994; Shakur et a l ,  1993). Members 
of this diverse family thus have the potential to modulate cyclic AMP 
metabolism to the specific requirements of the cell, including being able to 
integrate regulatory signals from phospholipid (DiSanto and Heaslip, 1995), 
tyrosyl (O'Connellefr//., 1996) and nitric oxide (Genaro eta l ,  1995) signalling 
pathways.
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1.4.2 Structure of cyclic nucleotide PDEs
It has become apparent that PDEs are multidomain proteins, with 
distinct catalytic and regulatoiy regions (Figure 16).
1.4.2.1 Catalytic domain of cyclic nucleotide PDEs
All the vertebrate and insect PDEs that have been isolated to date contain 
a putative catalytic domain, located in the carboyxl half of the protein, with 
approximately 30% amino acid identity (Beavo and Reifsynder, 1990). The 
catalytic domains of members of any one PDE class are more strongly related 
than those of any two different classes. As primary amino acid sequences have 
been determined, it has become clear that there is a conserved region of about 
270 amino acids (35kDa) present in nearly all PDE isoenzymes, displaying with 
typically 60 to 90% or greater homology between PDE families (Charbonneau 
et a l ,  1986). Outside the catalytic region, there is no region of sequence 
common to all PDE classes.
The conservation of this central 270 amino acid region led to the 
proposal that this was the catalytic domain, and this has been supported by a 
number of studies. The region was shown to contain a motif (Glu-Leu-Ala- 
Leu-Met-Tyr-Asn) which is also found in the regulatory subunits of cyclic 
AMP-dependent protein kinases and which has been suggested forms a cyclic 
AMP binding sequence motif (Scott, 1987). Limited proteolysis of different 
PDE isoenzymes, such as PDEl and PDE2, has revealed that the catalytic 
domains of these enzymes are distinct from their regulatory domains (Kincaid gf 
a l ,  1985; Stroop et a l ,  1989). A 35-40kDa fragment was produced in this 
way, which had a cyclic AMP hydrolysing activity, but could no longer be 
regulated by Ca^VCaM or cyclic GMP respectively. Furthermore, site-directed 
mutagenesis of residues within the conserved domain has revealed that selected 
amino acids in this central region are essential for catalysis (Jin et a l ,  1992). 
Among these are a number of invariant histidine residues found in PDEs 
obtained from divergent sources (Charbonneau, 1990; Charbonneau e t a l .
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Figure 1.6 SÆmnatie rejiresentat'O" of the catalytic and 
regulatory domains of cyclic nucleotide phosphodiesterases.
The diagram compares (from top to bottom), Ca^+/CaM stimulated, PDEl; 
cyclic GMP-stimulated, PDE2; cyclic GMP-inhibited, PDE3; cyclic AMP- 
specific, PDE4 and cyclic GMP-specific, PDE5. The black area indicates the 
consei*ved catalytic domain of about 270 amino acid residues between almost all 
PDEs. PDEl contains a CaM binding domain in the N-terminal region of the 
PDE (horizontal lines). PDE2 and PDE5 contain a homologous non-catalytic 
cyclic GMP binding domain (wavy-lined area). PDE3 has a 44 amino acid 
insert within its catalytic domain, unique to this class of PDEs. PDE4 is shown 
to contain upstream conserved regions (UCRl and UCR2) upstream of the 
conserved catalytic domain unique to this class of PDEs.
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1986; Francis et a i ,  1994). These amino acids appear to be important in 
sustaining enzymatic activity, as mutation of these residues abolished PDE 
activity (Jin e ta l ,  1992).
1.4.2.2 Regulatory domains of cyclic nucleotide PDEs
Members of each class of PDEs often share additional sequence motifs. 
These motifs are located in the amino termini of the protein and are generally 
postulated to have regulatory functions e.g. PDEl are regulated, at least in part, 
by a presumptive calmodulin-interaction domain near their N-terminal region 
(Charbonneau et ai ,  1991) and PDE2 are regulated by a cGMP-binding domain 
in the amino-terminal region of tlie protein. The interaction of PDE6 with their 
regulatory y-subunit is also believed to occur in their amino-terminal regions 
(Stryer, 1986; Chabre and Deterre, 1989). The cAMP-specific PDEs also 
contain two conserved amino-terminal regions, called upstream conserved 
regions 1 and 2 (UCRl and UCR2), which may have regulatory functions 
(Bolger, 1994; Bolger et al,  1996).
PDE2, PDE5 and PDE6 all possess a conserved domain which is 
separate from the catalytic domain and believed involved in cGMP-binding 
Charbonneau et a l ,  1989) (Figure 1,6). The degree of homology in this 
region is high (30% between PDE2 and PDE6) (Gillespie and Beavo, 1989; 
Stroop and Beavo, 1991). Studies using limited proteolysis on PDE2 have 
shown that cyclic GMP binding can be separated from the catalytic activity and 
is localised to a 60kDa chymotryptic fragment (Stroop and Beavo, 1991). 
PDE2 binds cyclic GMP with high affinity (Martins et al ,  1982) via both an 
allosteric domain and a catalytic domain (Charbonneau et a l ,  1986; Erneux et 
a l ,  1985; Yamamoto et a l ,  1983), This results in the display of complex 
kinetics due to actions mediated through the cyclic GMP-binding regulatory site 
(Erneux e ta l ,  1982; Manganiello e ta l ,  1990; Pyne e ta l ,  1986; Stroop e ta l ,  
1989). However, removal of the regulatory site by limited proteolysis has been
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shown to abolish the cooperativity of catalysis of cyclic AMP (Stroop and 
Beavo, 1992), This implies that the regulatory and catalytic domains are indeed 
separate.
1.4.3 Cyclic AMP specific PDE4
The cAMP-specific (PDE4) cyclic nucleotide phosphodiesterases 
(PDEs) are a diverse family of proteins that are important regulators of 
intracellular signalling (Beavo et aL, 1994; Conti et aL, 1991). Study of the 
stmctural and biochemical properties of the PDE4 isoenzymes may lead us to 
understand the PDE4 family and the functional basis of this diversity in the 
regulation of inti*acellulai* signalling.
1.4.3.1 Structural features and tissue expression of PDE4
Inspection of PDE4 cDNAs suggested that mammalian PDE4 aie coded 
for by four different genes, A, B, C and D (Davis et al ,  1989; Swinnen et al,  
1989a; Bolger et al ,  1993; Engels et a l ,  1994). Analysis of the amino acid 
sequences of the four rat (Figure 1^ 7) and human PDE4 reveals three distinct 
highly conserved regions. One of these conserved regions is the putative 
catalytic region (Jin eta l ,  1992), the two other regions, which are located in the 
amino-tenninal regions of the proteins, are called UCRl and UCR2 (Upstream 
Conserved Region). Although these regions are strongly conserved between 
organisms as evolutionarily divergent as prosophila inelanogaster and humans, 
they have no close homologues in any other sequences in the GenBank or 
EMBL data bases (Bolger et al,  1993). Additionally, UCRl, but not UCR2, 
undergoes alternative splicing (Bolger, 1994) suggesting that these conserved 
regions are likely to be important in the functioning or regulation of these 
proteins. For example, the different proteins encoded by various rat PDE4D 
mRNAs differ in their regulation by phosphoiylation (Sette et a l  1994) and
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Figure 1.7 Comparison of primary amino acid sequences of rat 
PDE4A. B. C and D.
The peptide sequences of rat PDE4 isoforms have been aligned. The PDE 
sequences are as follows from top to bottom: PDE4A (RDI) (Accession Nos: 
M26715, Jo4554); PDE4B2 (rat PDE4) (Accession Nos: M25350, M28413); 
PDE4C1 (RPDE36) (Accession Nos: L27061) and PDE4D1 (rat PDE3.1) 
(Accession Nos: M25349, M28412). * denotes an identical amino acid residue
shared in all sequences. The area of conseivation in the middle of the proteins, 
the catalytic domain (residues 220-500) and the two conserved regions N- 
terminal to this UCR2 (residues 176-200) and UCRl (residues 94-130), are 
also of note.
3 8
 a _ .........
- -
10
PDE4A1 PDE4B2 
PDE4Cl PDE4D1
PDE4A1PDE4B2PDE4C1PDE4D1
20 30 40
I
MPLVDF------------- ----------------------------- ----MKEQG— ----- GTVSGAGSSRGGGDSAMASLQ-------- PLQPNYLS
MIVTPFAQVLASLRTVRSNVAALAHGÂGSATRQALLGTP P Q S S QQAAP - MKEQP   SC-^AGTGHPSMAGYGRMAPFELAGGPVKRLRtESPF
50
I
60 70 80 90
•  M * FCETCSKPWL--- —— VGW------ —---- “”WDQFKRMLNVCLFAEESYQKLAMETLEELDWCLDQLETIQTYRSVSEMASNKFKRMLN AEESGLQLAQETLEELDWCLEQLETLQTRRSVGEMASNKFKRMLNPCLFAEEAYQKLASETLEELDWCLDQLETLQTRHSVSEMASNKFKRMLN
ICO 110 120 130 140
PDE4A1 RELTHLSEMSRSGNQVSEYISNTFLDKQNEVEIPSPTPRQRAFQQPPPS PDE4B2 RELTHLSEMSRSGNQVSEYISNTFLDKQNDVEIPSPTQKDREKKKKQ—PDE4C1 RELTHLSETSRSGNQVSEYISQTFLDQQAEVELPAPPTEDHPWP-^----PDE4D1 RELTHLSEMSRSGNQVSEYISNTFLDKQHEVEIPSPTQKEKEKKKRP—
150 160 170 180 190
PDE4A1 VLRQSQPMSQITGLKKLVHTGSLNTN-VPRFGVKTDQEDLLAQELENLSPDE4B2  QLMTQISGVKKLMHSSSLNNTSISRFGVNTENEDHLAKELEDENPDE4C1 ------- MAQITGLRKSCHTS-LPTAAIPRFGVQTDQEEQLAKELEDTNPDE4D1 ------- MSQISGVKKLMHSSSLTNSCIPRFGVKTEQEDVLAKELEDVN
200 210 220 230 240
I I I I I
" ' " I I '  I I  I •  I '  I I I I I . . . . . . . . . . . . . . . . . . . . . . . . . . .  '  I ' ' I I  ' I I ' 'PDE4A1 KWGLNIFCVSEYAGGRSLSCIMYTIFQERDLLKKFHIPVDTMMMYMLTL PDE4B2 KWGLNIFNVAGYSHNRPLTCIMYAIFQERDLLKTFKIS SDTFVTYMMTL P DE 4 Cl KWGLDVFKVAEL S GNRP LTAVIFRVLQERD LLKTFQIPAD TLLRYLLTL PDE4D1 KWGLHVFRIAELSGNRPLTVIMHTIFQERDLLKTFKIPVDTLITYLMTL
250 260 270 280 290
•  I ' "  M  I I . . . . . . . . . . . . . . . . . . . . . . . . . . I " "  I - - - - - - - - - - 1 . . . . . . . . . . . . . . . . . . . . . . . . . I ' "  I "  'PDE4A1 EDHYHADVAYHNSLHAADVLQSTHVLLATPALDAVFTDLEILÂALFAAA P D E 4 B 2 ED HYHS DVAYHNS LHAADVAQ S T HVLL S TPALDAVF TD LEILAAIFAAA 
PDE4C1 EGHYHSNVAYHN'SIHAADWQSAHVLLGTPALEAVFTDLEVLAAIFAGAPDE4D1 e d h y h a d v a y h n n i h a a d w q s t h v l l s t p a l e a v f t d l e i l a ATfA s a
300 310 320 330 340
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . I * 'PDE4A1 i h d v d h p g v s n q f l i n t n s e l a l m y n d e s v l e n h h l a v g f k l l q e e n c dPDE4B2 IHDVDHPGVSNQFLINTNSELALMYNDESVLENHHLAVGFKLLQEEHCD PDE 4 C1 i h d v d h p g v s n q f l i n t n s e l a l m y n d S SVLENHHLAVGFKLLQGENCD PDE4D1 IHDVDHPGVSNQFLINTNSELALMYNDSSVLENHHLAVGFKLLQEENCD
■350 360 370 380 390
I I I i  I
*  •  •  *  •  I I '  I  I "  I  •  •  •  I  •   . . . . . . . . . . . . . . . . . . . . . . . . . . I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .PDE4A1 IFQNLSKRQRQSLRKMVÎDMVLATDMSKHMTLLADLKTMVETKKVTSSG PDS4B2 IFQNLTKKQRQTLRKMVIDMVLATDMSKHMSLLADLKTMVETKKVTSSG PDE4C1 IF QNL S TKQKL S LRRMVIDMVLATDMS KHMS LLADLKTMVETKKVT S LG PDE4D1 IFQNLTKKQRQSLRKMAIDIVLATDMSKHMNLLADLKTMVETKKVTSSG
400 410 420 430 440
11PDE4A1 VLLLDNYSDRIQVLRNMVHCADLSNPTKPLELYRQWTDRIMAEFFQQGD PDE4B2 VLLLDNYTDRIQVLRNMVHeADLSNPTKSLELYRQWTDRIîpiEFFQOGD PDE4C1 VLLLDNYSDRIQVLQSLVHCADLSNPAKPL.P.LYRQWTERiiyiAEFFQQGD PDE4D1 VLLLDNYSDRIQVLQNMVHCADLSNPTKPLQLYRQWTDRIMEEFFRQGD
450 460 470
I
480
I
490
PDE4A1 RERERGME ISP MCDKHTAS VEK S QVGFID YI VHP LWET WADLVHP D AQD PDE4B2 KERERGMEIS P MCDKHTAS VEKS Q VGFT D YT VHP LWE T WAD LVQP D AQD 
PDE4C1 RERE S GLDIS PMCD KHTAS VEK S QVGF ID YIAHP LWE T WAD LVHP D AQE PDE 4 D1 RERERGME ISPMCDKHNAS VEK S QVGF ID YIVHPLWETWADLVHPD AQD
500 510 520 530
I IPDE4A1 ILDTLEDNRDWYHSAIRQSPSPPLEEEPGGLGHPSLPDKFQFELTLEEE PDE4B2 ILDTLEDNRNWYQSMIPQSPSPPPDE4C1 LLDTLEDNREWYQSRVPCSPPHAIG------------PDRFKFELTLEETPDE4D1 ILDTLEDNREWYQSTIPQSPSPAPDDQEDG— RQGQTEKFQFELTLEED
540
I
550 560 570 580
•  I •  1 •  I *  ! I I I I I  I '  I . 1  " I IPDE4A1 EEEDSLEVPGLPTTEETFLAAEDARAQAVDWSKVKGP STTWEVAERLK PDE4B2PDE4C1 EEEEEEDERHPDE4D1 GESDTEKDSGSQVEEDT— SCSDSKTLCTQ—  -DSESTEIPLDEQVE
590 600 610
I
620
I
630
PDE4A1 QE TASAYGAP QE SMEAVGC SFSPGTPILP DVRT LS S S EEAP GLLGLP S TPDE4B2PDE4C1PDE4D1 EEAVAE---------------------------- - ---------------- -
640 650 660 670
PDE4A1 AAEVEAPRDHLAATRACSACSGTSGDNSAIISTPGRWGSGGDPAPDE4B2PDE4C1PDE4D1  EESQPQTGVADDC— CPDT
those encoded by different rat PDE4A transcripts differ in cellular localization 
and activity (Bolger et al,  1996).
(a) PDE4A:
The full length cDNA encoding RDI (PDE4A1) was isolated from a rat 
brain library by homology cloning using the dune cyclic AMP PDE gene and 
expressed in yeast (Henkel-Tigges and Davis, 1989). This enzyme is 
specifically expressed in brain and may be involved in mood regulation 
(Henkel-Tigges and Davis, 1989).
Comparison of the sequences of RDI with the dunce-like cyclic AMP 
PDE4B1 (DPD) and the Drosophila dunce PDE (Davis et al., 1989) has 
identified a central region which is well conserved among these enzymes 
(approx.75%). However in RD I, over the C-terminal region of approx. 170 
amino acids and an N-terminal region of approx. 25 amino acids there is very 
considerable heterogeneity (> 90%). The possibility that the unique N-terminal 
region of RDI provides a domain which confers functional attributes upon this 
enzyme has been explored (Shakur et ai ,  1993). When transiently expressed in 
COS-1 cells then both the full-length RDI and an N-terminal truncated form 
(Met^^-RD I) was produced. Of these, the full length RDI was found to be 
exclusively membrane-associated with Met^^^'RDl being located exclusively in 
the cytosol fraction. These species also showed a marked difference in their 
thermostability. Thus, the N-terminal alternatively spliced region of RDI 
appears to serve as a signal for membrane association and also confers 
enhanced thermostability upon this PDE4A enzyme. That the unique N- 
terminal 25 amino acid domain of RDI is responsible for determining 
membrane association was confirmed by showing that it could direct the 
normally soluble, cytosolic enzyme CAT (chloramphenicol acetyltransferase) to 
the identical membrane locality as RDI (Scotland & Houslay, 1995). Thus, the 
N-teiminal domain of RDI contains structural information that targets proteins
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to the membrane. Furthermore, immunoblot analyses done with a PDE4A 
specific anti-semm also identified RDI as a membrane bound protein species 
upon immunoblotting of cerebellum homogenates in rat brain (Shakur et al ,  
1995). COS cells transfected with RDI cDNA showed RD I to be 
predominantly localized to plasma membranes but also associated with the 
Golgi apparatus and intracellular vesicles. Pooley e t a l ., (1996 submitted) also 
showed that stable transfection of RD I into thyroid FTC-133 cells led to 
localisation exclusively in the Golgi apparatus.
A second rat PDE4A transcript, rPDE6 cDNA, is also expressed in 
brain. This is a protein of 844 amino acids that is present in both particulate and 
cytosolic forms (Bolger et al ,  1994; McPhee et al ,  1995). Furthermore, 
analysis of brain regions shows that the expression patterns for RDI and rPDE6 
are very different (Bolger et al ,  Shakur et al,  1995), perhaps suggestive of 
distinct functional roles for these two species. Recently, a further alternatively 
spliced mRNA transcript from the rat PDE4A locus, called rPDE39 has been 
identified (Bolger et al,  1996). This is a rolipram-inhibited, cAMP-specific 
PDE of 763 amino acids that is found in both particulate and cytosolic forms. 
rPDE39 (Figure 1.8) has a structure consistent with alternative splicing at its 
extreme 5' end. When expressed in COS cells it migrates as a ~98kDa protein 
and a very similar size, of -;97kDa, is seen on immunoblotting of testis extracts. 
This tissue-specific distribution of the rPDE39 protein suggests that this PDE4A 
isoform has a specific functional role. Indeed, the highly distinct expression 
patterns of all PDE4A isoforms suggests that alternative splicing leads to the 
expression of proteins with specific functional roles in the cells that they are 
expressed in.
(b) PDE4B:
Splice variants of the PDE4B locus are targeted to different regions of 
rat brain (Lobban et a l ,  1994), indicating that differential splicing may
4 0
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Figure 1.8 Comparison of primary amino acid of rat
PDE4A splice variants.
The peptide sequences of rat PDE4 isoforms have been aligned. The PDE 
sequences are as follows from top to bottom: RDI (Accession No: M26715); 
rPDE39 (Accessopm No: L36467); rPDE6 (RPDE36) (Accession No: 
L27057). «denotes an identical amino acid residue shared in all sequences. *
denotes amino acid residues unique to the N-terminal of PDE6. Residues 
underlined are expressed only in the PDE isoform indicated.
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contribute to tissue specific-as well as subcellular-localisation of these enzymes 
(Houslay e ta l ,  1995). Analysis of the PDE4B gene (Monaco et al 1994) has 
shown that PDE4B1 (DPD) and rat PDE4B2 ("pde4") are splice variants of the 
same gene. From comparison of the protein sequences it can be seen that rat 
PDE4B2 has an extended N-terminus of 48 amino acids (Figure 1.7). It is 
possible, however, that products larger than PDE4B1 can be transcribed 
according to which methionine initiation codon is utilised. However, Lobban gr 
aLy (1994) have shown that PDE4B1 and rat PDE4B2 are likely to be the only 
products in vivo of the PDE4B gene, given that only one immunoreactive 
species was detected with the antisera specific for rat PDE4B2 and one which 
recognised rat PDE4B1/PDE4B2. Functional and tissue specific expression of 
PDE4B isoforms have been demonstrated in the rat brain (Lobban et al,  1994). 
PDE4B1 was found to be exclusively cytosolic and was selectively expressed in 
hippocampal, coitex, hypothalamus and striatum regions. Rat PDE4B2 on the 
other hand was located at the membrane of all brain regions with the exception 
of the midbrain (Lobban e t a l 1994).
(c) PDE4C:
Compared with the products of other PDE4 genes, PDE4C shows a 
very restricted distribution, for only two sequences coiTesponding to this gene 
have been found to date, one each in rat and human tissue (Swinnen et al ,  
1989; Bolger et al,  1993). This mRNA is found in testis (Swinne et al,  1989) 
but there are few or no transcripts in brain (Bolger et al ,  1994); Recently, 
Obernolte eta l ,  (1996) have identified four PDE4C splice variants by analysis 
of cloned human cDNAs from foetal lung and testis. The possibility of tissue- 
specific PDE4C isoforms and non-catalytic proteins should be considered in 
evaluating how PDE4C may modulate cellulai* responses to cAMP.
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(d) PDE4D:
The pattern of expression of multiple variants from rat PDE4D gene 
(Monaco et al,  1994; Sette et al,  1994) has shown that the heterogeneity of the 
different mRNAs lies in the 5’-region. The corresponding protein variants 
contain a common region encoded by exons 2 to 11 (Monaco et al,  1994) and 
divergent amino-terminal regions derived from the assembly of different 
upstream exons (Sette et al,  1994). The rat PDE4D1 and PDE4D2 mRNAs are 
generated by a start site controlled by an intronic promoter, which has been 
shown to be activated in Sertoli and FRTL-5 cells (Vicini et al,  1994). Another 
variant rat PDE4D3, detected in the brain and FRTL-5 cells, derives from the 
activity of a different promoter and transcription of upstream exons (Sette etal ,  
1994a). A fourth variant (PDE4D4) was also detected in human (Bolger et al ,
1993) and rat (Vicini and Conti, unpublished results), suggesting the presence 
of a third, distinct promoter. Human PDE4D1, PDE4D2 and PDE4D3 have 
been transiently expressed in human kidney 293 cells (Nemoz et al., 1996). A 
72kDa protein was expressed in cells transfected with PDE4D1 cDNA, a novel 
67kDa protein in cells transfected with PDE4D2 cDNA and a 93kDa protein for 
cells transfected with PDE4D3 cDNA (Nemoz et a l ,  1996). Therefore, 
recombinant human PDE4D2 and PDE4D3 proteins have molecular weights 
identical to those previously determined for the corresponding rat isoenzymes 
(Sette et al,  1994b).
Interestingly human PDE4D1, PDE4D2 and PDE4B (PDE4 splice 
variant) lack the UCRl (upsteam conserved region), a region of high homology 
with the drosophila dunce PDE sequence, which is present at the N-terminus in 
human and rat PDE4D3 and other PDE4 variants (Conti et al,  1995b, Bolger et 
al,  1993; Sette et al,  1994b), this might suggest an important function for the 
region encoded by this sequence (Bolger et al ,  1993). However, the existence 
of PDEs lacking this region in both rat and human, indicates that it is not 
essential for catalysis. The UCRl region may play a role in the regulation of
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enzyme activity and, indeed, the consensus site for PKA-mediated 
phosphorylation in rat PDE4D3 which confers activation of this enzyme resides 
witliin this region (Sette and Conti, 1995).
The complexity of the PDE4 family is apparent from the existence of 
over twenty splice variants discovered to date (Bolger, 1994). The importance 
of such a large family could be to enable cells to maintain a high degree of 
regulation on cyclic AMP degradation. Each PDE4 locus appears to have 
distinct tissue distribution, suggesting that these alternatively spliced transcripts 
have specific and subtle differences in regulation and sub-cellular targetting of 
samples.
' É
1.4.3.2 Cellular Regulation of cyclic AMP specific PDE4
It has been well established that cyclic AMP is at the centre of the 
control of many cellular functions, therefore enzymes involved in the 
metabolism of cyclic AMP, such as the PDE4 family, are poised to play a 
crucial role in these functions.
(a) Regulation of cyclic AMP PDE by hoitnones:
Many hormones exert their actions on target cells by elevating the 
intracellular concentration of cAMP. Glucagon through its second messenger 
cyclic AMP, stimulates both glycogenolysis and gluconeogenesis in 
hepatocytes, whereas insulin can sei*ve to antagonize this action by presumably 
depressing intracellular cyclic AMP concentrations (Loten and Sneyd, 1970).
The only known mechanism for the degradation of cyclic AMP is by the 
action of phosphodiesterases; these therefore provide potentially important 
regulatory sites. Evidence consistent with this has come, for example, from 
studies on hepatocytes. In these cells, a gentle homogenization procedure 
followed by a rapid subcellular fractionation of hepatocytes on a Percoll 
gradient was developed (Heyworth et al ,  1983) to resolve subcellular 
membrane fractions and identify associated cyclic AMP PDEs. Using such a
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procedure, at least three, high-affinity cyclic AMP PDEs species were found to 
be activated by insulin in hepatocytes (Heyworth et al ,  1983 and 1984). 
However, only one of these enzyme activities, the so-called 'dense-vesicle' 
PDE, which is located in a unique intracellular vesicle fraction, was also 
stimulated by glucagon (Heyworth et al ,  1983). Indeed, this enzyme is the 
only PDE identified in liver that is known to be stimulated by glucagon. 
Phosphoiylation of the 'dense-vesicle' PDE by protein kinase A was shown by 
Kilgour and co-workers (1989). This 'dense-vesicle' enzyme is a PDE3, 
cAMP-specific enzyme. Its ability to be rapidly regulated by protein kinase A 
action and by insulin is typical of this enzyme family, as has been shown in 
detail by Manganiello eta l ,  (1990) for adipocytes.
The so-called peripheral plasma membrane PDE was also activated by 
insulin. From in vitro studies, it appeared that this enzyme became 
phosphorylated through a cAMP mediated pathway since it was demonstrated 
that cAMP, as well as ATP, were required for the insulin activation of the 
{TOejfoijfRne. PDE. Furthermore, inhibitors of cAMP-dependent kinase 
blocked the insulin activation of the PDE activity (Pyne et al,
1989). However, studies done in intact cells indicated that this enzyme may be 
tyrosyl phosphorylated (Pyne et al ,  1989), indicating differences in the 
regulation seen in intact cells. This peripheral plasma membrane enzyme ‘15 
inhibited by Rol724 and appears to be a PDE4 enzyme, although the subtype is 
unclear. Furthermore, it was also noted that cholera toxin served to mimic the 
insulin-stimulated phosphorylation event (Heyworth et al,  1983) suggesting 
that the action of a guanine nucleotide regulatory protein could regulate this 
enzyme.
It is clear that at least two phosphodiesterase isozymes play key roles in 
the hormonal regulation of glycogenolysis in the liver. The stimulation of 
PDE3 enzymes by glucagon contributes to the transitory nature of the glucagon 
stimulated rise in cAMP and both a PDE3 and PDE4 enzyme mediate the ability
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of insulin to lower intracellular cAMP levels. However, insulin's activation of 
these two enzymes cannot account in full for the ability of insulin to decrease 
intracellular cyclic AMP concentrations (Heyworth et al,  1983) suggesting that 
additional enzyme(s) must be activated by a rapidly reversible process. In 
hepatocytes, the so-called cyclic GMP-activated cyclic AMP phosphodiesterase 
(Pyne et al ,  1988), but not the other insulin-regulated phosphodiesterases, is 
activated by a soluble 'mediator' preparation (Pyne et al,  1988).
(b) Up-regulation of cyclic AMP specific PDE4 activity by intracellulai' cAMP:
The activity of certain subtypes of PDE4 (4A-4D) can be increased in 
situ by eitlier a short term regulatory process involving protein phosphorylation 
or by a long term regulator process involving increased gene expression (Conti 
et a l ,  1991; Sette et al ,  1994a and 1994b). Both of these regulatory 
mechanisms are cAMP-dependent and can be triggered by a variety of activators 
of adenylyl cyclase (Bourne et al ,  1974; Conti et al ,  1991; Torphy gf al,  
1992). This raises the possibility that*PDE4 activity can be regulated in vivo by 
various hormones, drugs, and growth factors (Conti et al,  1991).
In the FRTL-5 thyroid cell line PDE4 activity is elevated in response to 
thyroid stimulating hormone (TSH), which is known to elevate intracellular 
cyclic AMP (Sette et a l ,  1994a). This hormone dependent cyclic AMP 
regulation in FRTL-5 cells involves an initial rise in cyclic AMP which returns 
to basal level within minutes. This return to basal occurs despite the constant 
presence of hormone, due to an activation of PKA and subsequent 
phosphorylation and activation of PDE4D. This investigation demonstrated that 
splice variants from the same locus could be differentially regulated on 
stimulation of the cell by a particulai’ homioiie (Sette ef al,  1994b). Differential 
regulation led to short-term activation of PDE4D3, via changes in 
phosphoi-ylation status and long-term regulation by stimulating de novo protein 
synthesis of two other splice variants PDE4D1 and PDE4D2. In addition
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agents that elevate cyclic AMP has also been demonstrated to cause to an 
increase in rat PDE4D3 expression in immature Sertoli cells on stimulation with 
follicle stimulating hormone (FSH) (Monaco et a l ,  1994; SQiiQ e ta l ,  1994a; 
Swinnen e ta l ,  1991) and in cardiac myoblasts (Kovala e ta l ,  1994).
Also in the U937 human monocyte cell line it has been shown that the 
up-regulation of PDE activity by agents tliat elevate cyclic AMP content was due 
to an increase in PDE4 alone (Torphy et al,  1992). Recently, when they used 
prostaglandin E2 (PGE2), an agent that activates adenylyl cyclase by a non-p- 
adrenoceptor-mediated mechanism, then after 4h treatment, cAMP accumulation 
was substantially decreased in cells in which PDE4 activity had been up- 
regulated (Torphy et al ,  1995). The difference in PGE2-stimulated cAMP 
accumulation between control and PDE4 up-regulated cells was greatly reduced 
in the presence of rolipram, consistent witli the notion that an increase in PDE4 
activity was responsible for the heterologous desensitization. Furthermore, 
Manning and co-workers (1996) showed that prolonged p-adrenoceptor 
stimulation increased PDE activity in monocytes. This was due to the up- 
regulation of PDE4. At least two of the four subtypes which were are up- 
regulated in blood monocytes were PDE4A and PDE4B (Manning et al, 1996).
Clearly PDE4 enzymes are extremely important for the regulation of 
cyclic AMP signalling pathway and this regulation process is mediated by 
cAMP-dependent protein kinase A.
(c) Phospholipid regulation of cyclic AMP specific PDE4:
There is also evidence for activation of PDE4 via interaction with the 
phospholipid signalling system. Marcoz et al ,  (1993) demonstrated that in rat 
thymocytes, physiological concentrations (lOpg/ml) of mixed phosphatidic acid 
(PAs) species increased the activity of two subtypes of PDE4. DiSanto and 
Heaslip (1993) reported the seperation of two PDE4 species from U937 cells 
(referred to as Peak 1 and Peak 2 PDE4), and found that the Peak 2 PDE4 was
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activated by phosphatidic acid (PA) (DiSanto and Heaslip 1994). Further 
studies (1995) were conducted to determine that rolipram's effectiveness versus 
Peak 2 PDE4 depended on the state of activation of the PDE by phosphatidic 
acid. Other phospholipids, such as lysophosphatidic acids (LPAs) and 
phosphatidylseiines (PSs) were also found to activate "Peak 2 PDE4" (DiSanto 
and H easlip  1995). H ow ever, phosphatidy lcho lines (PCs), 
phosphatidylethanolamines (PEs) and diacylglycerol (DAG) did not activate 
PDE4 (DiSanto & Heaslip 1995). It has also been demonstrated that exogenous 
PA could not stimulate either PDE2 or PDE3 preparations which had been 
partially purified from rat thymocytes, and that neither PDE 1 from porcine brain 
nor PDE3 from rat adipocytes were sensitive to modulation by PA or PS 
(Marcoz eru/., 1993; Macaulay u/., 1983; Wolff and Brostrom, 1976). Little 
information, however, is available as to whether human PDE4 is regulated by 
phospholipids in cells or whether such regulation would be produced 
specifically by individual phospholipid species. It has been suggested that 
phospholipid-induced PDE4 activation may represent a mechanism for rapid 
stimulus-specific modulation of PDE4 activity and hence cyclic AMP 
concentrations in cells expressing phospholipid-sensitive PDE4 isoforms 
(DiSanto e ta l ,  1995),
(d) SH3 domain interaction witli PDE4A:
The N-tenninal domain of tlie PDE4A family appears to have a variety 
of functional roles such as membrane targeting (Shakur et al, 1993; Scotland 
and Houslay, 1995; Shakur et al ,  1995; McPhee et al,  1995), regulation of 
enzyme activity (Vmax) (Shakur et al ,  1995; McPhee et al ,  1995) and 
conferring susceptibility to phosphorylation by protein kinase A (Monaco eta l ,
1994). The N-terminal splice region of rPDE6 is rich in both proline and 
arginine residues. This is characteristic of proteins able to interact with Src 
homology 3 (SH3) domains (Pawson and Gish, 1992; Mayer and Baltimore,
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1993; Terasawa et al,  1994; Musacchio et al,  1992), SH3 domains have been 
identified in a variety of cytoplasmic tyrosyl protein kinases as well as in 
cytoskeletal and adaptor proteins (Pawson and Gish, 1992; Mayer and 
Baltimore, 1993; Terasawa <7/., 1994; Miisacchio cr/., 1992). These SH3 
containing proteins perform a crucial role in recruiting specific proteins so that 
they can take part in signalling cascades and also in conferring distinct 
subcellular localisations upon proteins which bind to them (Pawson and Gish, 
1992; Mayer and Baltimore, 1993; Terasawa et al ,  1994; Musacchio et al,  
1992). O'Connell et al ,  (1996) have shown that rPDE-6 can bind to the SH3 
domain of v-Src by virtue of its N-terminal splice region. This provides the 
first direct connection between an enzyme involved in the cyclic AMP signalling 
pathway and SH3 domain expressing proteins and identifies selectivity in this at 
the level of both the particular SH3 domain species and the particular PDE4A 
splice variant (O'Connell et al ,  1996).
1.4.3.3 Inhibition of cAMP specific PDE4
Rolipram is a potent and selective inhibitor of PDE4 and has been 
reported to inhibit PDE4 from different cellular sources (Henkel-Tigges and 
Davis, 1990; McLaughlin et al ,  1993; Nemoz et al ,  1989; Torphy et al ,  
1992). Rolipram is known to interact with PDE4 in at least two distinct 
fashions: either by binding to high affinity binding sites at very low 
concentrations (Kd=0.4 to 6nM) or by a lower affinity interaction (Ki=0.06 to 
IjLiM) which is presumed to occur at the enzyme catalytic site (Schneider et al,  
1986; Torphy et al., 1992). In general, rolipram’s inhibition of cAMP 
catabolism by PDE4 has been correlated only with rolipram's low affinity 
interaction (Torphy eta l ,  1992).
The association of PDE4 hydrolytic activity and rolipram binding raises 
the question of the molecular relationship between the antagonism of rolipram 
binding and inhibition of PDE4 activity. Several studies have shown (Pinto et
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a i ,  1993; Barnett et a l,  1995; Jacobitz g? u/., 1994) that there is a lack of 
correlation between rolipram binding and PDE4 inhibition. Enzyme kinetic 
studies have, however, implied that the binding site for rolipram and the active 
site of cAMP hydrolysis may be identical. Although it cannot be excluded that 
the high-affinity binding site is located on the same protein as the PDE4 
hydrolytic activity.
1.5 Cyclic AMP dependent protein kinase (PKA)
Cyclic AMP-dependent protein kinase (PKA) has been found to be the 
only protein, apart from cyclic AMP phosphodiesterases, that binds cyclic AMP 
with high affinity, in eukaryotic cells. This has led to the suggestion that all the 
downstream effects o f cyclic AMP are mediated through protein 
phosphorylation via PKA (Taylor etal., 1990).
1.5.1 Structural and tissue distribution of PKA isoforms
PKA exists as two major isoforms, type-1 and type-II, that differ with 
respect to their regulatoiy (R) subunits, as identified by their differing molecular 
weights, antigenicity, amino acid sequence and affinity for cyclic AMP 
analogues. Isotypes of each of these regulatory domains have also been 
identified; RI (a  and p) and RII (a  and P) subunits, as well as the catalytic (C) 
(a , p and y) subunit (Figure 1.9). Expression of these isoforms varies 
between tissues, with type-II PKA being present in all cells, whereas the tissue 
distribution of type-I PKA is more restricted (Corbin et al., 1977; Rubin et al., 
1972). Intracellular localisation also varies, with RI isoforms found primarily 
in the cytosolic compartment of the cell, although a fraction has been found 
associated with the membranes of erythrocytes (Rubin et al., 1972) and 
associated with the T cell receptor of activated lymphocytes (Skalhegg et al.,
1994). The RII isofonns are generally particulate, with up to 75% of the
5 0
- -  :   :  ,
’Figure 1.9 Diagrammatic representatibn of protein kinase A
RI and RII; Regulatory subunits 
C; Catalytic subunits
cAMP; Adenosine 3', 5' cyclic monophosphate
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cellular RII pool being associated with the plasma membrane and cytoskeletal 
compartments (Nigg e/a/., 1985; Salavatori er <?/., 1990).
In all eases, the inactive holoenzyme form of PKA is a tetrameric 
conformation, consisting of two R subunits and two C subunits (R2C2) (Taylor, 
1989) (Figure 1.9). High affinity binding of 4 molecules of cyclic AMP to 
the R subunits, activates the complex by dissociation of the two catalytic 
subunits from the R subunit dimer (Beebe and Gorbin 1986), thereby, liberating 
the catalytic subunits to phosphorylate substrate proteins or to migrate to the 
nucleus (Nigg, 1990). This can be summerised in the reaction scheme:
R2 C2  + 4 cyclic AMP-— R2 • (cyclic'AMP)4  + 2C 
Studies have shown that the RII subunit has an additional function, namely the 
localisation of PKA (Scott, 1991).
The active catalytic subunits are able to phosphorylate their 
physiological substrates (serine in the context X-R-R-X-S-X) within a number 
of cytoplasmic and nuclear proteins. Both catalytic and regulatory subunits 
have been postulated to have a role in the transcriptional regulation of cyclic 
AMP-responsive genes (Lalli and Sassone-Corsi, 1994). However it appears 
that the catalytic subunits are both necessary and sufficient for this response.
1.5.2 Phosphorylation of target proteins by PKA
In order to perform specific phosphorylations that are necessary in the 
tight regulation of cellular metabolism one might expect that the activation of a 
kinase would be compartmentalised, in some way, to ensure targeting and 
specificity of phosphorylation of the desired substrate. The proposal of 
selective activation of PKA-pools, which are co-localised with key substrates, 
may provide the opportunity for this to occur. The type-I PKA isoenzyme has 
shown to be associated with the TCR/CD3 complex upon TCR ligation 
(Skalhegg et aL, 1994). Interestingly, the binding of cAMP to the inactive 
PKA R2C2 holoenzyme, much of which is anchored in the perinuclear region
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of the cytoplasm through membrane-associated anchoring proteins (known as 
AKAPs) (Scott and Carr, 1992), releases the active C subunit, which is then 
competent to phosphorylate its substrates on a single serine residue (ser 133). 
This phosphorylation results in increased transactivation activity, without a 
significant effect on GREB DNA-binding activity (discussed in the later 
section). The extent of ser-133 phosphoiylation correlates directly with the rate 
of transcription of cAMP-responsive genes (Hagiwara et ai, 1993)
A number of different AKAPs specific for type-II PKA have been 
identified in the literature by virtue of their molecular weights, subcellular 
localisation and differential hormone induction (Garr et aL, 1993; Garr et a l,  
1992; Keryer et al., 1993; McCartney et «/., 1995). Interestingly, these 
AKAPs do not appear to anchor PKAII alone, but have recently been reported 
to bind the protein phosphatase calcineurin (Goghlan et a l ,  1995). It has been 
noted that the first 5 amino acids of each RII subunit are critical for AKAP 
interaction (Hausken et a l ,  1994). However, it appears that AKAPs contain 
additional binding sites, possibly responsible for targeting them to cellular 
structures, such as DNA binding domains (Goghlan et a l ,  1994) and 
cytoskeletal binding domains (Glantz et a i,  1993). This added control coupled 
to a dynamic system, may allow the redistribution of PKAII to occur in 
response to external stimuli. The ability of signalling molecules to be grouped 
around AKAPs (Goghlan et a l ,  1995) may allow tight regulation of the 
phosphorylation state and thus activity of key substrates.
1,5.3. Modulation of transcription factors by PKA
As discussed above, binding of cyclic AMP to the PKA-holoenzyme 
causes the dissociation of the two regulatory subunits from the two active 
catalytic subunits (Krebs and Beavo, 1979; Taylor, 1989). The catalytic 
subunits are now free to phosphorylate serine/threonine residues of target 
proteins. Indeed, a fraction of this subunit population translocates into the
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nucleus, apparently through passive diffusion, where it phosphorylates its 
nuclear targets. Lalli and Sassone-Corsi, (1994) showed one of the major 
nucleai" PKA substi'ates to be the transcription factor CREB (cAMP responsive 
element binding protein). CREB binds to a palindromic response element 
(TGACGTCA), known as the cAMP-regulated enhancer (CRE), in cAMP- 
inducible genes. Thus the modulation of transcription factor activities, such as 
CREB or activation transcription factor (ATE) families, is thought to occur via 
phosphorylation. GREB/ATF proteins are the targets for several protein 
kinases including PKG and PKA, with phosphorylation of these factors 
stimulating or repressing transcription (de Groot et a l,  1993; Yamamoto et a l,
1988). Different forms of GREB/ATF proteins bind to different GRE sites, or 
even the same sites, with differing affinities following phosphorylation by such 
kinases.
GREB/ATF regulatory proteins are characterised by a leucine-zipper 
domain and a basic DNA binding domain that recognise the GRE site. These 
proteins have an important role in regulating basal gene transcription or induced 
gene transcription in response to cyclic AMP elevation. This family of 
transcription factors also share a certain degree of homology with members of 
the activator protein-1 (AP-1) family, Fos/Jun proteins. Indeed, hetero- 
dimerisation can occur between the families as well as homo-dimerisation, 
which creates enormous complexity, leading to a higher order of regulation, 
involving cross-talk between lipid and cyclic nucleotide signalling at the level of 
gene transcription (Altschul e ta l ,  1990; Hai and Gurran, 1991; Landschulz et 
a l ,  1988).
Attenuation or inhibition of cyclic AMP-stimulated gene transcription 
requires dephosphorylation of transcription factors to occur, representing a key 
mechanism in the negative regulation of GREB activity. It appears that protein 
phosphatase 2A (PP2A) and protein phosphatase 1 (PPl) oppose the action of 
PKA (Hagawara e ta l ,  1992; Wadzinski e ta l ,  1993).
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Another class of transcription factors involved in the transduction of 
cyclic AMP effects on transcriptional regulation are CRE-modulators (CREM) 
(Meyer and Habener, 1993). The complexity of the CREM protein repertoire is 
enhanced by alternative splicing mechanisms giving rise to various forms of 
CREM which can be activators or repressors of transcription (Foulkes and 
Sassone-Corsi, 1992).
1.6 Perspectives of the protein kinase C family in ceil regulation
Activation of PKC is an early event in a wide range of signal 
transduction processes. However, PKC" "activity" in represented by a large 
gene family of isoenzymes differring remarkably in their structure, expression, 
mode of activation and in substrate specificity (Parker, 1994; Nishizuka, 1992, 
Hug and Sarre, 1993). The role of specific PKC isoenzymes has yet to be fully 
elucidiated.
1.6.1 Classification of PKG isoenzymes
The division of the PKC family into subfamilies is based on the primary 
structure of the polypeptides and the implications of this on functional similarity 
within subfamilies have been discussed extensively (Nishizuka, 1992; Hug and 
Sarre, 1993). From early biochemical studies and purifications (Huang et al, 
1986a), PKC would seem to represent a gene of at least three isoforms a , (3, y. 
So far, however, the cDNAs coding twelve different PKC isoforms from 
different species and tissues or cell lines have been identified (Nishizuka, 1992; 
Asaoka et al,  1992; Parker et a l,  1989; Hug and Sarre, 1993). These can be 
divided into Ca^+-dependent or conventional cPKCs (a, (31, (311, y) and the 
Ca^+-independent or novel nPKCs (ô, e, rj, 6) (Ohno et a i, 1990). PKC-Ç 
constitutes what could be considered a separate branch (Parker et ai, 1994) as 
shown in Figure 1,10. PKC-i (Bacher et al., 1991 and 1992), X and fi have 
not been included in the dendrogram as no sequence data are available.
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Figure 1.10 Phylogenetic relationships between mammalian PKC
i$My-PJg_S
The diamond represents a common PKC ancestor. Evolutionary distance (bar, 
10% difference) is based upon alignment of the amino acid sequence of the PDE 
isotypes using the GCG multiple sequence alignment program.
Adapted from Dekker and Parker, 1994.
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However, it has been suggested that PKC“|i is a member of the PKC-6 , e, rj, 0 
subfamily whilst PKG-i and X are related to PKC-Ç (Dekker and Parker, 
1994).
1.6.2 Activation of PKC
Activation of cPKC is achieved in stimulated lipid metabolism, i.e. in 
signalling by phospholipases and phosphatidylinositol kinases (Meldrum et al,
1991). For the cPKCs, a model of activation was sufficient and convincing that 
included (1) the generation of DAG and Ins (1,4,5) P3 from plasma membrane- 
associated Ptdlns (4,5) P2 by the action of phospholipase C. Hormones such 
as glucagon, vasopressin and angiotensin which all elicit a rapid, transient 
increase in hepatocyte PKC activity (Tang and Houslay, 1992) act by this route.
(2 ) the release of Ca^+ from intracellular storage sites stimulated by 
I n s ( l ,4 ,5 )P 3 , (3) the binding of Ca^+ to (the C2 region of) PKC and 
subsequent translocation of the enzyme to the plasma membrane, (4) Activation 
at the plasma membrane (via the C l region) by DAG and PtdSer, the latter 
being constitutively present in the membrane (Bell and Burns, 1991). PKC is 
also known to act as a direct "receptor" protein and can be activated by phorbol 
esters; substances known to interfere dramatically with proliferative and 
differentiation events by promoting oncogenic transformation of cells in vivo in 
situ. In this model, phorbol ester would mimic the action of DAG and, by its 
persistence in the cellular membrane, lead to a long-term activation of PKC 
(Gschwendt et al, 1991).
On the other hand, nPKC show cofactor Ca2+-independence, whilst 
PKC-Ç is not activated by phorbol ester/DAG. Such behaviour is of great 
interest since it indicates that the signal transduction pathways in which PKC 
isotypes may be involved in vivo are not restricted to those leading to the 
generation of DAG but might also include those that activate the 
phosphatidylinositol 3-kinase (PI3-kinase) pathway. In addition controversy
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suiTounds the question (Farese ef a/., 1992; Glynn et aL, 1986; Vaartjes et ai,
1986) of whether insulin-induced increases in DAG result in PKC activation. 
However, there is now considerable evidence that DAG derived from 
phosphatidylcholine (PC) hydrolysis (Laviada et a l,  1991) and the de novo 
pathway (Lee et al., 1989) can ti'anslocate and activate PKC.
Recently it has been shown that other components of glycerolipid 
metabolism can be activators of PKC, at least in vitro (Lee and Bell, 1991; 
Chahan et a l,  1991). Cytokines such as IFN-% IL-1 and IL-3 which have 
been reported to induce phosphatidylcholine hydrolysis, but not inositol 
phospholipid turnover (Duronio et al., 1989) can activate PKC p and e. Thus, 
the signal-induced production of a distinct second messenger or activator may 
actually decide which PKC is activated and indeed the activation potency of 
different phorbol ester derivatives on PKC isoenzymes reveals quite distinct 
differences. {Ryves et al., 1991)
1.6.3 Structure of PKC isoenzymes
Amino acid structure of PKC can be divided into conserved and so- 
called function domains (C1-C4) which are separated by variable regions (VI- 
V5) (Figure 1.11). The C-terminal regions C3-V5 have been defined in all 
PKC isoforms as the catalytic domain, which is separated by the V3 region 
from the N-terminal regulatoi-y domain.
The N-terminal VI region of the PKC isoforms is a short stretch of 
aproximately 20 amino acids for which no function has been attributed. At the 
beginning of the C l region, a sequence motif is located that is similar to the 
consensus sequence found in the phosphorylation sites of prominent PKC 
substrates; the so called pseudosubstrate domain. A peptide reflecting this can 
act to inhibit kinase activity both in vitro and in situ (House and Kemp, 1987; 
Eicholtz et ai, 1990; Shen and Buck, 1990). The cysteine-rich region within 
the C l domain consists of two zinc finger motifs each with six cysteine residue.
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Figure 1.11 Domain structure of PKC isoenzymes
Ail PKC isoenzymes consist of constant (C) and variable (v) regions. The 
cysteine-rich repeats in the C l region and the ATP binding site in the C3 region 
are indicated by arrowheads. The aiTow points to the hinge region in the V3 
domain which separates the regulatory from the catalytic domain.
The functions of these domains are:
C l: The first conseiwed domain cotains a cysteine rich motif which is tandemly 
repeated in most but not all PKC isotypes.
C2: The second conserved domain present in only some PKCs appears to be 
responsible for confeiing Ca^"  ^-dependence.
C3 and C4: The conseiwed regions 3 and 4 cover the kinase domain. All the 
characteristic protein kinase sequences are present in tliis region.
V3: The third variable region includes the sites of cleavage associated with 
proteolytic activation.
V5: This C-terminal variable region is divergent among all the PKCs and also 
covers the splice variants p i and P2.
P: The pseudosubstrate site acts to inhibit kinase activity before effector 
binding.
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■This is a potential DNA-binding motif found in transcription factors like GAL4 
(Pan and Coleman, 1990). However, no such DNA-binding activity has been 
demonstrated for PKC, but the regulatory subunit alone, generated by 
proteolytic cleavage in the V3 hinge region, may bind to this. The use of 
deletion mutants of different PKC isoforms has revealed that the cysteine-rich 
region is necessary for DAG and phorbol ester binding (Muramatsu et a l,  
1989; Kaibuchi et a l, 1989; Bums and Bell, 1991). The Ca^+-independeht 
nPKCs lack the C2 region, which Is thought to represent the Ca^+ binding site, 
as it contains many acidic amino acids which are thought to participate in Ca^+ 
binding (Ohno et al, 1987). The V3 or hinge region separates the regulatory 
domain from the catalytic domain. This region is sensitive to proteolytic 
cleavage by trypsin or Ca^+-dependent neutral peptidase. The C3 region 
contains the ATP-binding site. However, here PKC-^ differs slightly from the 
consensus ATP-binding motif in that it contains an alanine instead of a glycine 
at position 264. The C4 region contains the substrate binding site and the 
phosphate transfer region. The aspartate residue here is thought to be 
responsible for the transfer of the phosphate group to substrates.
It is possible to give functional assignments to generalized PKC 
domains by comparing the varying degrees of identity between these enzymes. 
PKC-^ contains only one zinc finger and does not bind DAG or phorbol ester 
(McGlynn et al, 1992). This is in agreement with the finding that (Parker et 
al, 1994), at least in vitro, PKC-Ç exhibits a constitutive protein kinase activity 
and is resistant to activation-induced down-regulation. PK C-a is more 
resistant to proteolytic digestion that p and y  (Hug and Sarre, 1993). Could 
this be evidence that the V3 region of different PKC isoforms exhibit certain 
features that modify the susceptibility to proteolytic cleavage?
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1.6.4 Tissue expression
The tissue distribution of the PKC isoenzymes has been determined 
mostly by Northern blotting and, more recently, by Western blotting analyses 
using isoenzyme-specific antibodies. All PKC isoforms known so far are 
expressed in brain to varying amounts. PKC a , pI/II, 5 and Ç seem to be 
ubiquitously distributed, e.g. in brain, lung, spleen, thymus and skin 
(Nishizuka, 1988; Wada et a l,  1989; Yoshida et a l,  1988; Schaap et a l,  
1989), whilst PKC y is exclusively found in the central nervous system, e.g. 
brain (Nishizuka, 1988), and PKC-ri is strongly expressed in skin and lung 
and only slightly in brain and spleen (Osada et a l ,  1990). PKC-0 is 
predominantly expressed in skeletal muscle and to a clearly lower extent, in 
lung, spleen, skin and brain (Osada et al, 1992). PKC-a and e seem not to be 
present in liver, where PKC-p is the major isoenzyme (Rogue et a l,  1990). 
The isoforms of PKC therefore differ in tissue distribution and amounts 
expressed.
Employing the same techniques, PKC isoenzyme expression patterns of 
selected cell lines from various origins have been determined. PKC-a, pi/pil, 
Ô, e and Ç seem to be the most ubiquitously expressed isoenzymes, whilst PKC 
Y is restricted to a neuronal cell line (PC 12). Information on PKC r\ and 0 is 
yet too limited. PKC pi/pll are absent from mouse and rat fibroblasts, and the 
absence of PKC e appears to be a feature of cells from the myeloid but hot 
erythroid lineage of the haematopoietic system, i.e. macrophages, platelets and 
tlie promyelocytic leukaemia cell line HL60.
A true picture of PKC isoenzymes in a distinct signalling pathway may 
become evident once it is possible to define a given cell type unequivocally by 
its PKC isoenzyme expression pattern and by its signal response potential. 
Little is known about how the expression of various PKC isoenzymes are 
regulated, due to the fact that information on the gene and promoter structure is
:
6 1
limited. So far, only the promoters of the rat PKC-y (Chen et ai,  1990) and the 
human PKC (3 (Niino et al„ 1992) gene have been cloned.
With the detection of the various PKC isoenzymes, it became clear not 
only that there are tissue-specific expression patterns but that the amount and 
number of PKC isoenzymes varied within a given tissue depending on its 
developmental stage (Nishizuka, 1988). This again indicates that a certain set 
of PKC isoenzymes is necessary to guarantee the ordered sequence of 
proliferation and differentiation events which leads to and maintains the 
characteristics of a give tissue.
1.6.5 Regulation of PKC activity
Understanding the regulation of each PKC subspecies is a prerequisite 
essential for determining the potential roles of this enzyme family in signal 
transduction. The variable regions found in each PKC subspecies may play key 
roles in governing the individual enzymological characteristics and possibly 
their specific localization and function. Recently the biochemical properties of 
the different PKC isoenzymes have been investigated with respect to 
autophosphorylation, proteolytic activation/degradation and mechanisms of 
attenuation.
1.6.5.1 Inhibitors of PKC
Both regulatory (phospholipid-and phorbol ester-binding site) and 
catalytic domains (peptide-and ATP-binding sites) on PKC offer targets for 
inhibitor design.
Examples of inhibitors directed against the regulatory site include 
sphingosine (Hannun and Beil, 1987) and calphostin C (Kobayashi et al.„
1989). The latter is a perylenequinone which is competitive with phorbol ester 
and is three orders of magnitude more potent against PKC (IC5o=50nM) than 
against any other protein kinase. However, the mechanism of action of this
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compound appears to involve photo-activation to yield a short-lived species 
which reacts with PKC resulting in permanent inactivation of phorbol ester 
binding (Bruns e ta l ,  1991).
Peptide sequences directed against the substrate binding site, for 
instance the pseudosubstrate sequence PKC 19-36 (Smith et a l,  1990), whilst 
being potent and selective inhibitors do not penetrate cells, thus limiting their 
potential use.
By far the greatest progress has been make with the design of ATP- 
competitive inhibitors of PKC. An alternative approach to the design of 
selective ATP-competitive inhibitors was provided by the identification of the 
microbial metabolite staurosporine as a potent, but non-selective, protein kinase 
inhibitor (Tamaoki et al., 1986; Elliott et al, 1990). Replacement Of the 
methylamino substituent on the pyranose ring in this molecule with -OH 
(Figure 1.12) resulted in a considerable loss in potency against PKC (Osada 
et ai, 1990), suggesting the presence of a cation-binding site on the enzyme. 
The benzophenanthridine alkaloid, chelerythrine which, unlike staurosporine, 
blocks not only PKC but also a variety of other protein kinases (Ruegg and 
Burgess, 1989), is one of the most potent, selective inhibitors of PKC 
interacting with the catalytic domain of the enzyme. Chelerythrine did not alter 
any activity of other protein kinases such as protein tyrosine kinase, 
Ca^+/calmodulin-dependent protein kinase or cAMP-dependent kinase (PKA). 
These inhibitory agents are useful tools for clarifying the role of PKC in 
mediating functional responses in cells. For example, PKC plays a key role in 
cellular growth and differentiation (Nishizuka, 1986), the effects of tlie inhibitor 
chelerythrine showed potent cytotoxic effects on L-1210 cells (Herbert et al,
1990) where it prevents tumour cell growth. Given that bisindolylmaleimide 
PKC inhibitors are potent inhibitors of T-cell proliferation in vitro (Nixon et 
al, 1991) and can also effect T-cell-mediated inflammation in vivo, this implies 
that PKC inhibitors may have therapeutic potential in the treatment of diseases.
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'Figure 1.12 Structure of the serine/threonine protein kinase 
inhibitors chelerythrine and staurosporine.
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HNStaurosporine
1.6.5.2 Proteolytic regulation of PKC
PKC was originally detected as an undefined protein kinase, which was 
present in many tissues and could be activated by limited proteolysis with 
calpain (protease) (Inoue et al., 1977). This hydrolytic cleavage occurred at one 
or two specific sites in the V3 hinge region and thus produced two distinct 
fragments; a protein comprising the regulatory domain and a protein containing 
the kinase domain which is catalytically active in the absence of any activators 
(Kishimoto et ai, 1989). In vitro, this proteolytic activation can be achieved by 
a limited trypsin treatment (Huang et a/., 1989), though in vivo, activation of 
PKC and translocation to the cell membrane is thought to be a prerequisite for 
proteolytic cleavage.
The physiological significance of this proteolysis has not yet been 
unequivocally established. Two alternative possibilities may be considered. 
Firstly, this proteolysis may be a process to activate the PKC molecule, and the 
resulting protein kinase fragment may play some role in the control of cellular 
functions (Mellon! et al., 1986; Fournier, 1987). It is also possible that the 
regulatory fragment has some roles in the control of gene expression since it 
contains a putative DNA-binding motif. Secondly, in contrast, the limited 
proteolysis may be a process to initiate the degradation of PKC, eventually 
depleting the enzyme from the cell. PKC isoenzymes display different 
sensitivities to proteolysis. Compared to PKC P and y, PKC a  is relatively 
resistant to both calpain-and trypsin-mediated proteolysis (Kishimoto et a l,  
1989; Huang et al, 1989).
1.6.5.3 Down-regulation of PKC
In many cell types (Young et al,  1987; Ase et al,  1988), prolonged 
treatment with phorbol esters resulted in the complete depletion of cellular PKC 
level in a process termed down-regulation. This process prevented permanent 
kinase activation. PKC isoenzymes exhibit quite extreme differences in their
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susceptibility to down-regulation in vivo (Kishimoto e ta l ,  1989; Huang et at, 
1989; Kochs et a l,  1993; Schaap et al., 1990) which is in agreement with 
observations in vitro.
1.6.6 Phosphorylation of substrates
cPKC (Ca^+-dependent PKC) isoenzymes appeared to be non-specific 
Ser/Thr kinases in vitro. Thus histones H I or histones IIIS, myelin basic 
protein (MBP), protamine or any other basic protein or peptide could be used as 
an efficient substrate as long as it contained the phosphorylation site motif 
xRxxS/TxRx. Kinase activities of cPKC towards histone IIIS, protamine or 
MBP are very similar (Marais and Parker, 1989; Bums et al, 1990). Members 
of the nPKC (Ca^+-independent PKC) group differ significantly from cPKC 
isoenzymes in that they exhibit a rather poor kinase activity towards histone 
IIIS, MBP, protamine or protamine sulphate (Schaap and Parker, 1990; Olivier 
and Parker, 1991; Dekker etal., 1992). Thus, it was sometimes necessary to 
use synthetic peptides derived from the respective pseudosiibstrate sequence to 
detect kinase activity of nPKC isofonns, a fact that may explain the difficulties 
in detecting new PKC isoenzymes by biochemical analysis, i.e. the appropriate 
substrates are not yet available.
PKC is known to play an important role in phosphorylation of target 
proteins including various membrane proteins such as receptors (Houslay,
1991), the inhibitoiy guanine nucleotide regulatory protein Gia2 (Morris et al, 
1994, Bushfield et al., 1990; Murphy et a i,  1989) and adenylyl cyclase 
(Kawabe e ta l ,  1994).
In the absence of pure/specific  iso type-spec ific  PKC 
stimulators/inhibitors, it is difficult to assess the exact consequences of the 
activation of a certain isotype in terms of substrate phosphorylation and 
biological effect. However, a variety of stable cell lines have been generated 
(Chin et a l,  1993., Lehel et a l,  1994) that overexpress PKC isotypes,
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allowing the examination of their effects on biological processes or with specific 
proteins of interest.
By over-expressing PKC isotypes in Chinese hamster ovary cells, it has 
been possible to determine that insulin receptor phosphorylation can be 
mediated in vivo  by PKC-a, pi and y, but not e (Chin et a l ,  1993). 
Stimulation of PKC-a, pi and y, but not of PKC-e by TP A inhibited the 
insulin-dependent activation of PI-3 kinase in these cells, indicating that 
phosphorylation by specific PKC isotypes inhibits insulin-stimulated responses 
(Chin et al, 1993). The same results were found in both BC3H- Imyocytes 
(Vila et a l,  1989) and rat adipocytes (Graves et a l  1985) where both instilin 
and TP A rapidly and comparably phosphorylated the same specific peptide 
fragments from several typical PKC substrates, e.g. 40,000 and/or 80,000 
molecular weigh proteins.
In various cell types, the activation of PKC has been shown to result in 
alterations in the regulation of adenylyl cyclase activity (Houslay, 1991a). In 
some systems enhanced basal and agonist-stimulated actions have been 
observed, whereas, in others, a loss of receptor-mediated stimulation was 
recorded. The underlying molecular basis for these differences may lie in the 
cell-specific expression of particular control systems, where changes may be 
dependent on the expression of particular isoforms of PKC, adenylyl cyclase 
and cAMP phosphodiesterase, as well as the susceptibility of particular 
receptors to be phosphorylated. However, evidence from a number of studies 
(Houslay, 1991a, Bushfield e ta l ,  1991) has indicated that the inhibitory 
regulation of adenylyl cyclase, mediated through Gi, can be prevented by the 
action of PKC. Studies by Houslay, (1991a) and Bushfield et al, (1990a and 
1990b) indicated that PKC activation can lead to the phosphorylation of the a - 
subunit of the Gi2 iso form on ser^"^ and to the loss of GTP-elicited Gi 
functioning in hepatocytes (Houslay, 1991a; Bushfield et al, 1991a and 1991b; 
Morris e ta l ,  1994), U-973 cells (Daniel-Issakani e ta l ,  1989) and platelets
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(Haleiida et a l,  1986; Crouch et a l,  1988; Yalomi et a l ,  1992). Such 
phosphorylation, however, only appears to occur in certain cell types and an 
additional mechanism for the PKG-mediated loss of Gi inhibition may exist, 
such as phosphorylation of the catalytic unit of type II adenylyl cyclase (Chen 
and Iyengar, 1993).
The phosphorylation of various transcription factors by PKC and other 
signal-transducing kinases has recently been revealed (Meek and Street, 1992). 
It should also be noted that amongst PKC substrates there might be several 
other protein kinases like S6 kinase or raf kinase.
Most protein kinases exhibit a rather pronounced autophosphoiylation 
which is often, but not necessarily, linked to a modulation of kinase activity 
(M iller and Kennedy, 1986). Detailed studies on the role of 
autophosphorylation have mostly been carried out with cPKC isoenzymes and 
have revealed that it is an intramolecular reaction at serine and threonine 
residues on both the regulatory and catalytic domains (Huang et al, 1986b) and 
strictly dependent on the presence of activators, as the enzymes Km value for 
ATP is about 10-fold lower than that for substrate phosphorylation (Huang gt 
a l,  1986b). Autophosphorylation seems not to be a prerequisite for PKC 
activity. Protein phosphatases 1 and 2A are capable of dephosphorylating PKC 
without loss of PKC activity.
Based on the observation presented above, it is apparent that a large 
body of evidence has accumulated to indicate that PKC has a dual action, 
providing positive forward, as well as negative feedback, control over various 
steps in cell signalling processes.
1.7 Diabetes induced alterations in hepatocyte signalling  
pathways
Diabetics have long been known to have higher metabolic stress 
responses than non-diabetics ie. the catabolic pathways of glycogenolysis and
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lipolysis are more readily activated in response to catecholamines (Shamoon and 
Daly, 1980). Most (80-90%) cases are type 2 (non-insulin dependent) diabetes 
in which insulin resistance is present in the major insulin target tissues viz. 
adipose tissue, muscle and liver (Shamoon and Daly, 1980). Such 'resistance' 
in liver being responsible for most of the fasting hyperglycemia observed in 
diabetes (Gerich, 1990). Insulin resistance encompasses a number of defects, 
including impaired receptor tyrosine kinase activity, reduced glucose transport, 
reduction in activities of enzymes involved in glucose metabolism and abnoimal 
responses to other hormones (Defronzo etal., 1982; Swislocke etal., 1989).
1.7.1 Defects in hepatocyte adenylyl cyclase signalling in 
diabetes
Liver, being an insulin sensitive tissue, has been extensively used for 
studies of adenylyl cyclase signalling in diabetic animals. In diabetes, liver 
turns from a glucose-storing to a glucose-producing tissue. This follows a 
decrease in plasma insulin and increased plasma levels of the anti-insulin 
hormones, noradrenaline, adrenaline, glucagon and cortisol (Tamborlane et al, 
1979; Cryer, 1980). This increased liver responsiveness to anti-insulin 
honuones has also been observed in insulin-treated diabetic animals (Shamoon 
and Daly, 1980).
A common event of elevated cAMP was obseiwed in liver from animal 
models of both type 1 diabetes e.g. streptozotocin-induced diabetic rats (Pilkis 
et a l,  1974) and type 2 diabetes e.g. the obese Zucker rat and db/db mice 
(Herberg and Coleman, 1977). Studies of diabetic rats have revealed either 
increased (Soman and Felig, 1978), decreased (Srikant e ta l,  1977; Bhathena et 
al,  1978) or unchanged (Chamras et al, 1980) numbers of hepatic glucagon 
receptors, as well as elevated (Lynch et al, 1989) or reduced (Pilkis et al, 
1974) basal and agonist-stimulated adenylyl cyclase activity in liver plasma 
membranes from chemically-induced diabetic rats. One possible explanation is
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that animals differ in their toxic responses to diabetogenic agents. Changes in 
G-protein expression and function in liver from diabetic animals is suggested as 
being in part responsible for the altered adenylyl cyclase signalling. Gawler et 
ai, (1987) observed marked enhancement in the ability of glucagon to activate 
adenylyl cyclase in hepatocyte plasma membranes from diabetic rats which they 
suggested was due to a decreased level of expression of the inhibitory G-protein 
Gi. Extended analysis by Bushfield et a i,  (1990a) investigated the effect of 
streptozotocin-induced diabetes on the expression of the stimulatory G-protein, 
Gs, on the different froms of Gi and on G-protein p-subunits in both 
hepatocytes and liver, as well as analysing the phosphorylation state of Gia2 
(Bushfield et al, 1990). The decreased level of Gia2, reduced by about 50%- 
80% in diabetic animals compared with that found in normal animals, was 
consistent with the effect of diabetes in diminishing the number of Gia subunits 
available for pertussis-toxin-catalysed ADP-ribosylation in hepatocyte 
membranes (Houslay et a l,  1989). Also Bushfield et a l ,  (1990b) found a 
reduction in the levels of Giot3 and the 42 kDa form of Gsa in hepatocyte 
plasma membranes from diabetic rats, as well as increased expression of the 
adenylyl cyclase catalytic subunit. As G ial is not expressed in liver and Gia3 
is not thought to mediate adenylyl cyclase inhibition this finding suggested a 
dysfunctional Gia2. It was suggested in hepatocytes from diabetic animals, 
that the residual Gia2 appears to be fully phosphorylated, at the putative 'C- 
kinase site' (Bushfield et al, 1990a), under basal conditions. The decrease in 
the activity of this G-protein by phosphorylation through PKC can be shown by 
treatment of nonnal rat hepatocytes with agents which can activate PKC. This 
phosphorylates Gia2 leading to the loss of guanine nucleotide inhibition of 
adenylyl cyclase. It is tempting to speculate that such an increased 
phosphorylation of Gia2 may characterize many insulin-resistant states.
Changes in the ability of G-proteins to be labelled by pertussis toxin 
have been observed in diabetes. Lynch e ta l ,  (1989) found reduced pertussis
1
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toxin-catalysed ADP-ribosylation of total Gi in hepatocyte membranes from 
diabetic animals. The ability of pertussis toxin to label Gi in human diabetic 
liver has also been noted to be impaired (Caro et ai, 1991). They also noticed 
that the ability of insulin to attenuate pertussis toxin-catalysed ADP-ribosylation 
of Gi was impaired in liver tissue from diabetic humans. These findings tie in 
with the view of Rothenbeiy and Kahn (1988) who suggested insulin’s ability 
to inhibit pertussis toxin-labelling of G-proteins implied a functional interaction 
between the two signalling systems, possibly by insulin influencing Gj 
conformation. Recently, Moxham and Malbon (1996) used cells from 
transgenic mice harbouring inducible expression of RNA antisense to the gene 
encoding Gia2 (Moxham and Malbon, 1993; Moxham et a l, 1993) to show 
that Gia2 is critical for insulin action. The Gia2 deficiency creates a model for 
insulin resistance characteristic of non-insulin-dependent diabetes mellitus 
(Reaven, 1995), implicating Gia2 as a positive regulator of insulin action 
(Moxham and Malbon, 1996). These findings again raise the possibility of an 
abnoiTuality of Gi function in diatetes.
i
1.7.2 Diabetes induced alterations in PKC expression in hepatocytes
Activated PKC has indeed been reported in diabetes as a result of 
increased diacylglycerol levels formed from excess glucose (Greene et a l,
1987) and may impair insulin action by increasing insulin receptor 
phosphorylation. The observations of loss of tonic GTP-elicited Gi function 
(see above) also suggest a profound effect upon the level of expression and the 
disnibutioii of PKC isoforms in hepatocytes of streptozotocin-induced diatetic 
rats.
Tang et al., (1993) demonstrated that an overall increase in the 
expression of PKC-a, in both membrane and cytosol fractions of diabetic rat 
hepatocytes, coupled with translocation of a portion of the PKCa -81  KDa 
species to the membrane fraction. Streptozotocin-induced diabetes elicited a
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marked increase in the amount of cytosolic PKC-pII, this was also 
accompanied by the ability to detect immunoreactive PKC-pII in membranes 
from the hepatocytes of diabetic rats, implying that translocation of PKC-PII 
from the cytosol had occurred (Tang et a l,  1993). The increase in the levels 
and altered distribution (between membrane and cytosol compartments) of 
certain protein kinase C isoforms may thus provide an explanation for the 
abeiTant increase in the level of protein kinase C-mediated phosphorylation of 
Gia2 seen in the hepatocytes of streptozotocin-induced diatetic rats (Bushfield 
et ah, 1990b).
The changes in PKC expression are likely to have widespread effects, 
some of which may in themselves affect the action of insulin on target tissues. 
For the insulin receptor itself is known to provide a substrate for this enzyme 
(Takayama et a l,  1988; Houslay, 1989; Koshio et a l,  1989; Lewis et a l,
1989) with such modifications being implicated as attenuating at least certain of 
the functions fo the receptor and thus exerting a selective effect on its different 
signalling actions (Houslay, 1989). It may be then that aberrant expression of 
specific PKC isoforms can alter cell signalling pathways leading to selective 
hoiTnone resistant states.
1.7.3 Diabetes induced changes in cAMP phosphodiesterase 
activity
As well as defects at the level of the membrane, decreased cAMP 
phosphodiesterase activity may account in part for the increased catecholamine 
and glucagon responsiveness of diabetic liver. In fact, Solomon et al, (1986) 
found a reduction in the activity of the high affinity low Km cAMP 
phosphodiesterase in liver from streptozotocin diabetic rats which would allow 
the exaggerated intracellular cAMP respones. Meanwhile, streptozotocin- 
induced diabetic rats show elevated levels of glucagon and heightened 
glucagon-stimulated adenylyl cyclase activity in hepatocytes (Gawler et al,
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,1987; B u s h f i e l d al, 1990b). As such, it is likely that cAMP levels in these 
cells will have been chronically elevated upon onset of diabetes.
Calmodulin is a ubiquitous, highly conserved protein throughout the 
phylogenetic scale, in addition to its capacity to bind Ca^+, it serves as an 
important biochemical regulator as both CaM-dependent protein kinase(s) and 
cyclic nucleotide phosphodiesterase(s) have been identified (Cheung, 1970; 
Smoake and Solomon, 1989). Evidence presented in Smoake et a l,  (1995) 
suggested that low Kpi PDE is CaM dependent, as three different CaM 
antagonists reduced the activity of low Km PDE. Also^ insulin stimulated the 
activity of this PDE in isolated membranes in the absence of these inhibitors but 
not in their presence (Smoake e/ al, 1995),
This concept of CaM involvement in insulin regulation of PDE was 
suggested by Solomon (1981, 1986, 1987) with the observations of a reduction 
in both CaM and PDE activity from liver and adipose tissues from 
streptozotocin diabetic and spontaneously diabetic rats. PDE and CaM activities 
were returned to normal with insulin teatment (Solomon et al, 1979 and 1987). 
Hence, PDE alterations are known to occur in the diabetic state.
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Chapter 2
Materials and Methods
—     :
24 Materials
2.1.1 Tissue culture plastic ware: 
Costar Co 
U.S.A
Filters (0.22pm)
Falcon tissue culture flasks 75cm^ 
Multiple cell plates 
50ml centrifuge tubes 
Tissue culture pipettes
2.1.2 Tissue culture medium: 
Gibco Life Technologies
Paisley, UK
Hams-F12 medium
Dulbecco’s modification of Eagle’s
medium (lOx)
Foetal calf serum 
Glutamine (200mM)
Sodium bicarbonate (7.5%) 
Penicillin/Streptomycin (10000 lU/ml) 
Trypsin/EDTA
2.1.3 Radio chemicals: 
Amersham PLC, Amersham
Buckinghamshire, U.K.
[8_3h ] Adenosine-3 ’ 5 ’ -cyclic
monophosphate
[5, S-^H] Adenosine 3’5’cyclic
monophosphate
[i^^Ij-labelled anti-rabbit IgG
[l^C]-labelled protein molecular weight
markers
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2.1.4 General reagents:
2.1.4.1 Chemical compounds: 
BDH, MERCK Ltd 
Lutterworth, Leics, U.K.
Sigma
Poole, Dorest, U.K.
Fisons Scientific Equipment
Loughborough, U.K.
Boehringer
West Gennany
Glucose
Hepes
EDTA
Sodium dodecyl sulphate
Citric acid
Glycine
Methanol
Tris
Tween-20 
EGTA 
Triton X-100 
Sucrose 
Sodium Citrate 
Glycerol
Dimethyl sulphoxide 
Sodium Acetate 
Triethanolamine hydrochloride
2.1.4.2 Biochemical reagents: 
Rhone Merieux 
Harlow, Essex, U.K. 
Worthington Biochemical Co 
Freehold, New Jersey, U.S.A. 
Sigma
Poole, Dorest, U.K.
Sagatal
Collagenase
Cytochalasin B
Theophylline
Aprotinin
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Antipain 
Pepstatin A
Benzamidine hydrochloride
Phenylmethylsulphonyl fluoride
Sodium pyruvate
ATP
GTP
GppNHp
BSA
Calmodulin (bovine brain) 
Cyclic-AMP 
Cyclic-GMP 
Dextran T-500
Dowex 1X8-400 (chloride form 200- 
400mesh)
3-isobutyl-1 -methylxanthine
Snake venom ( Ophiophagus hannah)
Bromophenol blue
TEMED
Ponceau stain
p-mercaptoethanol
Collagen
Choiera toxin
12-O-tetradecanoylphorbol 13-acetate
Insulin
Glucagon
Vasopressin
Alkaline phosphatase
Streptozotocin
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Peptide Research Foundation 
London, U.K.
BDH, Merck Ltd
Lutterworth, Leics, U.K.
Calbiochem
Cambridge, U.K.
Boehringer Co ^
Lewes, East Sussex
Bio-rad Laboratories Ltd
Hertfordshire, U.K.
National Diagnostics
Buckinghamshire, U.K. 
M & B
Dagenham, UK.
BRL
Paisley, Scotland 
Amersham Life Science
Buckinghamshire, U.K.
Staurosporine 
Cheleiythrine 
Calphostin C 
Actinomycin D 
Leupeptin
Universal indicator 
Charcoal (Norit Gsx)
Dithiothreitol
Forskolin
Pansorbin
Diabur-Test 5000
Nicotinamide adenine dinucleotide
(reduced U.K.form)
Creatine phosphate 
Creatine kinase
30% Acrylamide/bis acryclimide mix 
(29:1)
Bradford reagent 
Ecoscint, scintillation fluid
Ammonium persulphate
Pre-stained molecular weight markers
ECL(Amersham enhanced 
chemiluminescence)
SAPU HRP Anti-rabbit IgG
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Scotland, U.K.
Gift from Aktiengesellschaft
Berlin, Germany 
Pfizer Central Research 
Sandwich, Kent, U.K.
Gift from Dr. M. Wigler
Cold Spring Harbor 
Long Island, U.S.A.
Rolipram
Cilostimide
cDNA encoding DPD (PDE4B splice 
variant)
2.1.5 Molecular Biology reagents: 
Pharmacia Biotechnolgies
Herts, U.K.
Sigma
Poole, Dorest, U.K.
Promega
Southampton, U.K.
Stratagene
Cambridge, U.K.
First strand cDNA synthesis kit
Tri-reagent 
Etliidium bromide
Diethyl pyrocarbonate (1% )in water 
Taq polymerase 
MgCl2 
Taq buffer
Deoxyribonucleoside trisphosphates 
Molecular weigh markers 
Wizard mini preps (DNA purification 
system)
“Taq Start Antibody”
“Perfect match”
2.1.6 Equipment: 
Fison
Loughborough, U.K. 
Progene
1 0 0 pm mesh screens
PCR amplification machines
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Cambridge, U.K. 
Belmont Instrument 
Glasgow, Scotland, U.K. 
Amicon
Gloucestershire, U.K.
Perfusion equipment (Watson-Marlow 
502S)
Pressure cell 8050 Max 75Psi, 
5.3kg/cm2
2.1.7 Animal resources
Male adult Sprague-Dawley rats were purchased from commercial 
sources with weight range between 200-250g. Settled animals were used as 
follows: (1) Injection with streptozotocin in order to induce diabetes or (2) 
dose with sagatal by i.p.(intrapeiitoneal) injection in order to anaesthetise the 
animal. This was checked by testing eye and leg reflexes (for consciousness) 
after which the perfusion procedure was carried out as described in method 
section 2.3.1.
2.1.8 Cell lines
P9 cells: This is a SV40-immortalised hepatocyte-derived cell line 
described by first by Livingstone et a i, (1994). This cell line was generated 
by transfection of rat hepatocytes with SV-40 to produce "hepatocyte-like" 
cells with an unlimited proliferative potential.
CHO cells: Wild-type CHO cells and cells transfected so as to 
overexpress the a ,  P-II, y an e forms of protein kinase C were generously 
given by Dr. Richard A. Roth, Department of Pharmacology, Stanford 
University, U.S.A. The generation and characterization of these cell lines, 
which were also transfected so as to overexpress the human insulin receptor, 
are described in Chin, et a l, (1993).
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2.2 Media, buffers and standard solutions
Chinese Hamster Ovary (CHO) cell were cultured in HAM-F12 medium 
supplemented with 1% (v/v) penicillin/streptomycin, 1% (v/v) glutamine and 1 0 % 
(v/v) foetal calf serum
P9. NIH-3T3 and COS-7 cell were cultured in DMEM(xl) medium supplemented 
with 1% (v/v) penicillin/streptomycin 1% (v/v), glutamine 1 0 % (v/v) and foetal 
calf serum
2% cell culture medium DM EM (x l) supplem ented with 1% (v/v)
penicillin/streptomycin 1% (v/v), glutamine 2 % (v/v) and foetal calf serum.
Serum -free medium DMEM (x l)  supplem ented with 1% (v/v)
penicillin/streptomycin, 1% (v/v) glutamine
Cell freezing buffer: supplement appropriate medium with 
2 5% foetal calf serum and 10% DMSO.
Rat hepatocyte perfusion buffer: Ca^+ free buffer containing final concentration of
25.3mM NaHCOa 
4.8mM KCl 
1.2mM MgSOa 
1.2 mM KH2PO4 
120mM NaCl 
5mM glucoseequilibration with 95% 02’.5%C02 
For Ca^+ containing buffer add 1.28mM CaCl2 .
Incubation buffer : As Ca^+ containing buffer but containing final concentrations 
of 2% (w/v) BSA & lOmM Hepes.
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Collagenase containing buffer: 40mg collagenase (added immediately before 
use) and 2% (w/v) BSA in Ca^+ containing buffer.
Protease inhibitor cocktail 2mM Aprotinin 
2mM Antipain 
2mM Pepstatin A 
2mM Leupeptin 
2mM Benzamidine 
O.lmM PMSF
diluted 1 :1 0 0 0  in buffer for use
Hepatocvte washing buffer: 20mM Tris/HCl (pH7.4) 
150mM NaCl 
5mM glucose 
protease inhibitor cocktail
Hepatocyte homogenisation buffer: 20mM Tris/HCl (pH7.4) 
2mM EDTA 
2mM EGTA
protease inhibitor cocktail
P9 cell washin g buffer: 145mM NaCl 
6 mM KCl 
lOmM glucose 
lOmM Hepes (pH 7.4) 
protease inhibitor cocktail
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P9 cell homogenisation buffer 2GmM Tris/HCl (pH7.4) 
ImM EDTA 
250mM sucrose 
protease inhibitor cocktail
PDE assay buffer: 20mM Tris/HCl (pH 7.4) 
lOmM MgCl2
cAMP binding assay buffer: 50mM Tris/HCl (pH7.4) 
4mM EDTA
Buffer for preparation of cAMP binding protein :
250mM Sucrose 
25mM KCl 
5mM MgSOa 
50mM Tris/HCl (pH 7.4)
Charcoal solution buffer: cAMP binding assay buffer containing
2% (w/v) charcoal (Norit GSX) 
1% (w/v) BSA
Adenylyl cyclase ATP regeneration x2
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Creatine Phosphate (7.4mg/ml) 
Creatine kinase (0.2mg/ml)
BSA (0.8mg/ml)
ATP (0.9mg/ml)
in x2  incubation medium of
25mM triethanolamine hydrochloride
(pH7.4 with KOH)
ImM EDTA
_____  _______
lOmM theophylline 
5mM magnesium sulphate 
DTT ImM
COS-7 cell washing buffer: lOmM Triethanolamine, pH7.2 
150mM KCl
COS-7 cell homogenisation buffer: (KHEM complete buffer)
50mM KCl 
50mM Hepes, pH7.4 
lOmM EGTA 
L92mM MgCl2 
ImM DTT
protease inhibitor cocktail 
20)ig/ml cytochalasin B 
KHEM imcomplete buffer: As KHEM complete buffer but not containing protease 
inhibitor and cytochalasin B.
RNA gel mnning buffer: (Q.5x): 45mM Tris/HCl, pH8 
45mM Boric acid 
ImM EDTA
Immunoprécipitation buffer: 1% Triton X-100 
lOmM EDTA 
lOOmM NaH2P0 4 .2 H2 0  
50mM Hepes, pH7.2 
protease inhibitor cocktail
83
SDS/PAGE resolving (S% gel): 30% aerylamide/bisacrylamide mix 
(29:1) 1.5M Tris/HCl, pH 8 .8  
10% (w/v)SDS 10% (w/v)ammonium 
persulphateO.06% (v/v) TEMED to a 
final volume of 30ml.
SDS/PAGE stacking (8 % gel): 30% aery 1 amide/bisacrylamide mix 
(29:1) l.OM Tris/HCl (pH 6 .8 )
10% SDS 10% ammonium persulfate 
0.1%TEMED to a final volume 8 ml
SDS/PAGE gel running buffer: 0.2M Glycine 
0.25mM Tris 
0.1% (w/v) SDS
Western blotting buffer: 0.2M Glycine 
25mM Tris 
0.1% (w/v) SDS 
20% Methanol
Laemmli buffer: 0.02M Tris/HCl pH 6 .8  
20% (v/v) Glycerol 
2% (w/v) SDS 
2mM EDTA
0.02% Bromophenol blue
add 5% of (3-mecaptoethanol before
use
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Tris buffered saline: 20mM Tris/HCl, pH7.5
0.5M NaCl
Cell transfection medium: Appropriate medium supplemented with
10% (v/v)Nu serum 
lOOjiM Chloriqine
Nu serum : a synthetic serum replacement obtained from Collaborative 
Biomedical Products, Catalogue No. 55000.
2.3 Methods
2.3.1 Hepatocye preparation
2.3.1.1 Hepatocvte isolation
Hépatocytes were prepared by a modification of the method of Berry 
and Friend (1969). The buffer used throughout the liver perfusion and the 
subsequent hepatocyte incubations was Krebs bicarbonate buffer as detailed 
previously (see 2.2). Male Sprague-Dawley rats weighing 225-250g were 
anaesthetised by intraperitoneal (i.p.) injection with sagatal (0.5ml). After 
about 1 0  minutes, the unconscious rats were used for perfusion as detailed 
below.
The abdomen was opened by a longitudinal incision, the viscera
displaced and the inferior vena cava and hepatic portal vein exposed. The
inferior vena cava was cannulated with a N°.15 gauge needle containing anti-
coagulant( lOOmM EDTA). The hepatic portal vein was immediately cannulated
with a 1.1 mm needle and perfused with Ca^+ free Krebs bicarbonate buffer
containing 5mM glucose at a rate of 30ml/minute. The thoracic cavity was
opened and the inferior vena cava ligatured just below the right atrium to
prevent back flow of the blood from the heart.
The buffer entered the liver through the hepatic portal vein and flowed
to waste via the inferior vena cava. Ca^"  ^free Krebs bicarbonate buffer was
required to flush the blood from the liver and to break down Ca^+ dependent
junctions between the cells. Approximately 250ml of this buffer was pumped
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through the liver before changing to a collagenase-containing buffer to digest 
the liver (Krebs bicarbonate containing 0.2% BSA with 40mg collagenase). 
This buffer was re-eirculated through the liver for 15-20 minutes until a 
suitable degree of digestion was obtained as indicated by a marked increase in 
leakiness and the appearance of blisters of buffer trapped beneath the surface 
of the liver. At this point the liver was removed to 60ml of Krebs bicarbonate 
buffer containing 5mM glucose, chopped with scissors and washed through
nylon mesh (pore aperture lOOjim) witli a further 1 0 0 ml of buffer.
Buffer were gased with 95%02:5%C02 before used.
2.3.1.2 Hepatocyte disruption by pressure
W ashed hepatocytes were resuspended in freshly prepared 
homogenisation buffer, and 4m 1 (approximately 4x10^ cells/ml) of this cell 
suspension was placed in plastic vials. These were then placed in a pressure 
cell, which was pressurised to 50PSI for lOmin with O2 free N2 . Finally the 
vessel was rapidly depressurized and the cells used for homogenisation after 
this stage.
2.3.1.3 Preparation of a hepatocyte (crude) membrane fraction
Cells (treated with appropriate ligands for desired incubation period), 
were placed on ice and 0.7ml samples of cell suspension quenched by adding 
an equal volume of ice-cold ImM KHCO3 pH7.2. All further procedures 
were performed at 4°C. Quenched reaction samples were then centrifuged at 
13,000rpm for 10min in a bench-top microcentrifuge, supernatant fluid was 
removed and the cells were resuspended in 300{il of ImM-KHCOg, pH 7.2. 
Following centrifugation on a bench-top microcentrifuge at 13,000rpm for 5 
min at 4^C, the pellet was resuspended in lOOfil of ImM-KHCOg, pH 7.2 to 
yield a crude membrane fraction. In all cases membranes were assayed within 
2  hours of preparation.
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2.3.1.4 Fractionation of hepatocvtes
Following incubation of hepatocytes with appropriate ligands, 
reactions were stopped by adding an equal volume of ice-cold washing buffer. 
Cells were then centrifuged at lOOOg for 2min at 4°C. The supernatant was 
aspirated and the cells were washed again by resuspension in the same 
washing buffer and centrifuged as before. After pressurisation, hepatocytes 
were homogenised gently in a glass vessel using a Teflon pestle and 
subsequently fractionated as described for P9 cells.
2.3.2 Attachment of hepatocytes to collagen plates
Hepatocytes isolated as described earlier (section 2.3.1.1) were plated 
out by adding 1ml of cell suspension to collagen-coated (0.3mg/ml) Petri 
dishes and placing them in an incubator for 4Gmin until the cells had adhered 
to the plates but not spread. After this peiiod, cells that had not adhered were 
aspirated and the plates were washed once with Krebs-Henseleit buffer 
(ImPwell) before the addition of hormones.
2.3.3 Assessing desensitization in immobilized cells
Hepatocytes were attached to collagen plates and incubated for 40 
minutes to allow adherence. Mediiim was then aspirated from the 
immobilized hepatocytes before the addition of fresh medium ( 1ml) 
containing the indicated ligands or with medium alone to determine the 
control state. They were then incubated for 6 min in this pre­
incubation/desensitization period. Cells were then washed with Krebs buffer 
(0.9ml/well) to remove the ligand, and left for 6 min at 37®C. Over this period, 
irrespective of the pre-incubation conditions, intracellular cyclic AMP levels 
stabilized to that seen for the cells at the start of the experiment under basal 
conditions. After this washing and stabilization period, glucagon
desensitization was assessed by determining the ability of glucagon to
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stimulate an increase in intracellular cyclic AMP. This was done by treating 
the cells with lOnM glucagon for 3min and subsequently harvesting them to 
determine the intracellular concentration of cyclic AMP.
2.3.4 Determination of ATP content of hepatocytes
The ATP content in isolated hepatocytes was determined by the 
lue if erase method on a neutralized HCIO4 extract. Cells with ATP 
concentrations of 8 .6  nmol/mg dry weight were judged to be viable, and were 
therefore used (Fleyworth and Houslay, 1983).
2.3.5 Treatment of hepatocytes
2.3.5.1 Incubation of hepatocvtes with ligands 
Cells were centrifuged at 4og for 2 minutes then resuspended in the
hepatocyte washing buffer; this washing procedure was repeated twice. The 
isolated hepatocytes were finally resuspended in 2% BSA/Krebs bicarbonate 
buffer with 5mM glucose. Cells were placed in plastic containers under an 
atmosphere of O2/CO2 : 95%/5%, which was maintained by gassing every 1 0 - 
15 minutes. The cell suspension was preincubaied for 30 minutes at 37°C in a 
shaking water bath with sufficient shaking to prevent the cells settling. Most 
experiments entailed addition of 2 ml of hepatocytes suspension to disposable 
vials containing the appropriate ligands. The vials were gassed with O2/CO2 : 
95%/5%, then sealed and placed in a shaking water bath at 37°C, for the 
desired time of incubation.
2.3.5.2 Treatment of hepatocyte membranes with alkaline phosphatase.
A hepatocyte membrane fraction was prepared and resuspended in the
buffer as described previously (section 2.2). Then lOOpl of this, containing 
2 0 0 pg membrane protein, was treated with 2 0  units of alkaline phosphatase
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for 10min at 37®C. An equal volume of 4% PCA was added to stop the 
reaction. The extract was then used for assay of adenyly I cyclase activity.
2.3.6 Cell culture
2.3.6.1 Culture of P9 cells
Cells were grown at 37<^ C, in a 5% C0 2 /9 5 % 0 2  humidified incubator 
in 7 5 cm^ cell culture flasks with DMEM (xl) as described earlier. Confluent 
cells were passaged by trypsinisation followed by centrifugation at 600rpm for 
5min. The cell pellet was re-suspended in complete culture medium and 
seeded at a split ratio of 1:6  into new cell culture flasks.
2.3.6.2 Culture of CHQ cells
For the culture of CHO cells, HAMS-F12 medium was supplemented 
by the addition of 1% penicillin/streptomycin and glutamine; 1 0 % foetal calf 
serum was also included. Cells were grown in 75cm^ flasks at 37°C in an 
atmosphere of 95% air/5 % CO2 in a humidified incubator. Confluence was 
attained within 3-4 days, and cells were routinely split 1:4 by trypsinisation.
2.3.6.3 Culture of NIH-3T3 cells
For the culture of NIH-3T3 cells, DMEM medium was supplemented 
by the addition of 1% penicillin/streptomycin and glutamine; 1 0 % foetal calf 
serum was also included. Cells were grown in 75cm^ flasks at 37°C in an 
atmosphere of 95% air/5 % CO .^ in a humidified incubator. Confluence was 
attained within 3-4 days, and cells were routinely split 1:4 by trypsinisation.
2.3.7 Treatment of P9 cells
2.3.7.1 Preparation of P9 membrane and soluble fractions
Confluent P9 cells were washed and then incubated on ice in the 
presence of 1.5ml (per flask) homogenisation buffer containing fresh pro tease
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inhibitors. Cells were scraped off the plate into microfuge tubes and spun for 
5min in a bench-top microcentrifuge to remove cell debris and hormone 
medium. 300|il of homogenisation buffer was added per tube and the pellet 
re-suspended and homogenised using a 1ml syringe within 30 up/down 
strokes. This was recognised as total homogenate. Lysed cells were spun at 
l,000g for lOmins at 4 ‘^ C, to yield supernatant regarded as a post nuclear 
fraction and a pellet of nuclei and cell debris, unbroken cells and plasma 
membrane. This supernatant was then spun at 100,000g at 4°C for Ih, to yield 
supernatant regarded as cytosol and a pellet considered as a membrane 
fraction.
2.3.7.2 Actinomycin D treatment of cells
After removing cell culture medium, cells were incubated with 2% 
serum medium supplemented with actinomycin D alone at the required 
concentration (lp,g/ml) for 45minutes before any agonist challenge. 
Incubation with other hoimones for the appropriate times was then perfoimed, 
still in the presence of actinomycin D.
2 3 ,1 3  Bacterial toxin treatment of cells
After removing cell culture medium, cells were incubated in serum- 
free medium (containing IBMX ImM and BSA 1% ) supplemented with 
cholera toxin at the indicated concentration for the stated times.
23.1 Â  Longterm hormone treatment of cells
After cells nearly 90% confluent in DMEM (xl) culture medium, cells 
were changed into 2 % serum medium supplemented with forskolin and 
cholera toxin at the concentration of lOOpM and Ipg/ml respectively for 
various time until 24 hours.
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2.3.8 Thermal dénaturation of adenyîyl cyclase
A washed membrane fraction was prepared as described in the method 
above (section 2.3.1.3) and the pellet fraction was resuspended in ImM 
KHCO3 (pH 7.2) buffer. Sample were incubated at 5CPC in a shaking water 
bath, aliquots (lOOpl) were then removed into ice-cold microfuge tubes every 
30 second over a period of lOmin. lOfil of samples were then assayed for 
adenylyl cyclase activity (section 2.3.10) with stimulation by forskolin.
2.3.9 Cyclic AMP binding assay.
2.3.9.1 Assav principle
The measurement of cyclic AMP concentrations was carried out as 
outlined by Kishihara et <7/., (1993) The binding protein utilised in the assay is 
cyclic AMP-dependent protein kinase (PKA) which has binding sites for 
cyclic AMP. A crude preparation of adrenal glands was made (Brown et al., 
1972), which is a rich source for this enzyme (section 2.3.9.2). Upon 
stimulation of the experimental cells, in the presence of the desired effectors 
for a fixed time, the cells reaction were stqped by adding 2 % final 
concentration of PCA. After neutralising the sample, the unknown cyclic 
AMP extraction were incubated with [^H]-cyclic AMP (5- and 8 - position of 
the adenine ring) and cyclic AMP binding protein, allowing competition of 
labelled and unlabelled cyclic AMP for a limited number of binding sites on 
the binding protein. A standard curve was obtained by incubating known 
concentrations of unlabelled cyclic AMP with fixed amounts of binding 
protein and radioactive cyclic AMP. Thus, the unknown cyclic AMP 
concentrations can be determined in samples by comparison with the standard 
curve. After incubation, activated charcoal was added to the sample to absorb 
unbound cyclic nucleotide from the solution. The charcoal (Norit GsX) with 
the bound cyclic nucleotide was removed by a brief centrifuging step, and a 
proportion of radioactivity in the sample was ascertained.
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2.3.9.2 Preparation of cyclic AMP binding protein.
Bovine adrenal glands (20-30), obtained from the abattoir were 
transported to the laboratory on ice. At 4°C, the fat was removed from the 
outside of glands and they were then hemisected revealing the pale coloured 
inner medulla and the darker outer cortex. The medulla was removed and 
discarded, retaining the cortex. One volume of tissue was homogenised in one 
and a half volumes of buffer (250mM sucrose / 25mM KCl / 5mM MgS0 4  / 
50mM Tris/HCl, pH7.4) in a Waring blender. The homogenate was filtered 
through muslin and then centiifuged at 15 OOOipm on MSB 18 for 15 minutes 
at 4°C. The supernatant was decanted through filter paper, and the eluate was 
aliquotted into 1ml fractions and stored at -20°C for up to 3 months. Separate 
samples were thawed and diluted for each assay.
2.3.9.3 Assessing intracellular cAMP concentrations
(A) For hepatocyte cell suspensions, after the appropriate incubation 
period, lOOpl of ligand treated sample was placed into a microfuge tube 
containing 100|il of 4% PCA (samples were assayed in triplicate for each 
condition). The precipitated protein was pelleted by centiifugation in a bench- 
top microcentrifuge for 2  minutes. Universal indicator was added to the 
supernatant and the solution was then neutralised by addition of 2M KOH / 
0.5M triethanolamine (TEA). Samples were then pelleted in a microfuge for 3 
minutes, and 50|il of the supernatant was removed for assay of intracellular 
cyclic AMP (section 2.3.9.4) using a cyclic AMP binding protein prepared as 
described previously (section 2 .3.9.2)
(B) Incubations of cultured cells with ligands (volumes added were not
more than 2 % of total incubation sample volume) were stopped by aspirating
the medium from the multiple-well plates in which cells were grown and
adding 250jil of 2% PCA to terminate the reaction. Cells were incubated on
ice for 2-3 minutes to allow lysis of the membrane, and the extraction of the
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cyclic nucleotides. Cells were then scraped and pelleted by centrifugation in a 
bench-top microcentrifuge for 2 minutes. Neutralisation of samples was then 
carried out as described in section (A).
2.3.9.4 Assay procedure
As mentioned previously, a standard curve was prepared for each 
assay, using cyclic AMP CLMOk/ntS between 0.0625 and 16 pmols. This 
part of the assay was carried out in duplicate, whilst the unknown samples 
were assayed in triplicate.
In each tube, assays were performed by adding 50ji.l of supernatant 
from the unknown samples to 50|il of cAMP binding assay buffer (50mM 
Tris/5mM  EDTA pH7.4). lOOpl of 5, 8-3H-adenosine 3'5' cyclic 
monophosphate (diluted in Tris/EDTA buffer to give approximately 
500,000cpm/ml) was added to the sample. For standards, cyclic AMP 
solutions containing 50p.l of known cAMP WOMltS (from 0.0625pmole 
to 16pmole) were added to 50|il of cAMP binding assay buffer, together with 
lOOp-1 of tritiated cAMP. lOOjal of binding protein was added to the samples 
and tubes were vortexed and incubated at 4°C for 2-3 hours. After this time, 
250|il charcoal solution was added, and tubes were immediately vortexed and 
centrifuged in a microfuge at 12,000gav for 5 minutes. A 3G0p,l aliquot was 
removed from the resulting supernatant, added to 2ml Ecoscint and counted 
and a curve fitting program used to determine pmols cAMP relative to the 
standard curve.
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2.3.10 Adenylyl cyclase assay 
Adenylyl cyclase activity was determined by a modification of an
assay described previously by Houslay et a l, 1976. Briefly, this involved 
using an assay mixture containing lOpl of membranes (30-40pg/p,l protein), 
50}il of buffer/ATP regenerating system (section 2.2), ligands present at the 
concentrations required and a final volume made up to lOOpl with water. 
These were then incubated at 30°C for 10 minutes before an equal volume of 
4% PCA was added to stop the reaction. The samples were centrifuged, the 
supernatants were neutralised with TEA/HCl pH7.4 and the cyclic AMP 
content was measured as described previously (section 2.3.9)
2.3.11 Cyclic AMP phosphodiesterase assay.
2.3.11.1 Assay principle
Cyclic AMP phosphodiesterase activity was assayed by a modification 
of the two-step procedure of Thompson and Appleman (1971) and Rutten 
et.al (1973) as previously described by Marchmont and Houslay (1980b).
The principle of the assay is outlined in Figure 2.1. Briefly, [^H]-cyclic 
nucleotide (8  position of the adenine ring) is hydrolysed to form labelled 
nucleotide mono-phosphate. The nucleotide mono-phosphate ring is then 
converted to the conesponding labelled nucleoside by incubation with snake 
venom which has 5’-nucleotidase activity. The conditions are such that 
complete conversion takes place within the incubation time. Unhydrolysed 
cyclic nucleotide is separated from the nucleoside by batch binding of the 
mixture to Dowex-1-chloride. This binds the charged nucleotides, but not the 
uncharged nucleoside
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2.3.11.2 Preparation of Powex-Cl
400g powex was added to 4L of IM NaOH and stirred gently for 
15min. This was left to settle, and the powex was washed in distilled water 
until a pH of approximately 7 attained.
4L of IM HCl was then added and stirred for 15min, Dowex resin was 
washed in distilled H2O until the pH was approximately 3. Dowex was stored 
as 1:1  (v/v) slurry solution in H2 O at 4°C , and used as 1 :1:1  
(Dowex:ethanol:H2 0 ) sluiry in the PDE assay.
2.3.11.3 Assay procedure
The enzymes sample (approximately 150|ig protein/25pl) was added 
to 20mM Tris/HCl, pH7.4, 5mM MgCla (25|il) containing the required 
phosphodiesterase effectors at the desired concentration, at 4°C. The reaction 
was started with the addition of 2jiM cAMP containing 0.15|aCi cAMP (SOpl), 
mixing the tubes by vortexing, and incubating for 10 minutes at 30°C. After 
this time the tubes were placed in a boiling water bath for 2  minutes to 
terminate the phosphodiesterase activity. The samples were then allowed to 
cool on ice. 25pl snake venom (1 mg/ml) was added to the tubes and they 
were incubated for lOmins in a 30°C waterbath. The tubes were then placed 
on ice, and freshly prepared slurry of Dowex : ethanol : water (1:1:1) (400pi) 
was added. Duiing this addition, the Dowex was stined gently to ensure that 
a homogeneous suspension was being added. The tubes were vortexed twice 
over a 15 minute period, and then spun in a benchtop centrifuge (Jouan) at 12 
OOOgav to sediment out the Dowex resin. An aliquot of 150pJ supernatant was 
removed and mixed with 2ml Ecoscint, before being counted in a liquid 
scintillation counter for 1 minute per sample.
All assays were conducted at 30*^0. PDE inhibitors were dissolved in 
DMSO at a stock concentration and subsequently diluted in 20mM Tris/HCl
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(pH 7.4) to provide a range of drug concentrations. Routine cyclic AMP-PDE 
activity assays use a cyclic AMP substrate concentration of IpM.
2.3.12 Bradford assay
The protein concentration in the membrane and cytosolic fractions was 
determined by the Bradford (1976) method using BSA as a standard.
2.3.13 Lactate dehydrogenase (LDH) assay
The assay was used to provide a measure of synaptosomal integrity. 
The level of LDH was ascertained by measuring the rate of oxidation of 
NADH. NADH absorbs at 340nmmnd therefore the rate of decrease of optical 
density at 340nm absorbance is a measure of enzyme activity.
Free LDH was measured first, the Triton (2% v/v final) was used to 
burst open any intact cells and total LDH measured. The difference between 
the total and the free LDH levels gives the occluded LDH in the cells under 
investigation. Each reaction comprised 1.35ml Tris/HCl (0.15M), 50pl 
sodium pyruvate (lOmM) and 50pl tissue sample in a final volume of 1.5ml 
where 50pl P-NADH (2mM) is added as substrate. A340  was determined 
before and after addition of LDH.
% Cells broken = Free LDH X 100 
Total LDH
2.3.14 Inducing diabetes in rats
Rats were subjected to i.p.(intraperitoneal) injection with 80mg/kg 
(each rat weighed 200-250g) streptozotocin (dissolved in 0.3ml citrate buffer 
which contained O.IM sodium citrate and O.IM citr|ç  acid pH 4.5). A 
diabetic state ensued after 3-7 days. Animals were judged to be diabetic with
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assessment of glucose levels in urine and blood, was done as described by 
Gawler e/â/., 1987.
2.3.15 Dissection of the rat brain
Animals were killed rapidly by decapitation and the fur covering the 
skull was removed. After dissecting the covering of the brain, the cavity was 
opened by peeling the two halves of the bone back off the brain. The intact 
brain could then be gently removed with a round ended spatula.
In the now empty brain cavity, it was possible to identify the olfactory 
bulb (at front of snout, possibly covered by membrane), the optic chiasima 
which is white neural tissue and the pituitary gland. With the front of the 
brain facing away, the cerebellum could be gently teased off with a spatula. 
The medulla is underneath this and could be cut away with scissors. To open 
up the cortex, a scalpel was gently inserted between the two lobes of the 
cortex to peel it open; this exposes the frontal and parietal cortex, the globus 
pallidus. the caudate putamen and the hippocampus.
The different regions were immediately weighed and used for the 
isolation of RNA.
2.3.16 RNA extraction
2.3.16.1 RNA extraction by Tri-reagent
This method is available to isolate RNA from tissue, cells in
suspension and monolayer. All procedures are under sterile conditions.
A small tissue sample was homogenised in Tri-reagent(T-R) (1ml per
50-100mg tissue) using a sterilized glass homogeniser. The homogenate was
left at room temperature for 5min and 1ml fractions transferred to microfuge
tubes. Cell membranes/high MW DNA/polysaccharide were spun down at
12,000g for lOmins at 4°C and the supernatant transferred to a new eppendorf 
tube.
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RNA was then separated from DNA and protein by the following
phase separation:
0.2ml RNAse-free chloroform was added per 1ml of T-R, vortexed for 
15 seconds and then stored at room temperature for 3 mins. Following 
centrifugation at 12,000g for 15 mins at 4 ^ ,  most of the upper aqueous phase 
was transferred to new eppendorfs.
RNA was then p recipitated from this phase by adding 
isopropanol(propan-2-ol): 0.5 ml per 1ml of T-R used initially. Samples were 
left at room temperature for 5-10 mins and centrifuged at 12,000g for lOmins 
at 4°C. RNA pelleted on side and bottom of tube.
The supernatant was removed and 1ml of 75% ethanol was added to 
wash the RNA. Samples can be stored at this stage at 4°C for a week or 
-20°C for 1 year. Ethanol was removed by spinning at 7500g for 5mins at 
4°C and the RNA pellet dried under vacuum for 5-10 mins. The RNA was 
resolubilised in (1%) DEPC treated water by pipetting a few times and 
incubating for 10-15 mins at 55‘^ C-60‘^ C.
2.3.16.2 Determining RNA concentration
The concentration of the RNA was determined by measuring the 
V A 260 of an aliquot of the final preparation. A 1/100 dilution of the 
resuspended RNA was used to read the absorbance at 260nm against a dH20 
blank, and the RNA concentration calculated as follows:
A solution of RNA with ' A260=l contains approximately 40|ig of 
RNA per ml, therefore multiply the reading by the dilution factor and by 40 to 
give the concentration per ml; the total amount of RNA can then be 
determined by multiplying this figure by the volume of the RNA. Thus, for 
example, an A26O reading of 0.213 gives:
RNA 0.213 X 100 (dilution) x 40 (factor) = 852iag/ml~ 0.852pg/|il
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This then allows dilution of the RNA to the required working concentration.
2.3.17 First strand cDNA synthesis
Sterile microfuge tubes and pipette tips were used throughout the 
whole procedure.
5pg of RNA was added to a sterile 0.5ml microfuge tube with DEPC 
treated water to a total volume of 20pl. This was then heated to 65°C in a 
PCR machine for 10 mins.and the sample chilled on ice.
To a second, sterile 0.5ml microcentrifuge tube, the following 
components were added;
11 pi of " Bulk 1st strand reaction mix"
Ipl of "DTT" solution
Ipl of "Not I-d(T) 18" (0.2pg/pl) primer
After gently pipetting up and down and following a brief spin, 2Gpl of 
heat-denatured RNA from first tube was added to this mix and incubated at 
37®C for 1 hour. The resultant first strand cDNA synthesised using the RNA 
as a template was then stored at -7 0 ^ .
2.3.18 PCR (polymerase chain reaction)
The following components were combined in a 0.5ml microcentrifuge
tube with dNTP (0.2mM), MgCl2 (25mM); Taq polymerase (5units/pl); 5'
primer (25pmole); 3' primer (25pmole) and Ipg of template DNA to a total
volume of 50pl with DEPC treated H2 O. The reaction mix was overlayed
with 40pl of mineral oil and used in a PCR machine programmed for
approximately 40 cycles of denaturation/annealing and extension. For
example a PCR programme may employ 40 cycles of the following conditions
Dénaturation 94°C Imin
Annealing 50°C 2min
Extension 72^C 3min
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Annealing temperatures, however, are dependent on the true melting 
temperatures of the individual primers, see individual experiments for exact 
conditions used.
2.3.19 Purifîcaton of oligonucleotides
2.3.19.1 Precipitation of oilgonucleotides
Synthesised oligonucleotides were supplied as NH4 OH solutions and 
had to be purified before use. This was:
Oligonucleotide solution 300pl
3M sodium acetate (pH 4.6) 3Gpl
70% absolute ethanol lOOOpl
This was incubated with 3M sodium acetate pH4.6 and 70% ethanol at 
-70^C for at least 15 mins. Samples were then spun in a microcentrifuge at 
12,000g for 15mins. The supernatant was removed and discarded, leaving the 
pellet visible in the bottom of the tube. The pellet was then washed with 
lOOOpl of 70% ethanol and spun as above, after which it was vacuum dried for 
15 mins. and then resuspended in 30pl of sterile dH2 0 .
2.3.19.2 Quantitation of oligonucleotides
The principles of oligonucleotide concentration measurements are the 
same as for RNA except that here a solution of oligonucleotides with an 
/\260=1 contains approximately 33pg of RNA per ml, therefore multiply the 
reading by the dilution factor and then by 33 to give the concentration per ml.
2.3.20 DNA purification
After the PCR reactions were complete the mineral oil was removed
and the sample extracted with an equal volume of chloroform to remove
residual oil. A small fraction of the sample (5pi) was removed and retained
whilst the remainder was digested with the required restriction enzymes
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.according to the manufacturers' instructions (normally digest samples
overnight at 37 ®C).
After digestion the fragment was cleaned to remove small digestion 
products by mnning the entire reaction mixture on a 1.5% low melting agarose 
gel.
The band of interest was then excised from the gel and purified from 
the agarose by using Promega DNA purification systems as follows.
The agarose slice containing the DNA fragment was melted by heating 
at 70°C for 2min, then 1ml of the purification resin was added and the 
solution vortexed for ISseconds. The resin was then applied to a minicolumn 
connected to a 2m 1 plastic syringe and washed by running 2ml of 80% 
isopropyl alcohol through the syringe. After discarding the syringe, the 
minicolumn was transferred to a 1.5ml microfuge tube and spun for 20 
seconds.
The minicolumn was placed in a fresh microcentrifuge tube and 30- 
50pl of dH20 (preheated to 70^,G) was added to the minicolumn. After 
incubation at room temperature for Imin the DNA was collected by spinning 
the tube in a microfuge for 5 second.
DNA prepared in this manner was then used in ligations.
2.3.21 Antibody preparation
2.3.21.1 Antibody production
Polyclonal PDE antisera used for immunoblotting were raised in New
Zealand White rabbits against synthetic peptides. These were synthesised
with a cysteine at the C-termiiius in order to facilitate conjugation to keyhole
limpet haemocyanin (KLH), as described by Lerner (1981). Antiserum was
normally added to KLH-Sepharose and mixed overnight at 4°C before being
centrifuged briefly to pellet the sepharose. The supernatant was collected and
dialysed overnight against 20mM Tris/HCl pH 8/1.4M NaCl at 4°C. In each
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instance the sera from rabbits were used with up to 3 different bleeds with 
essentially identical results being obtained. Peptide used are listed below:
Antisemm Code 
1992 
652/653 
Anti4D
Peptide used PDE epitope Antisemm name
TPGRWGSGGDPA RDI 598-610 PDE4A 
ATEDKSSLIDT DPD 508-517 PDE4B 
Sequence unavailable C-terminal mPDE4D PDE4D
2.3.21.2 Preparation of anti-serum
10-20ml blood was obtained from the ear artery of rabbits and left 
overnight at 4°C to allow clot formation and contraction. The serum was 
removed and centrifuged at lOOOg for 5min. The supernatant was retained 
and 0.05% sodium azide added. This was then split into small aliquots (eg. 
lOOpl) and stored at -80 °C. The test of anti-serum was carried out by ELISA.
2.3.21.3 ELISA
This method was used to detect the most effective antibody dilution. 
Antigen was diluted with PBS (1:100) and used to coat the sensitized plastic 
plate overnight. The plate was then incubated in PBS buffer (containing 0.1% 
BSA, 0.1% Tween-20) for 2 hours and washed with PBS buffer 3 times. 
Addition of first antibody (50fil/well) at various dilutions for 2 hours was 
followed by washing in PBS 3 times. The second antibody (HRP-anti-rabbit 
IgG 1:1000 dilution with PBS) was added for 30mins. After washing as 
before, the plate was developed with H2O 2 in 0-phenylenediamine (OPD) 
containing buffer for 5min. The amount of test antibody was measured by 
assessing the amount of coloured end-product by reading _ A492nm. From 
this value the most effective antibody dilution could be determined.
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2.3.22 Gel electrophoresis
Sodium dodecyl sulphate polyacrylamide gel electrophoresis was 
earned out by the method of Laemmli (1970).
2.3.22.1 Resolving gel preparation
8% (w/v) acrylamide gels were prepared using mixtures as detailed in 
the section 2.2. Solutions were poured between 180x160mm glass plates 
separated by 1.5mm spacers and allowed to set at room temperature.
2.3.22.2 Stacking gel preparation
Stacking gels were prepared as detailed in the section 2.2 and the 
solution layered on top of the resolving gel and allowed to set around a 10- 
well teflon comb. Gels were run at 8mA/gel overnight or 50mA/gel for 4- 
5hours with cooling.
2.3.23 Western blotting
Proteins were transferred from the SDS gel to nitrocellulose at lAm^ 
setting for 2 hours in a transblot apparatus (Hoefer Instruments). The 'blotting 
buffer' used was described previously in the section 2.2.
The nitrocellulose was then incubated in 20mM Tris/HCl pH7.5 with 
500mM NaCl (i.e. TBS) and 5% dried milk powder for 2 hours at room 
temperature. This stage blocks any non-specific protein binding. After 2 
hours the 5% dried milk powder/TBS was poured off and the nitrocellulose 
washed briefly with distilled water before washing twice with TBS containing
0.2% Nonident P40 and twice with TBS, each for 5 minutes. The 
nitrocellulose was then immunoblotted with TBS containing 1% dried milk 
powder and a 1:250 dilution of the appropriate antisera for 2 hours.
After immunoblotting, the nitrocellulose was washed as before and
incubated for 2 hours in TBS with 1% dried milk powder plus lOpl of anti-
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rabbit peroxidase linked IgG or ^^^I-labelled anti-(rabbit IgG). With 
antirabbit peroxidase linked IgG, the Amersham enhanced chemiluminescence 
(ECL) Western blotting visualization protocol was used to detect the bands, 
w hilst i^^I-labelled bands were visualised by autoradiography or 
phosphoimaging. Quantification of the relative amounts of antigen present in 
each of the fractions was done in a variety of ways, as described (Bushrield et 
al 1990), in order to identify situations where a linear relationship held 
between the amount of antigen present and the magnitude of the signal 
detected. The densitometric scanning of the ECL experiments was done using 
both photosensitive Amersham film and X-ray film with various exposure 
times and a range of applied protein concentrations so as to identify a linear 
detection range. Confirmation was also obtained in selected instances using 
125_i labelled anti-rabbit IgG with excision of the labelled bands identified by 
auto-radiography, for counting, as described previously by Bushfield et ciL, 
(1990); Tang (1993).
2.3.24 COS cell transfection
2.3.24.1 DEAE Dextran COS cell transfection
The SV40-transformed monkey kidney cell line (COS-7) was cultured 
at 37°C in an atmosphere of 5% C02/95% air in a complete growth medium 
containing DMEM (xl) and 10% (v/v) penicillin/streptomycin (lOOunits/ml) 
supplemented with 10% (v/v) foetal calf serum.
Confluent flasks were split to 1/3 confluence by plating in 75cm^
flask/10cm plates, and left overnight. DNA for transfection (5p.g) was diluted
to 250|il in lOmMTris/HCl, ImM EDTA buffer and 200|il of DEAE dextran
was added. This DNA/dextran mix was then left at room temperature for
15min. Medium was aspirated from the COS cells and 10ml transfection
medium added. The DNA/DEAE dextran mix was added drop wise onto the
cells and mixed by swirling the flask. Cells were incubated for 3-4 hours at
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3 7 0 c  in an atmosphere of 95% air/5% CO2 . Medium was then aspirated and 
5ml of 10% DMSO in PBS added for 2min at room temperature (the longer 
DMSO stays in contact with cells, the more DNA is taken up but, as damage 
is also caused to the cells, then more cells will die). Cells were washed with 
PBS and 10ml of DMEM (xl) containing 10% (v/v) serum was added to the 
plates before tliey were incubated at 37®C for 72 hours. Maximum expression 
should occur during this time.
Mock-transfected cells were treated as above but received no DNA.
2.3.24.2 Preparation of cell extracts
After cells were transfected as described above, they were prepared for 
homogenization as follows: the growth medium was removed and the cells 
incubated in complete KHEM for 45min at 4^C. Cells were then washed with 
5ml of lOmM triethanolamine/0.15M KCl at 4®C for lOmin, the TEA/KCl 
was aspirated and cells washed with 5ml of KHEM imcomplete buffer. 
Finally cells were washed with 1ml complete KHEM for 2min and then 
drained of buffer. Cells were scraped into a final volume of lOOpl per plate 
and this cell suspension was homogenised by 20 down strokes in a glass 
dounce homogeniser. Subcellular fractionation was performed as described 
for P9 cells (section 2.3.7.1).
2.3.25 Immunoprécipitation of PDE activity
Solubilized membrane fractions, homogenate and cytosol (500jig of
starting material) fractions were used as sources of material for the specific
immunoprécipitation of PDE activity. Anti serum was added to each sample at
a dilution of 1:10 to 1:100 and the samples brielly vortexed before being left
overnight at 4°C in order to allow conjugation to occur. Pansorbin (10%) was
then added and the resultant suspension gently mixed at 4°C for 2h. The
preparations were then centrifuged at 14000g for 2min and the pellets were
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resuspended in the immiinoprecipitaLion buffer before being recentrifuged as 
before. The resultant pellets were then washed twice more. The final pellet 
was resuspended in PDE assay buffer (section 2.2) and assayed (section 
2.3.11) immediately.
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Chapter 3
Insulin and vasopressin elicit inhibition of cholera-toxin- 
stimulated adenylyl cyclase activity in both hepatocytes and 
the P9 immortalized hepatocyte cell line through an action 
involving protein kinase C
Introduction
The adenylyl cyclase system is responsible for generating the 
intracellular second messenger cyclic AMP. It is now recognised that this 
activity is expressed by a large m ulti-gene family whose regulatory 
characteristics would seem to be remarkably different (Cooper et ah, 1994; 
Jacobowitz et a l,  1993; Chen and Iyengar, 1993; Yoshimura and Cooper, 
1993). For example, there are distinct isoforms whose activity can be regulated 
by Ca^VCaM, phorbol esters and G-protein py subunits. All species reported 
on to date, however, appear to be activated by the diterpene forskolin which 
acts directly upon the catalytic unit of the enzyme (Seamon et al, 1981) and 
also by the G-protein Gg, which mediates not only the effect of stimulatory 
hormones but also the action of cholera toxin (Bimbaumer et a l,  1990; Gilman, 
1987; Gierschik and Jakobs, 1990), Thus, occupied receptors interact with Gg 
causing it to bind GTP and dissociate to yield a GTP-bound a-subunit which 
serves to activate adenylyl cyclase (Bimbaumer et al, 1990; Gilman, 1987; 
Gierschik and Jakobs, 1990). Cholera toxin achieves adenylyl cyclase 
activation after a characteristic lag phase (Houslay and Elliott, 1979) which is 
considered (Houslay and Elliott, 1981; Orlandi et a l,  1993) to reflect toxin 
entry into the cell by endocytosis with subsequent processing to deliver the 
activated cholera toxin a-subunit to the cytosol surface of the plasma 
membrane. This activated species then elicits the N A D ^-dependent 
ADP-ribosylation of G%t(Birnbaumer e ta l ,  1990; Gilman, 1987; Gierschik 
and Jakobs, 1990) allowing it to dissociate in a GTP-bound state. However, 
ADP-ribosylated G%gs unable to hydrolyse GTP and undergo inactivation. 
Thus the entire pool of Gg becomes chronically activated by attaining the fully 
activated GTP-bound state, leading to the constitutive activation of adenylyl 
cyclase (Bimbaumer etal., 1990; Gilman, 1987; Gierschik and Jakobs, 1990).
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Hepatocytes have an adenylyl cyclase system that is able to be potently 
activated by the hormone glucagon (Johnson et a l, 1972; Hey worth and 
Houslay, 1983; Murphy er o/., 1987; Refnes et al, 1989). However, in intact 
cells, this activation is rapidly followed by a profound desensitization effect 
which occurs independently of any increase in intracellular cyclic AMP 
concentrations (Heyworth and Houslay, 1983; Murphy e ta l ,  1987; Refnes gr 
al,  1989; Murphy and Houslay, 1988). This effect is in itself transient with 
resensitization attaining near completion some 20min after hormonal addition 
(Houslay, 1991). The nature of this desensitization appears to take the foi*m of 
an uncoupling of the ability of the glucagon receptor to stimulate Gg with no 
inhibition being evident of either the catalytic activity of adenylyl cyclase or Gg- 
adenylyl cyclase coupling (Heyworth and Houslay, 1983; Murphy e ta l ,  1987; 
Houslay, 1991; Houslay, 1994). Such a process appears to be mediated 
through the action of protein kinase C (Murphy et al, 1987; Houslay, 1991; 
Houslay, 1994; Savage et a l,  1995), which itself becomes activated in 
hepatocytes in response to glucagon (Pittner and Fain, 1991). Thus 
desensitization can be mimicked by hormones such as vasopressin and 
angiotensin as well as the tumour promoting phorbol ester PM A, all of which 
activate protein kinase C in hepatocytes (Houslay, 1991; Houslay, 1994; 
Savage et a l, 1995; Tang and Houslay, 1992) and whose abilities to elicit 
desensitization can be blocked by protein kinase C inhibitors (Savage et a l,  
1995).
It has previously been shown that cholera toxin activates hepatocyte 
adenylyl cyclase activity after a characteristic lag time of -15 min. (Houslay and 
Elliott, 1979; Houslay and Elliott, 1981). Additionally it was noted that the 
maximal degree of activation that was achieved by cholera toxin could be 
attenuated by the presence of the hormones glucagon and insulin (Heyworth at 
a l ,  1984). These hormones neither affected the lag time for the action of
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choiera toxin nor did they alter the degree of ADP-ribosylation of Gg 
(Heyworth 1984).
In this study I have shown that a profound inhibitoiy action on the ability 
of cholera toxin to stimulate hepatocyte adenylyl cyclase can be achieved 
through either the activation of protein kinase C or the inhibition of protein 
phosphatase activity (Zeng and Houslay, 1995). Such inhibition appears to be 
regulated through the phosphorylation of a membrane protein. This target may 
be provided by a specific foim of adenylyl cyclase which can be phosphorylated 
by particular isoforms of PKC. Such inhibition could be demonstrated in 
hepatocytes and the immortalised hepatocyte P9 cell line but it was not apparent 
in either NIH-3T3 fibroblasts or CHO cells.
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Results
Cholera toxin is known to cause the NAD+ dependent ADP-ribosylation 
of the Gsa-subunit; This ADP-ribosylation, occurring in the presence of GTP, 
causes the dissociation of Gg to release a free Gga-subunit,which is trapped in 
its active GTP-bound form. This species caused the constitutive activation of 
adenylyl cyclase activity at a range of cholera-toxin concentrations (Figure
3,1) after a well-defined lag period of around 10-15min in hepatocytes 
(Figure 3.2). However, the magnitude of this stimulatory effect of cholera 
toxin was shown to be profoundly attenuated if either glucagon or insulin was 
added to hepatocytes along with cholera toxin (Figure 3.3) without any 
change in the lag time for onset of activation of adenylyl cyclase.
In addition to this, we showed here that both the hormone vasopressin 
and the tumour-promoting phorbol ester PM A can also attenuate cholera-toxin- 
stimulated adenylyl cyclase activity (Table 3.1) without affecting the lag time 
for activation by this toxin.
This inhibitory effect on adenylyl cyclase elicited by both insulin and 
vasopressin could be blocked by challenging the hepatocytes with either of the 
selective PKC inhibitors, staurosporine or chelerythrine (Nixon e ta l ,  1992; 
Herbert et a l,  1990; Gordge and Ryves, 1994) (Table 3.1; Figure 3.4). 
These compounds had, however, no apparent effect on the magnitude of 
activation of adenylyl cyclase by cholera toxin achieved in the absence of these 
hormones (Table 3.1).
In contrast with this, exposure of cells to the protein phosphatase inhibitor 
okadaic acid elicited a profound decreased in the cholera-toxin-stimulated 
adenylyl cyclase activity (Figure 3.5).
Treatment of membranes with alkaline phosphatase (Table 3.1) has 
been used to achieve the dephosphoi^lation of phosphorylated cellular proteins 
(Savage et a l,  1995; Pears et al, 1992). Diminished cholera-toxin-stimulated
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adenylyl cyclase activity was observed in membranes from cells which had been 
challenged with PM A, vasopressin or insulin (Table 3.1). In each of these 
instances, however, membrane treatment with alkaline phosphatase increased 
adenylyl cyclase activity up to a level approaching diat seen in membranes from 
cells which had only been challenged with cholera toxin (Figure 3.6).
Interestingly, when incubated together, the ability of insulin, PMA and 
vasopressin to inhibit cholera toxin stimulated adenylyl cyclase was not additive 
(Figure 3.7). Furthermore, I have shown here that treatment of hepatocytes 
with the phorbol ester PMA did not inhibit the activity of either the catalytic unit 
of adenylyl cyclase (assayed by monitoring both basal activity and that 
amplified by forskolin (Figure 3.8 (a)) or Gg-stimulated adenylyl cyclase 
when monitored with NaF (Figure 3.8 (b)).
An immortalized hepatocyte cell line, generated using SV40 DNA 
(Livingstone et al., 1994) was shown to express G-protein-regulated adenylyl 
cyclase activity and a functional high-affinity insulin response (Livingston et 
al., 1994). Here I demonstrated that the adenylyl cyclase activity in such cells 
could be markedly stimulated by cholera toxin (Figure 3.9) and that this 
activity could be inhibited by either PMA or insulin treatment (Figure 3.10) 
in a similar fashion to that seen with native hepatocytes. Such inhibitory effects 
were obseiwed when adenylyl cyclase activity was assessed, either directly in 
membranes isolated from such cells or, in situ, by assessing cAMP 
accumulation in the presence of the phosphodiesterase inhibitor IBMX (Table
3 .2) .
Cholera toxin was also able to achieve a marked stimulation of adenylyl 
cyclase activity in both CHO (Figure 3.11; Table 3.3) and NIH-3T3 cells 
(Figure 3.12; Table 3.3). However, in contrast with expriments done with 
hepatocyte and P9 cells, this activity was not attenuated by treatment with the 
phorbol ester PMA (Figure 3.13; Table 3.3). Indeed, treatment of NIH- 
3T3 cells with PMA led to an increase in cholera-toxin-stimulated adenylyl
112
cyclase activity when assayed either in membranes isolated from such cells Ort 
in situ, by assessing cAMP accumulation in the presence of the 
phosphodiesterase inhibitor IBMX (Figure 3.14; Table 3.3). This was not 
observed in the native CHO cells (Table 3.3). Meanwhile, I also investigated 
the action of PMA in CHO cells which had been transfected so as to 
overexpress various PKC isoforms. In no instance, however, did I observe 
any inhibition by phorbol ester. Interestingly though, we noted that PMA 
mediated an increase in the cholera-toxin-stimulated adenylyl cyclase activity of 
CHO cells transfected so as to overexpress PKC-y (Table 3.3). These 
observations appeared to be independent of whether adenylyl cyclase activity 
was gauged by direct membrane assay or through determining intracellular 
cyclic AMP accumulation in the presence of a phosphodiesterase inhibitor.
The thermostability of adenylyl cyclase in hepatocytes and CHO cells was 
carried out as described in methods section 2.3.8. Results are shown as % 
activity plots for the decay of adenylyl cyclase activity in enzyme fractions 
incubated at different temperatures. Figure 3.15 shows dénaturation of 
adenylyl cyclase activity with increasing temperature. One component of the 
activity was fully denatured at 40°C in CHO cells whereas, in hepatocytes, 
similar dénaturation of adenylyl cyclase is observed up to 50°C (Figure
3.15). From the level of thermostable activity remaining, it would seem that in 
hepatocytes more adenylyl cyclase activity appears to be temperature sensitive 
whilst in CHO cells, more adenylyl cyclase appears temperature insensitive 
(Figure 3.15). When enzyme fractions were incubated at elevated 
temperatures (50°C) for both hepatocyte and CHO cells, the decay of adenylyl 
cyclase activity in hepatocytes was observed as two single exponentials, as 
indicated by the linear semi-logarithmic plots of activity against time (Figure
3.16). This was consistent witli at least two enzyme activities being analysed. 
The same profile for CHO cells also contained two single exponentials 
supporting the presence of at least two types of adenylyl cyclase activity being
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present (Figure 3.16). However, this did contrast with hepatocytes where 
the linear semi-logarithmic plots were different indicating that different enzymes 
may contribute to adenylyl cyclase activity in those cells. Meanwhile, assay of 
the thermostability of adenylyl cyclase activity in P9 cells showed a similar 
profile of thermostability to that indicated in hepatocytes (Figure 3.17), 
implying similar adenylyl cyclase activity to be expressed in both cells.
In order to see if there were indeed different adenylyl cyclase isoforms in 
hepatocyte, P9, NIH3T3 and CHO cells, RT-PCR was carried out with sense 
and antisense primers. These were able to detect type I, II, IV, V and VI 
adenylyl cyclase isofonns specifically. Under the appropriate reaction condition 
(see individual figure legends), PCR products were analysed by running in 2% 
minicgoifotie gel and visualising products with ethidium bromide under UV light. 
Results showed that there was neither type I (Figure 3.18 (a)) nor type II 
adenylyl cyclase (Figure 3.18(b)) in any of these cells; there was type IV 
adenylyl cyclase in hepatocytes and CHO cells but not in the P9 and NIH-3T3 
cells (Figure 3.18 (c)). As for the type V adenylyl cyclase, this was found 
in both hepatocyte and P9 cells but not in the CHO and NIH-3T3 cells (Figure 
3.18 (d)). Whilst results showed that type VI adenylyl cyclase was expressed 
in the hepatocyte, P9 and NIH-3T3 cells, it was not found in the CHO cells 
(Figure 3.18 (e)). The use of adenylyl cyclase-specific primers to analyse 
PCR products obseived within different tissues, therefore, indicated that certain 
types of adenylyl cyclase are tissue specific. Here we demonstrated the 
presence of type V and VI adenylyl cyclase in hepatocyte and P9 cells. It is 
likely that type V could provide the target membrane protein for 
phosphorylation by particular isoforms of PKC (see section 1.3.4.3), as it is 
not expressed in the CHO and NIH-3T3 cells (Figure 3.18 (d); (e)), where 
protein kinase C-mediated attenuation of adenylyl cyclase activity was not 
detectable.
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These results also show the thermal denatuation profiles to be an 
oversimplification, as on the basis of transcript analysis more than the 
predicated two fonms of adenylyl cyclase were shown to exist in hepatocytes,
i.e. at least types IV, V and VI occur. Similarly, in CHO cells thermal 
dénaturation showed (Figure 3.16) two forms of adenylyl cyclase to exist, 
yet by PCR studies, we were only able to detect type IV adenylyl cyclase. Of 
course other isoforms of adenylyl cyclase may occur in these cells which we 
have not looked at, either due to lack of available tools (e.g. for type III 
adenylyl cyclase) or because they remain, as yet unidentified isoforms.
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Figure 3.1 Dose dependence of cholera toxin-stimulated cAMP
response in hepatocytes
Hepatocytes were treated with increasing concentrations of cholera toxin in the 
presence of ImM IBMX for 60min at 37°C. Intracellular cAMP was determined 
as described in methods section (2,3.9.3). Results are means±S.E. for n=3 
experiments using different cell preparations from different animals.
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Figure 3.2 Time dependence of cholera toxin-stimulatedadenylyl cyclase 
response in hepatocytes
Hepatocytes were treated with l|ig/ml of cholera toxin at different times over a 
period of 60min at 37^C. At the indicated times, adenylyl cyclase activity was 
determined as described in methods section (2.3.10). Results are means±S.E. 
for n=5 experiments using different cell preparations from different animals.
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Figure 3.3 The presence of insulin and glucagon attenuates the
ability of cholera toxin to activate adenylyl cyclase in intact
hepatocytes
Hepatocytes were treated at 37°C with l|ig/ml cholera toxin (a) in the absence 
of any other ligands, (b) in the presence of lOnM-insulin or (c) in the presence 
of lOnM-glucagon over 60min. At the time points shown, cells were haiwested 
and a washed membrane fraction was taken to assess basal adenylyl cyclase 
activity see methods section (2.3.10). Results are means±S.E. for n=2 
experiments using different cell preparations from different animals.
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Figure 3.4 PKC inhibitors can blocked the vasopressin and 
insulin mediated attenuation of cholera toxin stimulated adenylyl 
cyclase activity, in hepatocytes
Hepatocytes were incubated for Ih with cholera toxin (l|ig/ml), harvested, and 
a washed membrane fraction was then prepared and taken to assess adenylyl 
cyclase activity as described in methods section (2.3.10). Where indicated, 
other ligands were added together with cholera toxin in the hepatocyte 
incubation; vasopressin was added at a final concentrations of lOnM, PMA was 
added at lOOnM and staurosporine and chelerythrine were added at final 
concentrations of lOOnM and 10(iM respectively.
Results are means±S.E. for n=3 experiments using different cell preparations 
from different animals.
In experimental sets the cholera toxin stimulated adenylyl cyclase value (7.6 
praols/min/mg of protein) was taken as the native stimulation regarded as 
100%.
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Figure 3,5 Okadaic acid mimics PKC*s ability to attenuate
cholera-toxin stimulated adenylyl cyclase activity in hepatocytes
Hepatocytes were treated at 37°C with cholera toxin (Ipg/ml) in the absence of 
any other ligand or in the presence of lOOnM okadaic acid, harvested and a 
washed membrane fraction was then prepared and taken to assess adenylyl 
cyclase activity as described in methods section (2.3.10). Results are 
means±S.E. Similar* data were obtained in two other experiments from different 
animals.
In experimental sets the cholera toxin stimulated adenylyl cyclase value (9.2 
pmols/min/mg of protein) was taken as the native stimulation regarded as 
100%.
120
>
u<
120 1
1 0 0  -
80 -
60 -
40 -
20  -
yre1o+c
X2
2reo
Figure 3.6 Alkaline phosphatase reversed the PKC attenuation of
cholera-toxin stimulated adenylyl cyclase activity in hepatocytes
Hepatocytes were treated at 37°C with cholera toxin (l|ag/ml) in the presence of 
various ligands like vasopressin (lOnM), insulin (lOnM) and PMA (lOOnM) for 
60 mins. In some instances the isolated membrane fraction was subsequently 
treated with alkaline phosphatase (lunit/|il) as described in the method section 
(2.3.5.2). The adenylyl cyclase activity was then assessed by methods section 
(2.3.10). Results are means±S.E. Similar data were obtained in three other 
experiments from different animals.
In experimental sets the cholera toxin stimulated adenylyl cyclase value (5.8 
pmols/min/mg of protein) was taken as the native stimulation regarded as 
100%.
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Figure 3.7 Insulin, PMA and vasopressin were not additive in
their ability to inhibit cholera-toxin stimulate adenylyl cyclase
activity in hepatocytes
Hepatocytes were treated at yi^C  witli cholera toxin (Ipg/ml) in the presence of
other indicated ligands like insulin (lOnM), vasopressin (lOnM) and PMA
(lOOnM) for 60min. The isolated membrane fraction was then obtained for use
in assessing adenylyl cyclase activity by methods section (2.3. IG). Results are
means+S.E. Similar results were obtained in an other experiments.
In experimental sets the cholera toxin stimulated adenylyl cyclase value (6.5 
pmols/min/mg of protein) was taken as the native stimulation regarded as 
100%.
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Figure 3.8 (a) PMA_ treatmen^ Qf did not affect th e
cata ly t ic unit  o.£..ad.eiiy.lyi g y  class
Hepatocytes were incubated alone at 37°C for Ih or in the presence of PMA 
(lOOnM). As the indicated times, a membrane sample was obtained for use in 
assessing basal or forskolin (10|iM) stimulated adenylyl cyclase activity by 
methods section (2.3.10). Similar results were obtained in another experiment.
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■Figure 3,8 (b) PMA treatment of hepatocytes did not affect Gs~
stimulated adenylyl cyclase aclm ty
Hepatocytes were incubated alone at 37°C or in the presence of PMA (lOOnM) 
for over a period of Ih. As the indicated times, a membrane sample was 
obtained for use in assessing basal or NaF (15mM) stimulated adenylyl cyclase 
activity by methods section (2.3.10). Similar results were obtained in another 
experiment.
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Figure 3.9 Time dependence of cholera toxin-stimulated cAMP
response in immortalized hepatocyte P9 cells
P9 cells were treated with Ifig/ml of cholera toxin in the presence of ImM 
IBMX at different times over a period of 60min at 37°C. After the indicated 
time, intracellular cAMP was determined as described in methods section
(2.3.9.3). Results are means±S.E. for n=3 experiments using different cell 
preparations showing similar data.
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Figure 3.10 Inhibition of cholera toxin stim ulated adenylyl
cyclase activity by insulin and PMA in P9 cells
Immortalised hepatocyte P9 cells were incubated with cholera toxin (l|xg/ml) 
for the indicated times together with the cyclic AMP phosphodiesterase inhibitor 
IBMX (ImM). cAMP was assessed by methods section (2.3.9.3).
Data is shown for treatment with either cholera toxin alone or in combination 
with either insulin (lOnM) or PMA (lOOnM) in the hepatocyte incubation. 
Results are means+S.E. This shows typical data of experiments that were done 
on three separate occasions. Intracellular cyclic AMP was expressed as pmol 
cyclic AMP/10^ cells.
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Figure 3.11 Time dependence of the cholera toxin-stim ulated
intracellular cAMP response in CHO HIR ceils
CHO-HIR cells were treated with Ipg/ml of cholera toxin in the presence of the 
phosphodiesterase inhibitor IBMX (ImM) at different times over a period of 2h 
at 37°C. After the indicated times, intracellular cAMP was determined as 
described in methods section (2.3.9.3). Results are means±S.E. for n=5 
experiments using different cell preparations showing similar results.
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Figure 3.12 Time dependence of the cholera toxin-stimulated
intracellular cAMP response in NIH-3T3 cells
NIH-3T3 cells were treated with l|ig/ml of cholera toxin in the presence of PDE 
inhibitor ImM IBMX at different times over a period of 90min at 37°C. After 
the indicated times, intracellular cAMP was detemiined as described in methods 
section (2.3.9.3). Results are mean+S.E. for n=3 experiments using different 
cell preparations showing similar results.
1 2 8
_______ I___________:__ :____________________:____ :______________ ____
.CO
i l<o  co &- ™ 
CO —
2 Ë
fl> CO O W£ Ô *  Ê
20
T
20 40 60 80
t i m e ( m i n u t e s )
________ I'/ y \.X ...... . -A ?" 'Ü:/! .
Figure 3.13 Cholera toxin actived adenylate cvclase activity in 
CHQ cells in a manner which is resistant to inhibition bv PMA
CHO cells were incubated for 2h with cholera toxin (1 jag/ml) in the presence of 
the phosphodiesterase inhibitor IBMX (ImM). They were then harvested, and 
the intracellular concentration of cAMP was determined as desciibed in methods 
section (23 .93). Experiments were done with cholera toxin either alone or 
together with PMA added to the incubations at lOOrtM final concentration. 
Result are means±S.E. Data are typical of experiments done on three separate 
cell preparations.
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Figure 3,14 PMA enhanced cholera-toxin-stimulated adenylyl
cyclase in NIH-3T3 cells
NIH-3T3 cells were incubated for 2h with cholera toxin (l|ag/ml) in the 
presence of the phosphodiesterase inhibitor IBMX (ImM). They were then 
harvested, and the intracellular concentration of cAMP was determined as 
described in methods section (2.3.9.3). Experiments were done with cholera 
toxin either alone or together with PMA added to the incubations at lOOhM final 
concentration. Results are means±S.E. Data are typical of experiments done on 
three sepaiate cell preparations.
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Figure 3.15 Thermal dénaturation of adenylyl cyclase activities
in CHO cells and hepatocytes
Washed membrane fractions were obtained as described in methods section
(2.3.1.3) from hepatocyte and CHO cells. Membranes were incubated at 
increasing temperatures for lOmin. At tlie indicated temperatures, samples were 
taken for assay of adenylyl cyclase activity by methods section (2.3.8). Data 
are typical of experiments done on two other separate preparations.
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Figure 3.16 Thermostability o f adenylyl cyctase activities in
GHO cells and hepatocytes
Washed membrane fraction were obtained as described in methods section
(2.3.1.3) from hepatocyte and CHO cells. Membranes were incubated at the 
elevated temperature 50°C for various times up to lOmin. At the indicated 
times, samples were taken for assessing adenylyl cyclase activity by methods 
section (2.3.10). The plots shown are typical of ones perfoiined at least three 
times using different cell preparations.
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Figure 3.17 ThermostaWlity _of adenylyl cvclase activities in P9
cells
Washed membrane fractions were obtained as described in methods section 
(2.3.7.1) from P9 cells. Membranes were incubated at the elevated temperature 
50°C for various times up to lOmin. At the indicated time, samples were taken 
for assay of adenylyl cyclase activity by methods section (2.3.10). The plots 
shown are typical of ones performed at least three times using different cell 
preparations.
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Figure 3.18 (a) RT-PÇR analyses of type-1. gdet>ylyl cyclasg
transcripts in different cells
This was done as described in methods (section 2.3.18) using the degenerate 
primers designed (Sense; GATCCTGCTC TCCGGGCTCA. Antisense; 
CTTCTCAGCA GCCGGTGGAC T) to detect transcripts selectively for the 
type~I adenylyl cyclase in a species independent fashion. PCR reaction 
conditons employed here utilized 1 cycle at 95°C for 5min, 60®C for Imin and 
l l^ C  for Imin, followed by 30 cycles at 95®C for 30 seconds, 60®C for Imin 
and 72^C for Imin, then 1 cycle at 95®C for 30 seconds, 60*^0 for Imin and 
72°C for 5min. This reaction condition allowed the detection of a 830bp 
fragment for type I adenylyl cyclase.
Analyses were performed on rat hepatocytes (H), immortalised hepatocytes 
(P9), CHO cells (C) and NIH-3T3 cells (N). Marker (M), plasmid control (P).
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Figure 3.18 (b) RT-PÇR analyses of type-II adenylyl cyclase
transcripts in different cells
This was done as described in methods (section 2.3.18) using the degenerate 
primers designed (Sense; CACGGATCTCCCTCACAATCGTCA. Antisense; 
TGCGAGTGGG TATCAACCAT GGGC) to detect transcripts selectively for 
the type-II adenylyl cyclase in a species independent fashion, PCR reaction 
conditons employed here utilized 1 cycle at 9 5 ^  for 5min, 6 0 ^  for Imin and 
72°C for Imin, followed by 30 cycles at 95^C for 30 seconds, 60^C for Imin 
and 72°C for Imin, then 1 cycle at 95®C for 30 seconds, 60°C for Imin and 
72°C for 5min. This reaction condition allowed the detection of a 980bp 
fragment for type II adenylyl cyclase.
Analyses were performed on rat hepatocytes (H), immortalised hepatocytes 
(P9), CHO cells (C) and NIH-3T3 cells (N). Marker (M), plasmid control (P).
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Figure 3.18 (c) RT-PCR analyses of type-IV adenylyl expiase 
transcripts in different cells and type V aÆen cyclase 
transcripts in hepatocytes and P9 cells
This was done as described in methods (section 2.3.18) using the degenerate 
primers designed (Sense; CAGGAGCACC TCCTCTTGTC TAT. Antisense; 
GTTGTTCGAT GACCTGGAAG AAC) to detect transcripts selectively for tlie 
type-IV adenylyl cyclase in a species independent fashion. PCR reaction 
conditons employed here utilized 1 cycle at 95®C for 5min, 60°C for 1 rain and 
72°C for Imin, followed by 30 cycles at 95®C for 30 seconds, 60°C for Imin 
and 720C for Imin, then 1 cycle at 95®C for 30 seconds, 60®C for Imin and 
l l ^ C  for 5min. This reaction condition allowed the detection of a 966bp 
fragment for type IV adenylyl cyclase.
For the type V adenylyl cyclase, an aiTow indicating the 861 bp fragment is 
shown only in hepatocytes and P9 cells. For PCR reaction condition see next 
Figure (3.18 (d)).
Analyses were performed on rat hepatocytes (H), immortalised hepatocytes 
(P9), CHO cells (C) and NIH-3T3 cells (N). Marker (M), plasmid control (P).
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Figure 3.18 (d) RT-PCR analysés of type-V adenylyl çyçlase
transcripts in CHO and NIH-3T3 ceils
This was done as described in methods (section 2.3.18) using the degenerate 
primers designed (Sense; CTACAACCAC TTGGGTGGCA AC. Antisense; 
ATACCGTAAC CGCCACTGGT C) to detect transcripts selectively for the 
type-V adenylyl cyclase in a species independent fashion. PCR reaction 
conditons employed here utilized 1 cycle at 9 5 ^  for 5min, 6 0 ^  for Imin and 
72°C for Imin, followed by 30 cycles at 95<^ C for 30 seconds, 60°C for Imin 
and 72®C for Imin, then 1 cycle at 95°C for 30 seconds, bO^ C^ for Imin and 
72°C for 5min. This reaction condition allowed the detection of a 861 bp 
fragment for type V adenylyl cyclase.
Analyses were performed on rat hepatocytes (H), immortalised hepatocytes 
(P9), CHO cells (C) and NIH-3T3 cells (N). Marker (M).
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-Figure 3,18 (e) RT-PCR analyses of type-VI adenylyl cycïase
transcripts in different cells
This was done as described in methods (section 2.3,18) using the degenerate 
primers designed (Sense; CGGAAAGTAGACCCTCGTTTCGGA. Antisense; 
TGCTTAGCGT CCATGGCTTG GC) to detect transcripts selectively for the 
type-VI adenylyl cyclase in a species independent fashion. PCR reaction 
conditons employed here utilized 1 cycle at 95°C for 5min, 60°C for Imin and 
12^C for Imin, followed by 30 cycles at 95®C for 30 seconds, 60°C for Imin 
and 72°C for Imin, then 1 cycle at 95<^ C for 30 seconds, 60°C for Imin and 
72^C for 5min. This reaction condition allowed the detection of a 637bp 
fragment for type VI adenylyl cyclase.
Analyses were performed on rat hepatocytes (H), immortalised hepatocytes 
(P9), CHO cells (C) and NIH-3T3 cells (N). Marker (M), plasmid control (P).
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Table 3,1 Cholera-toxin-stiniulated adenvlyl 
hepatocyte membranes
Hepatocytes were incubated for Ih with cholera toxin (l|ig/ml), harvested, and 
a washed membrane fraction was then prepared and taken to assess adenylyl 
cyclase activity as described in the methods section (2.3.10). Where indicated, 
other ligands were added together with cholera toxin in the hepatocyte 
incubation. Vasopressin, insulin, PMA, staurosporine and chelerythrine were 
added at final concentrations of lOnM, lOnM, lOOiiM, lOOnM and lOpM 
respectly. In some instances the isolated membrane fraction was subsequently 
treated with alkaline phosphatase (lunit/pl) as described in methods section 
(2.3.5.2). Data were presented relative to that activity seen in membranes from 
cells tieated with cholera toxin alone (100%). Results are means±S.E. for n=3 
experiments using different cell preparation from different animals
■;Vy
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Treatment activity
%
cholera toxin (100)
cholera toxin + vasopressin 47 ± 8
cholera toxin + PMA 62 ± 7
cholera toxin + insulin 55 ± 4
cholrea toxin+staurosporine 92±5
cholera toxin+cheleiythrine 93±6
cholera toxin, then membrane alkaline phosphatase tieated 97±6
cholera toxin (60min) then cell PMA treatment (15min) 63+10
m
li:$
Table 3.2 Cholera toxin-stimulated adenylyL cyclase activity in
P9 cells,
The effect of cholera toxin (1 jig/ml; 60min) on P9 cell adenylyl cyclase function 
vyas assessed either by measuring adenylyl cyclase activity in an isolated 
membrane fraction (membrane) or by incubating P9 cells in the presence of the 
cyclic AMP phosphodiesterase inhibitor IBMX (ImM) and measuring the 
intracellular concentration of cyclic AMP (intracellular) as described in the 
methods section (2.3.9). Resting cells had an intracellular cyclic AMP 
concentration of 1.5-2.6 pmol of cyclic AMP/IO*^ cells, which was typically 
raised to 28-37pmol/10^ cells after Ih treatment of the intact cells with cholera 
toxin (l|ig/m l) (range; n=3). Membrane adenylyl cyclase activity in resting 
cells was 2.1+0.4 pmol of cyclic AMP/min per mg of membrane protein. This 
rose to 9.8+0.6 pmol/min per mg of membrane protein after cholera-toxin 
treatment. Where indicated, other ligands were added together with cholera 
toxin in the P9 cell incubation, with insulin and vasopressin at final 
concentrations of lOnM and PMA at lOOnM. Experiments were done five times 
with different cell preparations, and results are given as mean+S.D. Shown are 
changes in cholera-toxin-stimulated adenylyl cyclase activity relative to that 
found in cells not simultaneously challenged with ligands (100%).
1 4 0
.  .
Treatment
cholera toxin
cholera toxin + vasopressin 
cholera toxin + PMA 
cholera toxin + insulin
Adenylyl cyclase activity Intracellular cAMP
in membranes levels .
( 100) (100)
57±6 48+5
59+8 68±4
63+6 61+8
^ __________________
Table 3.3 Cholera toxin-stimulated adenylyl cyclase activity in
CHO and NIH-3T3 cells.
Cells were incubated for 2h with cholera toxin (l|ig/ml) in the presence of the 
phosphodiesterase inhibitor IBMX (ImM). They were then harvested and the 
intracellular cyclic AMP concentration determined as described in methods 
section (2,3.9). The concentration of cyclic AMP was given in pmol cyclic 
AMP/10^ cells for cells tieated either with toxin alone or with PMA added to the 
incubations at lOOnM. An indication of the effect of PMA on the cholera toxin 
stimulated accumulation of cyclic AMP is given by expressing the levels of 
cyclic AMP accruing with PMA and cholera toxin added together as a 
percentage of those found when cholera toxin was added alone. The various 
CHO cell lines are denoted as k, wild-type CHO cells; T, transfected so as to 
overexpress the human insulin receptor and otherwise with Greek letters 
indicating the particular isofoim of PKC that these cells have been transfected to 
overexpress. All CHO cells overexpressing PKC isoforms also overexpressed 
the human insulin receptor (Chin et aL, 1993), NIH-3T3 cells were wild-type 
cells. Experiments were done 3 times with different cell preparations and errors 
given as means ±S.D.
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Table 3.4 Summary of adenylyl cyclase expression in different
cell lines
1 4 2
Adenylyl cyclase isotype Hepatocyte P9 NIH3T3 CHO
I - - - -
II - - - -
IV + " " +
V + + - -
VI + + +
N.B. + stands for signal expressed in cells, - stands for signal not expressed in 
cells.
Discussion
These experiments showed that treatment of intact hepatocytes with 
cholera toxin led to the constitutive activation of adenylyl cyclase activity after a 
well-defined lag period (Figure 3.2). This lag time was also observed in 
other cell lines (Figure 3.11; Figure 3.12.). The molecular basis of this 
lag period remains to be defined, although it can be altered by changing 
temperature, cholera-toxin concentration and membrane fluidity (Van, 1977; 
Vaughan and Moss, 1978; Houslay and Elliott, 1979). The lag time may, in 
part, be connected with a requirement for cholera toxin to undergo endocytosis 
(Houslay and Elliott, 1981) before it can act on Gs at the cytosolic surface of the 
plasma membrane. The magnitude of this stimulatory effect of cholera toxin 
was shown to be profoundly attenuated if either glucagon or insulin was added 
to hepatocytes along with cholera toxin (Figure 3.3). Such inhibitory effects 
were observed when adenylyl cyclase activity was assessed either in 
membranes isolated from such cells or, in situ, by assessing cAMP 
accumulation in the presence of the phosphodiesterase inhibitor IBMX. These 
hormones did not affect the lag time for the action of cholera toxin nor did they 
alter the degree of ADP-ribosylation of Gs (Irvine and Houslay, 1988), 
suggesting that either the functioning of the catalytic unit of adenylyl cyclase 
was attenuated or its ability to be stimulated by G$ was diminished.
Glucagon is known to generate a number of intracellular signals in 
hepatocytes (Houslay, 1991 and 1994). These include the well-established 
elevation of intracellular Ca-+ levels (Blackmore and Exton, 1986; Manger and 
Claret, 1985; Mine et ciL, 1988) and also stimulation of both phosphatidyl­
choline (Pittner and Fain, 1991) and inositol phosphate metabolism (Wakelam 
et a l, 1986; Whipps et a l,  1987; Wiliamson et al, 1986), which elicit the 
production of diacylglycerol (Pittner and Fain, 1991; Blackmore and Ex ton, 
1986; Bocckino et al, 1985) and thus the activation of protein kinase C (Tang
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'and Houslay, 1992). Glucagon clearly can not be exerting its inhibitory effect 
on the ability of cholera toxin to activate adenylyl cyclase tlirough any elevation 
of intracellular cyclic AMP levels as cholera toxin itself achieves just that 
(Houslay and Elliott, 1979 and 1981; Heyworth et al, 1984). This suggested 
that such an action of glucagon might be mediated through protein kinase C 
activation. Thus, in order to ascertain whether protein kinase C activation might 
exert an inhibitory effect on cholera toxin-stimulated adenylyl cyclase activity, 
We incubated hepatocytes with either the phorbol ester PMA or with 
vasopressin; agents which have been shown to activate protein kinase C in 
hepatocytes (Nixon et al, 1992; Nishizuka, 1989; Parker et ah, 1992; Greba ef 
ah, 1983). In both instances we observed inhibition of the cholera toxin 
response (Table 3.1) although this attenuation was not additive (F igu re
3.7). However, inhibition of cholera toxin stimulated-adenylyl cyclase activity 
by the above ligands may occur independently, although the quantitative 
contributions were not additive. It has been shown that PMA exerts its effects 
through a well-established, direct action upon the regulatory site of protein 
kinase C (Nixon et a l,  1992; Nishizuka, 1989; Parker et al,  1992) where it 
mimics the endogenous activator, DAG. In contrast, vasopressin stimulates 
inositol phospholipid metabolism in hepatocytes (Creba et al, 1983) to produce 
DAG (Pittner and Fain, 1991; Blackmore and Exton, 1986; Bocckino et al., 
1985) which leads to the activation of protein kinase C (Pittner and Fain, 1991; 
Tang and Houslay, 1992). The different pathways by which these compounds 
act suggested tlieir ability to inhibited cholera toxin-stimulated adenylyl cyclase 
was through a common final action which is mediated by protein kinase C. The 
non-additive effect of these ligands is consistent with this. Confirmation was 
gived by the inclusion of the compounds staurosporine and chelerythrine, 
which can serve as protein kinase inhibitors with some selectivity in their action 
as regards the inhibition of protein kinase C (Nixon et al, 1992; Herbert et al, 
1990; Gordge and Ryves, 1994), which ablated the inhibitory action of
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vasopressin (Figure 3.4). Interestingly, however, they also served to ablate 
the inhibitory action of insulin (Figure 3.4), implying that insulin also exerted 
effects on adenylyl cyclase activity through the action of protein kinase C. In 
this regard, it has been suggested that insulin might activate protein kinase C 
activity in various cells (Farese e ta l ,  1992). However, it is also possible that 
members of the protein kinase cascade known to form one branch of the 
pleiotropic network which comprises the insulin receptor signalling system 
(White and Kahn, 1994), may transduce the inhibitoiy effect of insulin noted 
here and that such a species could be inhibited by these compounds.
It has previously been suggested that, under resting conditions in 
hepatocytes, there is an active phosphorylation/dephosphbrylation cycle 
involving protein kinase C action (Bushfield et al, 1991; Houslay, 1991). As 
such the level of phosphorylation of any protein which provides a target for 
protein kinase C can be profoundly amplified by the action of the protein 
phosphatase inhibitor okadaic acid (Tachibana et ai, 1981; Cohen et al, 1990; 
Bialojan and Takai, 1988; Haystead e ta l,  1989). This compound can therefore 
serve as a novel tool for the study of protein phosphorylation in intact cells and 
like phorbol esters, okadaic acid acts as a tumour promoter, presumably by 
increasing the phosphorylation of key regulatory proteins. However, unlike 
phorbol esters, okadaic acid exerts its effect by inhibiting protein phosphatases 
1 and 2A (Bialojan and Takai, 1988) rather than by activation of protein kinase 
C. Thus exposure of hepatocytes to okadaic acid has been shown to mimic the 
effect of protein kinase C action in eliciting the phosphorylation of the inhibitoi*y 
G-protein Gicx^  at the protein kinase C phosphorylation (C )  site, seri^4 
(Monis et al, 1994). Okadaic acid also appears able to mimic protein kinase C- 
mediated glucagon desensitization of adenylyl cyclase activity in hepatocytes 
(Savage et a l,  1995). In contrast, under such basal conditions then no 
phosphorylation of the inhibitory G-protein Gi^%at the protein kinase A 
phosphorylation ('AN') site ser^O? was elicited by okadaic acid (Morris et al,
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1994). Consistent with the contention that protein kinase C effects an inhibitoiy 
action on cholera toxin-stimulated adenylyl cyclase activity in hepatocytes, the 
obseiwation here of a profound attenuation of cholera toxin to stimulate adenylyl 
cyclase activity by okadaic acid in hepatocytes (Figure 3.5) would be 
consistent with PKC mediation of this response.
Such data imply that protein kinase C action can attenuate cholera toxin- 
stimulated adenylyl cyclase activity. This is intriguing as we also have shown 
that treatment of hepatocytes with the phorbol ester PMA, for example, did not 
inhibit the activity of either the catalytic unit of adenylyl cyclase, assessed by 
monitoring both basal activity and that amplified by forskolin (Figure 3.8 
(a)), or Gs-stimulated adenylyl cyclase when monitored using NaF (Figure 
3.8 (b)). However, in such experiments hepatocytes were challenged with 
agents which activated protein kinase C under very different conditions from 
those prevailing in the cells which have been exposed to cholera toxin. For, in 
the presence of cholera toxin then not only do intracellular levels of cyclic AMP 
rise above the threshold for activation of protein kinase A (Houslay, 1991; 
Heyworth et al, 1983) but adenylyl cyclase is subject to chronic stimulation by 
Gs5. It may be that either one or both of these conditions is a pre-requisite for 
protein kinase C to be able to modify a component of the Gg-adenylyl cyclase 
system and thus attenuate cholera toxin-stimulated adenylyl cyclase activity. 
The possibility that chronic elevation of intracellular cyclic AMP levels may 
allow for this novel action of protein kinase C might be inferred from an earlier 
study by Murphy and Houslay, (1988). In that case, it has been shown that 
when hepatocytes were exposed to glucagon in the presence of the 
phosphodiesterase inhibitor IBMX then a stable, profound inhibition of 
membrane adenylyl cyclase activity ensued rather than a ti'ansient inhibition as 
seen using glucagon alone (Murphy and Houslay, 1988; Houslay, 1991; 
Houslay, 1994). Indeed, in the presence of both glucagon and IBMX then the 
levels of cyclic AMP achieved were comparable to those observed in
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:hepatocytes treated solely with cholera toxin (Murphy and Houslay, 1988). 
Such data might be taken to imply that elevated intracellular cyclic AMP levels 
in hepatocytes allow protein kinase C to act at a site which can lead to the 
attenuation of Gg-stimulated adenylyl cyclase activity.
That an attenuated cholera toxin-stimulated adenylyl cyclase activity can be 
observed in an isolated hepatocyte membrane preparation might imply that a 
component of this system is stably phosphorylated. Consistent with this, 
treatment of membranes with alkaline phosphatase has been used to achieve the 
dephosphorylation of phosphorylated cellular proteins (Savage e ta l ,  1995; 
Pears et al, 1992). Such a treatment did not affect the adenylyl cyclase activity 
of membranes obtained from hepatocytes which had been treated with cholera 
toxin alone (Table 3.1). However, it did increase the cholera toxin-stimulatbd 
adenylyl cyclase activity seen in membranes from cells which had also been 
treated with either PMA or vasopressin or insulin (Table 3.1; Figure 3;6). 
In each of these instances such a treatment increased adenylyl cyclase activity up 
to a level which indicated that it had been able to reverse the inhibitory effect 
exerted by these various agents. This is consistent with the notion that such an 
inhibitory process occurred as a result of the phosphorylation of a membrane 
protein. In this regard, we had previously concluded that inhibition was not 
due to any impedance in the mechanism of cholera toxin action per se (Irvine 
and Houslay, 1988). For internalisation did not appear to be attenuated, as lag 
times for the onset of activation were not delayed (Irvine and Houslay, 1988) 
and no change in the ability of cholera toxin to elicit the ADP libosylation of a- 
Gs was evident (Irvine and Houslay, 1988). This conclusion is also supported 
by the demonstration here (Table 3.1) that PMA was capable of causing a 
similar degree of inhibition of cholera toxin-stimulated adenylyl cyclase activity 
when it was added to intact hepatocytes at a time (60min) when cholera toxin 
had already achieved near maximal stimulation of this system rather than at the 
stait of the incubation with the toxin.
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An immortalised hepatocyte cell line generated using SV40 DNA 
(Livingstone et al, 1994) was also investigated for a similar mediated action of 
PKC. This P9 cell line was shown (see section 1.3.6.2) to express G-protein 
regulated adenylyl cyclase activity and a functional, high affinity insulin 
response. Here we demonstrated that the adenylyl cyclase activity in such cells 
could be markedly stimulated by cholera toxin (Figure 3.9) and that this 
activity could be inhibited by either PMA or insulin treatment (Figure 3.10) 
in a similar fashion to that seen with native hepatocytes. This was true of 
adenylyl cyclase activity assessed either in membranes isolated from cells or, in 
situ, by assessing cAMP accumulation in the presence of the phosphodiesterase 
inhibitor IBMX (Table 3.2). This provided further evidence that P9 cells 
should provide a useful cell line for analysing various receptor regulated 
functions which are representative of native hepatocytes. Intriguingly, the 
observation that vasopressin could elicit an inhibition of cholera toxin- 
stimulated adenylyl cyclase activity which was comparable with that seen in 
native hepatocytes (Table 3.1), is to our knowledge the first evidence of an 
immortalized hepatocyte cell line to have functional vasopressin receptors.
As with experiments done on hepatocytes and P9 cells, cholera toxin 
achieved a marked stimulation of adenylyl cyclase activity in both CHO and 
NIH-3T3 cells (Figure 3.11; Figure 3.12). However, this activity was 
not attenuated by treatment with the phorbol ester PMA when adenylyl cyclase 
activity was assessed either in membranes isolated from such cells or, in situ, 
by assessing cAMP accumulation in the presence of the phosphodiesterase 
inhibitor IBMX (Table 3.3; Figure 3.13; Figure 3.14), implying a 
fundamental difference in susceptibility of these systems. One possible 
explanation for this might be that levels of protein kinase C were limiting in 
such cells or that a specific isoform of protein kinase C may be required. 
However, this would appear to be unlikely, as PMA failed to inhibit cholera- 
toxin-stimulated adenylyl cyclase activity in CHO cells which had been
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transfected so as to overexpress various protein kinase C isoforms (Table 
3.3) (Chin et aL, 1993), representative of both the Ca^+-dependent and 
independent families (Nishizuka, 1992; Asaoka etal., 1992; Parker etal., 1989; 
Ohno et a l,  1990). The insensitivity to phorbol ester action in these cells may 
thus be due to the expression of different target proteins for the action of protein 
kinase C.
As indicated above, either ' Gsnor the catalytic unit of adenylyl cyclase 
could form two possible targets for the action of protein kinase C. In this 
regard, ' Gg^has been shown to be a single gene product whose sequence is 
highly conserved between species (Birnbaumer et al, 1990; Gilman, 1987; 
Gierschik et al, 1990; Kaziro, 1990). In contrast, adenylyl cyclase forms part 
of a large multi-gene family where differential expression in various cells is well 
established (Krupinski et al, 1992; Krupinski e ta l,  1989; Cooper efc;/., 1994) 
(Table 3.4), and differential susceptibility to phorbol esters has been noted, 
with enhancement of the activity of certain, but not all, isoforms of adenylyl 
cyclase occurring (Yoshimura and Cooper, 1993; Chen and Iyengar, 1993; 
Jacobowitz et a l,  1993; Kawbe et a l,  1994). On this basis, the prejudice 
would be that the the differences in susceptibility to PMA action in these cells 
were due to the expression of different forms of adenylyl cyclase. RT-PCR 
(Figure 3.18 (a)-(e)) and thermostability studies of adenylyl cyclase 
(Figure 3.16; Figure 3.17) com firmed that there are different levels of 
adenylyl cyclase activities expressed in these cells. A particular species of 
adenylyl cyclase, namely type V or VI, may provide a major fraction of the 
activity in hepatocytes and P9 cells whilst supplying the target to be modified by 
protein kinase C. With this in mind it has been shown that the type-V isoform 
of adenylyl cyclase in vitro can be stimulated by phosphorylation mediated by 
PKC (Kawabe et a l ,  1994), and that PKC isoforms a  and ô specifically 
mediated this effect (Jacobowitz et a l ,  1993). The type V adenylyl cyclase 
isoforms was not expressed in NIH-3T3 and CHO cells (Figure 18 (d; e)
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and Table 3.4) and indeed we were unable to detect a protein kinase C- 
mediated phosphorylation of adenylyl cyclase in these cells.
Certainly there is a precedent for the notion that adenylyl cyclase may be 
phosphorylated by PKC, albeit in studies indicating that phorbol ester treatment 
can enhance the activity of certain, but not all, isoforms of adenylyl cyclase 
(Yoshimura and Cooper, 1993; Chen and Iyengar, 1993; Jacobowitz et a t, 
1993; Kawbe e ta l ,  1994). Whilst in certain of these isoforms the effect is due 
to the removal of Gi-mediated inhibition, in other instances it is thought to be 
due to the modification of the catalytic unit (Chen and Iyengar, 1993; 
Jacobowitz et al, 1993). In this regard we noted that treatment of NIH-3T3 
cells with PMA led to a recognisable increase in the cholera toxin-stimulated 
adenylyl cyclase activity (Table 3.3; Figure 3.14). Additionally, in CHO 
cells we observed a PMA-mediated increase in the cholera toxin-stimulated 
adenylyl cyclase activity of cells transfected so as to overexpress PKC-y 
(Table 3.3). This may indicate a specificity for the action of particular protein 
kinase C isoforms in being able to modify a particular adenylyl cyclase isoform 
in CHO cells. It does not appear to relate to differences in the relative 
magnitudes of protein kinase C activity in these transfected cell lines. For, 
compared to total protein kinase C levels seen in wild type CHO cells. Chin ef 
a l,  1993 have shown that the PKC pi transfectants exhibited the highest levels 
of PKC expression, with levels 18-fold higher, followed by PKC-e 
transfectants, with levels 10-fold higher, and then the PK C-a and PKC»y 
transfectants, with levels 5-fold higher. More dramatic elevations of activity 
would therefore be expected in CHO PKC-p cells. This is clearly not the case 
(Table 3.3). We also noted an increase in the cholera toxin stimulated 
adenylyl cyclase activity of cells transfected so as to overexpress CHO-e 
(Table 3.3). However, whilst such an increase could be due to the 
modification of adenylyl cyclase activity caused by the basal activity of the
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enlarged protein kinase C pool, there are other possibilities which include 
altered expression of either adenylyl cyclase or Gs.
These experiments showed that in both hepatocytes and the immortalised 
hepatocyte P9 cell line attenuation of cholera toxin-stimulated adenylyl cyclase 
activity can be achieved by either the activation of protein kinase C (achieved 
either directly by PMA, or by the homiones glucagon, insulin and vasopressin) 
or the inhibition of protein phosphatase activity. Such an inhibitory effect can 
be reversed by alkaline phosphatase treatment of membranes, consistent with a 
phosphorylation event. That insulin and vasopressin can exert such an 
inhibitory action on cholera-toxin-stimulated adenylyl cyclase in the P9 
immortalized hepatocyte cell, indicates that these cells can provide a useful 
model of a hoiTnonally responsive system. The study thus identified a novel 
point of cross-talk between the cyclic AMP and the phospholipid and tyrosine 
kinase signalling pathways involving protein kinase C, which highlights and 
extends the range of actions of this protein kinase in being able to modulate 
signal transduction processes.
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Chapter 4
Induction of specific cyclic AMP phosphodiesterase FDE4 
splice variants by forskolin and cholera toxin-treatment of 
the P9 immortalised hepatocyte cell line
(Basic PDE4 transcripts profile (PCR) is in chapter 5)
____ ____ ________________________________
Introduction
Control of intracellular cAMP concentration is critical to the regulation 
of many cellular responses to extracellular stimuli. This is achieved through 
regulation of both its synthesis, by adenylyl cyclase, and its degradation by 
cyclic nucleotide phosphodiesterases (PDEs). PDE activity in cells is 
contributed by a lai'ge and diverse group of enzymes that catalyze the hydrolytic 
cleavage of cAMP's 3' phosphoester bond to form 5 'AMP which cannot 
activate protein kinase A (PKA). Although most of the known cyclic nucleotide 
PDEs share a highly conserved 270-amino acid catalytic domain, they vary 
widely with respect to their kinetic characteristics, substrate specificity, cellular 
distribution and sensitivity to various endogenous and synthetic activators and 
inhibitors (Beavo, 1988). At least seven classes of PDE isozymes exist, some 
of which contain multiple subtypes (Conti et al,  1991; Beavo et al, 1994). All 
of these isozymes, as well as many of the subtypes, are encoded by distinct 
genes (Beavo et al, 1994). Recently much interest has been expressed in the 
cyclic AMP specific PDE4 family where compounds able to exert selective 
inhibition of such enzymes can exert anti-depressant and anti-inflammatory 
actions (DiSanto and Heaslip, 1993 and 1994). CuiTently such PDE4 selective 
inhibitors are being considered for the treatment of asthma (Chan et a l,  1993; 
Torphy e ta l ,  1992; Peachell e ta l ,  1992; Torphy, 1988). Molecular cloning 
studies (Bolger, 1994; Conti et al, 1991a) have, however, led to the realisation 
that there are four gene families (A, B, C and D) which can be mapped to three 
chromosomes in both man and mouse with PDE4A and PDE4C being located 
on human chromosome 19, PDE4B on chromosome 1 and PDE4D on 
chromosome 5 (Horton et a l,  1995; Milatovich et a l,  1994; Bolger et a l,  
1994; Conti et al, 1991a). However, further complexity is apparent as, in each 
instance, alternative splicing leads to the possible formation of a range of 
different protein products from each of these genes (Bolger et al, 1994; Conti
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et al, 1991a). The alternative splicing appears to take the form of 5'domain 
swops which leads to the production of enzymes with distinct N-terminal 
regions. The putative role of such regions is believed to relate to regulation of 
enzyme activity, stability (Shakur et al, 1993) and intracellular targeting 
(Scotland and Houslay, 1995).
A common feature of the hormone-dependent cAMP regulation is that 
after an initial increase, the cyclic nucleotide concentration returns toward basal 
levels in spite of the continuous presence of hormone. This phenomenon 
involves the expression of active intracellular mechanisms terminating the 
hormonal stimulation, since extracellular dissociation of the hormone from the 
receptor might not be the primary cause of cessation of a stimulus (Dohlman gf 
a l ,  1991, Collins et a l ,  1992). It is also thought to be the result of 
mechanisms that protect the cell from excessive stimulation (desensitization). 
Uncoupling of the hormone receptor complex from the G sa component of 
adenylyl cyclase, receptor sequestration and down-regulation are some of the 
mechanisms causing the termination of the hormonal stimulation and/or 
desensitization (Benovic et a l,  1985; Hausdorff et al, 1989; Clark et a l,  
1989). Indeed, multiple phosphorylations of the receptor by cAMP- 
independent and cAMP-dependent protein kinase are a primary signal of the 
uncoupling of the receptor from the transduction system. (Dohlman et al, 1991; 
Benovic er ûf/., 1986; Benovic er «/., 1987).
A decrease in cAMP synthesis is not the only mechanism which can 
cause an enhanced rate of return of cAMP to basal levels in the target cell even 
in the continous presence of hormone. The activation of cAMP 
phosphodiesterases, by PKA-mediated phosphorylation can also play an 
important role in terminating the hormonal stimulus and in inducing 
desensitization in the target cell (Corbin et al, 1985; Gettys et a l, 1987). 
Indeed, several reports have provided evidence that the activity of specific PDE 
isofomis may be regulated by hormones or other stimuli (Conti et al, 1981;
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Conti et a i ,  1982; Ball et a i ,  1980; Narindrasorasak et a l ,  1982). 
Additionally, long term up-regulation of PDE activity, that requires hours to 
develop, can also play a role. This may involve the activation of cAMP- 
dependent protein kinase and requires both protein and mRNA synthesis (Conti 
et al., 1991).
Streptozotocin-induced diabetic rats show elevated levels of glucagon 
and heightened glucagon-stimulated adenylyl cyclase activity in hepatocytes 
(Gawler et a l,  1987; Bushfield et a l ,  1990b). As such, it is likely that 
hepatocyte cAMP levels in these cells will have been chronically elevated upon 
onset of diabetes. There have been reports that streptozotocin-induced diabetes 
caused changes in high-affinity PDE activities. In view of this and because little 
is known about the regulation of alternative splicing in the PDE4 enzyme 
family, we wished to determine the effect of chronic elevation of cAMP levels 
on hepatocyte PDE4 expression. Furthermore, as PDE inhibitors are finding 
use therapeutically and are likely to increase cAMP levels chronically in many 
cells, then we felt it could be of interest to determine any changes occurring in 
an important metabolic cell type, such as the hepatocyte. Given the problems in 
maintaining hepatocytes in prolonged culture, we decided to study the P9, 
SV40-DNA immortalised hepatocyte cell line which has been shown to exhibit 
many of the characteiistics of native hepatocytes (Livingston et al, 1994). As a 
prelude, however, we compared the PDE4 complement in these cells to native 
hepatocytes.
1 5 4
Results
P9 cells transformed by S V40 viral DNA retain a variety of differentiated 
enzyme activities characteristic of hepatocytes (Livingstone et a l,  1994). 
Compounds selective for effects on specific PDE isoforms (Beavo, 1990; 
Houslay and Kilgour, 1990; Manganiello et al, 1990; Reeves and England, 
1990; Nicholson et al, 1991) were used to identify and gauge the magnitude of 
the activity of various PDE isoforms in this cell line, which were then compared 
to those expressed in hepatocytes. It is strikingly apparent from such studies 
that P9 cells have a much lower total PDE activity than hepatocytes. However, 
use of isoform selective PDE inhibitors shows both cell types to express PDE2, 
PDE3 and PDE4 activities (Table 4.1). No evidence for PDEl was apparent 
(17.7±3.2pmoles/mg/min, n=3) when Ca^+/CaM (50pM; lOunits) was added 
to assays done in the presence of EGTA. i.e. PDEl activity is defined as being 
activated by Ca^+ in the presence of the Ca^+-binding protein calmodulin. The 
absence of detectable PDEl activity in these cells may arise due to sufficient 
endogenous Ca^+ being carried over into the assay mixtures from the cell 
homogenates to stimulate any PDEl enzyme in full. To obviate this, assays 
were performed in the presence of EGTA (ImM, 2mM or 5mM) with PDE 
activity being detennined in both the presence and absence of (2mM, 5raM or 
8mM respectively) Ca^+ (plus 10 units CaM). That no activation was elicited 
by Ca^+ZCaM under any of these conditions indicated the absence of any PDEl 
activity from this cell type.
PDE3 species (cGMP-inhiblted PDE) can be selectively inhibited by low 
concentrations of cilostimide, exhibiting IC50 values of 0.1-IpM  when assayed 
at IpM  cAMP (Manganiello et al, 1990; Charbonnear, 1990) in contrast with 
other PDEs which are either insensitive to cilostimide or show IC50 values that 
are typically some 500-fold higher (Manganiello et al, 1990; Nicholson et al, 
1991). With assays performed at IpM cAMP and lOpM cilostmide, which can
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be expected to inhibit all of the PDE3 activity, we have shown (Table 4.1) 
that PDE3 activity in P9 cells is a small component compared to that in 
hepatocytes. Indeed, comparison of isoform activities showed that levels of 
PDE3 were dramatically reduced (62%) (Table 4.1) in P9 cells.
PDE4 species are cAMP-specific and can be inhibited selectively by 
rolipram (Conti and Swinnen, 1990; Bolger, 1994; Reeves and England, 1990; 
Shakur et ai, 1993; Wilson er P/., 1994; Sullivan era/., 1994). They typically 
exhibit IC50 values of 0.1-IpM rolipram when assayed at IpM cAMP, whereas 
other PDE species are either insensitive to rolipram or show IC50 values some 
50-100 times higher (Conti and Swinnen, 1990; Reeves and England, 1990; 
Lobban et al., 1994; Nicholson et al., 1991). Thus assays carried out in the 
presence of lOpM rolipram, with IpM cAMP as substrate, can be expected to 
yield complete, or near complete, inactivation of PDE4 activity. Using this 
approach, we were able to show that PDE4 isoforms constitute a major fraction 
of the total PDE activity in P9 cells (Table 4.1), with activities remarkable 
similar to those in hepatocytes.
PDE2 activity is characterized by its activation by low concentrations of 
cGMP (Beavo, 1990; Houslay and Kilgour, 1990; Reeves and England, 1990; 
Pyne et al, 1986). Here, however, low (IpM) concentration of cGMP showed 
only a slight activation of PDE activity, with the inclusion of the PDE2 selective 
inhibitor, EHNA (Podzuweit er a/., 1992; Michie et al, 1996) at lOpM again 
causing only a slight attenuation. As with PDE3, comparison of isoform 
activities showed that levels of PDE2 were dramaticaly reduced (91%) in P9 
cells.
PDE7 species specifically hydrolyse cAMP in a manner that is resistant to 
inhibition by the non-selective reversible PDE inhibitor, IBMX (Lavan et al, 
1989; Michaeli et al, 1993; Weiss et al, 1981). There is no satisfactory way 
of quantifying PDE7 activity. Nevertheless, one can reasonably calculate, on 
the basis of Km (cAMP) and Ki (IBMX) values for various PDE species
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(Houslay and Kilgour, 1990; Jin é ta l ,  1992; Nicholson et a l,  1991), that, in 
the absence of any PDE7 activity, P9 cells PDE activity can be predicted to be 
inhibited by about 90%“95% when assayed in the presence of lOOpM IBMX 
and IpM  cAMP. That a value considerably lower that this was observed 
(Table 4.1) might indicate the presence of PDE7 activity.
To characterize further the PDE4 activity in P9 cells, the subcellular 
distribution of this activity type was determined. Cell homogenates were 
fractionated into a low speed pellet (P i), a high speed pellet (P2, includes 
membranes) and a high speed supernatant (cytosol). Table 4.2 demonstrated 
that PDE4 activity was found in both cytosol and membrane (P2 pellet) 
compartments from P9 cells, but with a high specific activity seen in the 
cytosol.
The level of rolipram-inhibited PDE4 activity was, however, 
dramatically increased in P9 cells when these cells were chronically challenged 
with the diterpene forskolin (F igure 4.1). Forskolin serves to activate 
adenylyl cyclase by direct stimulation of the catalytic unit of the enzyme. This 
can be expected to increase cyclic AMP levels, depending upon the prevailing 
PDE activity. PDE activity in such forskolin treated cells began to increase after 
around 6h and was still increasing 24h after challenge with forskolin. At this 
point, PDE4 activity was ~4 fold higher than at the start. Over a similar time, 
the PDE4 activity of the control cells remained constant. Treatment of P9 cells 
with forskolin resulted in a nearly 3-fold increase in total homogenate PDE 
activity as compared with control. Adenylyl cyclase can also be stimulated by 
cholera toxin, which elicits the NAD+-dependent ADP-ribosylation of Gs 
causing it to become constitutively activated (Gilman, 1987; Houslay and 
Elliott, 1979, 1981). Using cholera toxin I was able to demonstrate that 
rolipram-inhibited PDE4 activity rose ~8 fold to reach a specific activity of 
23.7±1.8 pmol/min/mg (Figure 4.2) (n-3).
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Assessing intracellular cAMP levels, we Were able to show that chronic 
challenge with forskolin did increase intracellular cAMP levels (Figure 4,3). 
However, these reached a maximum after about Ih and then fell dramatically. 
We presume that this was due to enhanced PDE activity (Figure 4.1). 
Consistent with this, blockade of PDE activity using the non-specific inhibitor 
IBMX led to levels being chronically elevated (Figure 4.3). The slow 
decrease in cAMP levels with IBMX reflecting enzyme induction and the fact 
that this is a reversible inhibitor. Interestingly, rolipram potentiated forskolin 
stimulated cAMP levels initially almost as well as IBMX, perhaps indicating 
PDE4 species play a major role in cAMP metabolism (Table 4.1) under such 
conditions. However, after this initial rise then a marked fall occurred 
indicating the action of novelly induced of PDE species other than PDE4 in 
these cells. Figure 4.4 shows that an almost identical intracellular cAMP 
profile was obtained employing cholera toxin to enhance adenylyl cyclase 
activity. Namely cyclic nucleotide levels peaked after Ih, with blockade of PDE 
activity (presumably mainly PDE4) potentiating this effect. Again, long term 
exposure to high nucleotide levels led to the apparent induction of another PDE 
species.
Both the action of forskolin and cholera toxin in increasing PDE4 
activity showed a slow time dependence with little or no change in activity being 
evident after Ih of challenge (Figure 4.1 and Figure 4.2). This suggested 
that the effects were due to the de novo synthesis of new enzyme. Consistent 
with this, we noted that both forskolin and cholera toxin were unable to increase 
rolipram-inhibited PDE4 activity after a challenge of 9h in cells which had been 
treated with the transcriptional inhibitor, actinomycin D (Table 4.3). This 
treatment not only completely blocked the ability of both forskolin and cholera 
toxin to increase PDE4 activity, it also depressed the levels of this activity 
below those of the control {Table 4.31. This might imply a relatively rapid 
turnover of members of the PDE4 family.
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The breadth of splice variants arising from each of the four genes which 
encode PDE4 activity is not as yet fully appreciated. However, to date, all 
active protein products differ at the 5' regions of their mRNAs but not at the 3’ 
regions of the mRNAs. Thus, in order to determine which PDE4 families are 
present in P9 cells we have designed generic PCR primers so as to be able to 
detect the presence of presumed active PDE4A, B, C and D family members 
(Figure 4.5). Using such 'generic' primers, and appropriate positive 
controls, we were able to ascertain the presence of transcripts in P9 cells RNA 
for PDE-4A (Figure 4.6 and Figure 5.2 in Chapter 5) and PDE-4D 
(Figure 4.7) but not for PDE-4B or with a very low signal expressed 
(Figure 4.8) and PDE-4C (Figure 4,9). Using the same approach with 
RNA from native hepatocytes we were, additionally, able to detect transcripts 
for PDE4B (Figure 5.3).
The PDE4A gene in both rat and humans produces multiple splice 
variants which are expressed in a tissue specific fashion. In rat, the splice 
variants RD I, rPDE-6 and rPDE-39 have been characterised, although it is 
likely that other species occur in various specialised cells. These species all 
arise from 5' domain swops and thus specific probes can be generated. Using 
these we failed to identify RDI in both P9 cells and hepatocytes (Figure 5.6). 
This is perhaps not surprising as this species seems only to occur in the CNS. 
We also failed to detect rPDE-6 in P9 cells (Figure 5.7). This surprised us 
as, altliough rPDE-6 has been characterised in the CNS, it is considered to have 
a much more general distribution. Indeed, rPDE-6 has been suggested to occur 
in liver on the basis of RNAase protection studies. However, only 50% of liver 
cells are of parenchymal origin (hepatocytes), suggesting that the source of 
'liver' rPDE-6 may be Kuppfer cells/macrophages or blood cells which 
commonly 'contaminate' extracts made from crude liver. Intriguingly, 
however, we obtained a positive response for probes generated against a very 
recently described PDE4A splice variant; rPDE-39 (Bolger et ai, 1995). This
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species appears to have a very restricted redistilbution with the only recognised 
good source to date being testis (Bolger et al., 1996). Here, however, PCR 
detected rPDE39 to also be expressed in P9 cells (Figure 5.8), with the 
conformation of protein expression of this splice variant in P9 cells being 
demonstrated by Western blotting (Figure 4.10).
Two splice variants of the rat PDE4B gene have been recognised to date, 
namely PDE4B1 (DPD) and the so-called PDE4B2 ("pde4"). Again tliese differ 
at the 5'-end. It appears likely that at least PDE4B1 arises as a 5' truncated 
species as the start codon of the initiator methionine in the cloned cDNA does 
not have the characteristics reflecting the beginning of a full length protein. 
Consistent with this, much larger cognate species have been cloned from human 
beings (Beavo et al., 1994). Not with standing this, PDE4B1 and PDE4B2 
undoubtedly reflect two distinct PDE4 splice variants and, as such, diagnostic 
PCR primers can be designed to unique 5' regions. Using these we failed to 
detect the presence of either species in RNA from P9 cells (Figure 5.9 and 
Figure 5.10 respectively), although transcripts were apparent in hepatocytes.
The 4D family is also subject to complex multiple splicing, again at the 5'- 
end. Using specific primer pairs we were able to detect the presence of the 
PDE4D3 variant in both P9 cells (Figure 4.11) and hepatocytes (Figure 
5.12). Indeed, the signal for this variant was consistently greater (3 
experiments) in hepatocytes compared to P9 cells. Transcript for PDE4D1 
could also be detected in hepatocytes, although it was completely absent from 
P9 cells (Figure 4.12). No satisfactory primers were available for PDE4D2 
analysis. PCR analyses done on equivalent amounts of RNA from cells can 
provide useful qualitative information concerning transcript levels. We thus 
examined whether treatment of P9 cells with either forskolin or cholera toxin, 
for 24h, would affect the PCR signals obtained. In such experiments we 
observed that similar signals were obtained using primers designed to amplify 
up a region of the cytoskeletai protein actin. This was re-assurance that similar
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levels of mRNA were present in our experiments, all of which were done using 
at least three different RNA preparations. For RNA preparations from cells 
with chronically elevated cAMP levels, we noted a decreased signal for PDE4A 
generic transcripts (Figure 4,6 ), no change in the results for RD I, rPDE-6 
and rPDE39 transcripts (Table 4.4), nor did we observe any signal using 
generic PDE4C (Table 4.4). However, for both forskolin and cholera toxin 
we observed an enhanced signal using the generic PDE4B primers (Figure
4.8). Subsequent analysis using the two PDE4B specific splice variant 
primers failed to yield a signal with the PDE4B1 primers (Table 4.4 and 
Figure 4.13) but yielded a clear signal for PDE4B2 transcripts (Figure 
4.14) where none had been evident before. Analysis of PDE4D showed an 
apparent increase in the intensity of the signal for the generic primers using 
RNA from both forskolin and cholera toxin treated cells (Figure 4.7). This 
appeared to be attributable to an enhanced transcript level of the '3.3' splice 
variant form of PDE4D (Figure 4.11). Western blots were performed here to 
look for detectable changes in the protein level for PDE4D (Figure 4.15). It 
showed the increased activity of PDE4D is due to PDE4D3 which codes for a 
93kDa enzyme.
Other investigators have studied the effect of increased cAMP levels on 
PDE4 activities in monocyte (Torphy et a l, 1992) and macrophage cell lines 
(Toiphy et a l, 1995) as well as in Sertoli cells (Sette et a l, 1994b). In contrast 
to the studies done here, in both of the blood cell lines PDE4A was up- 
regulated. However, such studies indicated that this was due to a particular 
splice variant, equivalent to rat rPDE-6. This form is not expressed in P9 cells 
which indicates that different promoters may control the expression of splice 
variants of the PDE4A gene. However, in both such studies the induction of a 
PDE4B product was noted which was cognate to the rat PDE4B2 gene product 
(Table 4.4). This adds further support to the notion that the expression of 
one of the splice variants of the PDE4B gene is regulated by cAMP. Analysis
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of PDE4D expression shows some differences (Table 4.4). In the U937 
macrophage cell line (Torphy et a l, 1995) no indication of PDE4D activity 
ensued. However, in both monocytes (Torphy et a l, 1992) and Sertoli cells 
PDE4D (Sette et a l, 1994b) was induced, but as different species, namely 
PDE4D1 and PDE4D3, respectively. Our studies on P9 cells show that, as 
with Sertoli cells, elevation in cAMP levels induced the PDE4D3 form. This 
might indicate cell-specific differences in the cAMP-mediated regulation of 
PDE4D splice variants.
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Figure 4.1 Time course of forskolin activated total PDE and PDE4 
gCtiyity,
P9 cells were grown to nearly 90% confluence with 10% serum medium, then 
changed to 2% serum medium and incubated for different times up to 24h in the 
absence or presence of lOOjiM forskolin. At the end of the incubation, cells 
were rinsed twice, haiwested and homogenized as described in method section 
2.3.7.1. The PDE activity was determined at the time indicated, in the absence 
(regarded as total PDE activity) or presence of lO^M final concentration of 
rolipram (regarded as PDE4 activity) using the cell homogenates. Assays 
employed IpM  cAMP as substrate (2.3.11). Each point represents the 
mean±S.E. of at least three different experiments, each caiiied out in tiiplicate.
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Figure_4.2 Time course of cholera toxin activated total PDE and
PDE4 activity.
P9 cells were grown to nearly 90% confluence in 10% serum medium and then 
changed to 2% serum medium. They were then incubated for the indicated 
times up to 24h in the absence or presence of 1 mg/ml cholera toxin. At the end 
of the incubation, cells were rinsed twice, harvested and homogenized as 
described in method section 2.3.7.1. The PDE activity was determined in the 
absence (regarded as total PDE activity) or presence of lOpM final 
concentration of rolipram (regarded as PDE4 activity) using the cell 
homogenates. Assays employed IpM cAMP as substrate (for detail see method 
section 2.3.11), Each point represents the mean+S.E. of at least three different 
experiments, each carried out in tiiplicate.
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Figure 4.3 Time course of forskolin elevated intracellular cAMP
in P9 cells.
P9 cells were grown to nearly 90% confluence in 10% serum medium in 75cm^ 
flasks then transfered into 6-well plates with 2% serum medium. Cells were 
then incubated for different times up to 24h in the absence or presence of 
lOOpM forskolin and in presence or absence of lOpM rolipram and lOOjiM 
IBMX. cAMP content was determined (see methods section 2.3.9.3) at the 
times indicated. Each point represents the mean+S.E. of at least three different 
experiments, each earned out in triplicate.
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Figure 4.4 Time course of cholera toxin elevated intracellular
cAMP in P9 cells.
P9 cells were grown to nearly 90% confluence in 10% serum medium in 75cm^ 
flasks then transfered into 6-well plates with 2% serum medium. Cells were 
then incubated for different times up to 24h in the absence or presence of 
I mg/mL cholera toxin and in presence or absence of lOpM rolipram and lOOfiM 
IBMX. cAMP content was determined (see method section 2.3.9.3) at the 
times indicated. Each point represents the mean±S.E. of at least three different 
experiments, each earned out in tiiplicate.
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Figure 4.5 (a) Design of primers for RT-PÇR detection of 
PDE4A
Alignment of rat PDE4A cDNAs with the consensus. Thick line is sequence 
found in more than one cDNA in a given species. Thin line is sequence unique 
to a given cDNA in a given species. Numbers above the sequences are the 
amount of unique sequence in nucleotides (without brackets) and amino acids 
(brackets). Molecular weights of conceptual translates of each sequence are 
given along with real molectilar weights where available.
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Figure 4.5 (b) Design of primers for RT-PGR detection of 
PDE4B
Alignment of rat (r) PDE4B cDNAs with the consensus. Thick line is sequence 
found in more than one cDNA in a given species. Thin line is sequence unique 
to a given cDNA in a given species. Numbers above the sequences are the 
amount of unique sequence in nucleotides (without brackets) and amino acids 
(brackets). Molecular weights of conceptual translates of each sequence are 
given along with real molecular weights where available.
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Figure 4.5 (c) Design o f primers for RT-PCR detection of
PDE4C
Alignment of rat PDE4G cDNA with the consensus. Thick line is sequence 
found in more than one cDNA. Thin line is sequence unique to this cDNA. 
Molecular weight of conceptual translate of this sequence is shown to be 
60kDa.
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Figure 4.5 (d) Design of primers for RT-PCR detection of
PDE4D
Alignment of rat (r) PDE4D cDNAs with the consensus. Thick line is sequence 
found in more than one cDNA in a given species. Thin line is sequence unique 
to a given cDNA in a given species. Numbers above the sequences are the 
amount of unique sequence in nucleotides (without brackets) and amino acids 
(brackets). Molecular weights of conceptual translates of each sequence are 
given along with actual molecular weights where available.
N.B. Due to leaky scanning (or removal of the 86nt intron) rPDE4Dl produces 
two translation products, one identical to the rPDE4D2 translation product 
(Monaco et al, 1994)
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Figure 4.6 RT-PCR analyses of hormone effects on P P E 4 A
'generm' transcripts in P9 cells
This was done as described in methods using the degenerate primers designed 
to detect transcripts selectively for PDE4A forms in a species independent 
fashion. (Sense; GCGGGACCTRCTGAAGAAATTCC. Antisense; 
CAGGGTGRTCCACATCGTGG). PGR reaction condition employed here 
were dénaturation; 94®C for Imin, annealing; 57°C for 2min and extension; 
72°C for 3min. 40 cycles of each condition were utilized. This reaction 
condition allowed the detection of a 232bp fragment.
Analyses were performed on Marker (M), Brain control (B), P9 control (C) and 
forskolin (F) treated (24h) sample.
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Figure 4.7 RT-PCR analyses ôf hormone effects on P D E 4 D
generic' transcripts in P9 cells
This was done as described in methods using the degenerate primers designed 
to detect transcripts selectively for PDE4D forms in a species independent 
fashion. (Sense; CCYYTGACTGTTATCATGCACACC. Antisense; 
GATCYACATCATGTATTGCACTGGC). PCR reaction condition employed 
here were dénaturation; 94^0 for Imin, annealing; 55°C for 2min and 
extension; 72°C for 3min. 40 cycles of each condition were utilized. This 
reaction condition allowed the detection of a 262bp fragment.
Analyses were performed on Marker (M), P9 control (C), 100|iM forskolin (F) 
and 1 mg/ml cholera toxin (CTX) treated (24h) samples.
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Figure 4.8 RT-PCR analyses of hormone effects on P D E 4 B
'generic* transcripts in P9 cells
This was done as described in methods using the degenerate primers designed 
to detect transcripts selectively for PDE4B forms in a species independent 
fashion. (Sense; CAGCTCATGACCCAGATAAGTGG. Antisense; 
GTCTGCACARTGTACCATGTTGCG). PCR reaction condition employed 
here were dénaturation; 94^>C for Imin, annealing; 55^C  for 2min and 
extension; 72®C for 3min. 40 cycles of each condition were utilized. This 
reaction condition allowed the detection of a 786bp fragment.
Analyses were performed on Marker (M), P9 control (C), lOOpM forskolin (F) 
and 1 mg/ml cholera toxin (CTX) treated (24h) samples.
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Figure 4.9 RT-PGR analyses of hormone effects on P DE 4 C
'generic* transcripts in P9 cells
This was done as described in methods using the degenerate primers designed 
to detect transcripts selectively for PDE4G forms in a species independent 
fashion. (Sense; ACTGAGTCTGCGCAGGATGG. A ntisense; 
CMTCCTCTTCCTCTGYCTCCTC). PCR reaction condition employed here 
were dénaturation; 94oc for Imin, annealing; 58<^ C for 1 min 20sec and 
extension; 72°C for Imin lOsec. 40 cycles of each condition were utilized. 
Thess reaction conditions were optimised for the detection of a 388bp fragment 
(see Fig 5.5), although no transcript could be detected here.
Analyses were performed on Marker (M), P9 control (C), lOOjiM forskolin (F) 
and 1 mg/ml cholera toxin (CTX) treated (24h) samples.
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Figure 4.10 Immunoblot analysis of rPDE39 In P9 cells
Immunoblot analyses were done with PDE4A antisera as described in methods 
section 2.3.23. In these samples, P9 cell homogenates containing 2OO|0,g of 
protein were analysed by SDS-PAGE, transfered to nitrocellulose and Western 
blotting was performed with antisera specific for the indicated foims of PDE4A. 
In experiments using testis as a positive control (C) for rPDE39 (Bolger et a l, 
1995), the strong band of 97kDa reflects the specific identification of rPDE39. 
This species was also found in P9 cells as the arrow points out.
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MFigure 4,11 RT-PCR analyses of hormone effects on PDE4D3
transcripts in P9 cells
This was done as described in methods using the degenerate primers designed 
to detect transcripts selectively for PDE4D3 forms in a species independent 
fashion. (Sense; CTAATTTGCAAGATCGCGCACCCAGC. Antisense; 
CCTGGTTGCCAGACCGACTCATTTCA). PCR reaction condition 
employed here were dénaturation; 94®C for Imin, annealing; 58®C for Imin 
20sec and extension; 72^C for Imin lOsec. 40 cycles of each condition were 
utilized. This reaction condition allowed the detection of a 255bp fragment. 
Analyses were performed on Marker (M), P9 control (C), lOOfxM forskolin (F) 
and 1 mg/ml cholera toxin (CTX) treated (24h) samples.
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Figure 4.12 RT-PCR analyses of hormone effects on PDE4D1
transcripts in P9 cells
This was done as described in methods using the degenerate primers designed 
to detect transcripts selectively for PDE4D1 forms in a species independent 
fashion. (Sense; TCCGGTGAAGCGCTTAAGAACTGAGTCC. Antisense; 
CCTGGITGCCAGACCTACTCAnTCA). PCR reaction condition employed 
here were dénaturation; 94°C for Imin, annealing; 620C for Imin 2 0 sec and 
extension; 72°C for Imin. 40 cycles of each condition were utilized. These 
reaction conditions were optimised for the detection of a 226bp fragment (see 
Figure 5.11), although no transcripts were detected here.
Analyses were performed on Marker (M), P9 control (C), 100|iM forskolin (F) 
and 1 mg/ml cholera toxin (CTX) treated (24h) samples.
M c  F CTX
1078bp —
1053bp
310bp
Figure 4.13 RT-PCR analyses of hormone effects on PDE4B1
transcripts in P9 cells
This was done as described in methods using the degenerate primers designed 
to detect transcripts selectively for PDE4B1 forms in a species independent 
fashion. (Sense; AAACCTTCACGGAGCACCGAACAAGAGG. Antisense; 
GCCACGTTGAAGATGTTAAGGCCCCATT). PCR reaction condition 
employed here were dénaturation; 94PC for Imin, annealing; 58^C for Imin 
20sec and extension; 720C for Imin lOSEC. 40 cycles of each condition were 
utilized. These reaction conditions were optimised for the detection of a 507bp 
fragment (see Figure 5.9)^ although no transcripts were detected here.
Analyses were performed on Marker (M), P9 control (C), lOOfiM forskolin (F) 
and 1 mg/ml cholera toxin (CTX) treated (24h) samples.
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Figure 4.14 RT-PCR analyses of hormone effects on PDE4B2
transcripts in P9 cells
This was done as described in methods using the degenerate primers designed 
to detect transcripts selectively for PDE4B2 forms in a species independent 
fashion. (Sense; TTGGTAGATCACTGACACCTCATCCCG. Antisense; 
GCCACGTTGAAGATGTTAAGGCCCCATT). PCR reaction condition 
employed here were dénaturation; 94^C for Imin, annealing; 58°C for Imin 
20sec and extension; 12^C for Imin lOSEC. 40 cycles of each condition were 
utilized. These reaction conditions were optimised for the detection of a 667bp 
as shown.
Analyses were performed on Marker (M), P9 control (C), lOOpM forskolin (F) 
and Img/ml cholera toxin (CTX) treated (24h) samples.
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Figure 4.15 Immunoblot analysis of hormone effects on PDE4D3
in P9 cells
In the samples of P9 cell homogenates containing 200pg of protein were 
analysed by SDS-PAGE, trànsfered to nitrocellulose and Western blotting was 
done with antisera specific for the indicated forms of PDE4D (see method 
section 2.3.23). Experiments used P9 control (C), lOOpM forskolin (F) and 
1 mg/ml cholera toxin (CTX) treatment for 24h. The band of 93kDa reflects the 
specific identification of PDE4D3. Result shows typical experiments of ones 
done at least three times using different cell preparations.
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Table 4.1 Assessment of cAMP phosphodiesterase activities in P9
cells and hepatocytes.
PDE assays of hepatocyte and P9 cell homogenates were performed in the 
absence (regarded as total PDE activity) or presence of either lOpM rolipram 
(regarded as PDE4 activity) or lOjaM cilostimide (regarded as PDE3 activity) or 
lOOpM IBMX (IBMX insensitive PDE activity). EHNA (IGpM) was added in 
either the presence or absence of cGMP (lOjiM) to determine PDE2 levels; Data 
is given as with mean±S.E. of at least 3 separate experiments employing 
different cell preparations. In each experiment triplicate PDE assays were 
performed and an average value taken. PDE assays were done in the presence 
of l|iM  cAMP as substrate (see metliod section 2.3.11).
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Table 4.2 Sub-CfJlular distribution of PDE4 in P9 cells
Preparation of P9 cells liomogenate, cytosol and membrane fractions were 
carried out as described by method section 2.3.7.1 PDE4 activity assays were 
perfoiTned in the presence of a final concentration of lOpM rolipram using IfiM 
cAMP as substrate (for details see method section 2.3.11) in the assay. Each 
point represents the mean±S.E. of at least three different experiments, each 
carried out in triplicate.
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Table 4.3 Attenuation by actinomycin D of forskolin and cholera
toxin stimulated induction of PDE4 activity in P9 cells
P9 cells were treated with lOOjiM forskolin or Img/ml cholera toxin in either 
the presence or absence of l|ig/m l actinomycin D (see method section 2.3.7.2) 
for 9hrs. After this, cells were harvested, homogenised and PDE4 activity was 
assayed in the presence of a final concentration of lOjiM rolipram using IpM 
G AMP as substrate (for details see method section 2.3.11). Each point 
represents the mean±S.E. of at least three different experiments, each carried 
out in triplicate.
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Table 4.4 Summary of hormone mediated induction of PDE4 
splice variants.
This table summaries the occurence of PDE4 splicing transcripts after treating 
P9 cells for 24h with lOOpM forskolin and/or 1 mg/ml cholera toxin.
1 8 4
Untreated Forskolin treated Choiera toxin treated
4A generic < n.d.
RDI - = =
rPDE6 - =
rPDE39 = n.d.
4B generic - > >
DPD - = =
pde4 > >
4C generic - = =
4D generic > >
3.1 - = =
3.2 - > n.d.
3.3 + > >
N.B. - stands for no signal expressed, = stands for equal signal expressed, + 
stands for normal signal expressed , > or < stands for stronger signal or weaker 
signal than untieated respectively, n.d. stands for not determined.
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D iscussion
Four different genes coding for the low Km cAMP-specific PDE4 have 
now been identified in the rat (Swinnen et ai, 1989a and 1989b) where their 
expression is cell and tissue-specific (Swinnen et al., 1989b). Hormonal 
regulation of the mRNA level and of the protein expression of some of these 
isoforms has been reported (Swinne et a i,  1989a; Swinnen et al, 1991; 
Takahashi ef a/., 1991).
Considerable attention has been focused on two general mechanisms by 
which the activity of PDE4 is regulated by hormones, particularly those that 
stimulate adenylyl cyclase activity. One regulatory mechanism, designated 
"short term activation", involves a protein kinase A-mediated phosphorylation 
of a specific splice variant PDE4D3 (Sette et al, 1994a). Tliis phosphorylation 
results in an increase in catalytic activity, perhaps by allosteric modification of 
the catalytic domain (Sette é?/ al,  1994b). The short-term activation of a PDE 
and the consequent increase in cAMP degradaton contributes to the termination 
of the hormone stimulation. A second regulatory mechanism, designated "long 
term activation", has been shown to occur with two splice variants of PDE4D1 
and PDE4D2 (Swinnen et al, 1989b and 1991). Activation of protein kinase A 
in intact cells increases the expression of these later fomis by enhancing mRNA 
synthesis or increasing mRNA stability.
Despite the growing body of evidence suggesting that the activity of 
PDE4 can be up-regulated by hormonal stimulation, little is known about the 
biological importance of this regulation. We have begun to address these 
deficiencies by examining the nature and functional consequences of PDE4 up- 
regulation in P9 cells; an SV40 transformed immortalized hepatocyte cell line 
(Livingston e ta l ,  1994).
In these studies, mRNA transcripts encoding PDE4 subtypes were 
identified through RT-PCR methodology using subtype-specific oligonucleotide
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primers (Table 4.4). In untreated P9 cells, the only PCR products detected 
were those corresponding to PDE4A (Figure 4.6) and PDE4D (Figure 
4.7), neither PDE4B (Figure 4.8) nor PDE4C (Figure 4.9) were 
expressed in P9 cells. A distinct pattern of splice variant expression is then 
seen, with rPDE39 (Figure 5.8), an enzyme of highly restricted distribution 
previously only reported in testis (Bolger et al., 1995), also appearing to 
provide the PDE4A enzyme in P9 cells; whereas the PDE4D3 species provides 
the sole PDE4D component in P9 cells (Figure 4.11). Thus, P9 cells appear 
to express a distinctive pattern of PDE4 splice variants.
Intriguingly, elevation of intracellular cyclic AMP levels achieved using 
either forskolin or cholera toxin appeared to have a profound effect in inducing 
PDE4 activity by around 4-8 fold (Figure 4.1 and Figure 4,2). This 
appeared to be due to the increased levels of mRNA and new protein synthesis 
of PDE4 splice variants. Specifically, PCR products for PDE4B transcripts 
was barely detectable in untreated cells, but a PCR product of the appropriate 
length was observed clearly and consistently in stimulated cells (Figure 4.8). 
In addition, the amount of PCR product corresponding to PDE4D appeared to 
increase (Figure 4.7), whereas that corresponding to PDE4A appeared to 
decrease (Figure 4.6), The functional consequences of these apparent 
changes in steady-state transcripts levels as they relate to PDE4A and PDE4B 
protein expression remains to be determined. Furthermore, we have detected 
profound changes in levels of specific PDE4 splice variants, namely PDE4B2 
(Figure 4.14) and PDE4D3 (Figure 4.11), which are generated from the 
PDE4B and PDE4D genes repectively. These findings suggested that 
prolonged treatment with hormones was accompanied by an increase in total 
cAMP hydrolysing capability that appears to include up-reguiation of PDE4. 
This increase in the activity of PDE4 appears to be due to at least two distinct 
forms namely PDE4B and PDE4D which are also differentially regulated, 
thereby adding further flexibility.
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The increased activity of PDE4 by hormone treatment is prevented by 
actinomycin D (Table 4.3), an inhibitor of RNA synthesis. Such data 
indicate that the up-regulation of PDE4 activity depends upon the synthesis of 
mRNA. Western blot analysis confiitned the presence of PDE4D in P9 cells 
and showed protein levels to be increased after treatment with forskolin and 
cholera toxin (Figure 4.15). The results of PCR analysis are consistent with 
those obtained from immunoblot experiments and indicate, in light of earlier 
actinomycin D experiments, that the mechanism of protein induction probably 
involves increases in the rates of PDE4D gene transcription. However it is 
possible that transcription of some other genes (PDE4B) results in stabilization 
of PDE4 message. Our ability to detect decreased PDE4A mRNA in forskolin- 
treated P9 cells leads to speculation that this subtype could be dowuriegulated 
by cAMP. Indeed, recently Edorgan and Houslay (1996 unpublished data) 
have shown that human Jurkat T cells, challenged with forskolin for 9hrs 
demonstrated a decreased PDE4A mRNA level which was also accompanied by 
decreased protein expression.
PDE4D primers can be used to amplify a portion of cDNA refered to as 
rat PDE4D3 which codes for a 93kDa enzyme that is rapidly activated by 
cAMP-dependent protein kinase mediation (Sette et al, 1994a). We have found 
that in P9 cells long time challenge with hormone leads to PDE4D protein levels 
being increased (Figure 4.15). This is due to the activation of PDE4D3, as 
Western blotting showed enhanced levels of a 93kDa protein following such 
hormone treatment. This change in PDE4D3 protein synthesis by hormones 
had also been confirmed by their expression at mRNA levels (Figure 4.11). 
This might contrast with the notion by Nemoz et al, (1996) that the activation 
and expression of the PDE4D1 and PDE4D2 variants are involved in the long­
term adaptation and desensitization of target cells to hormones. However, our 
hypothesis is in agreement with a recent report describing the induction of 
proteins very similar to PDE4D1 and PDE4D2 by cAMP in a human
■:s;
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promonocytic cell line (Verghese et ai,  1995). It may be that there are cell- 
specific controls in the regulation of the PDE4D gene. The newly identified 
human PDE4D1 and PDE4D2 lack the so-called U CRl, a region of high 
homology with the drosophila dunce PDE sequence, which is present at the N- 
terminus in human and rat PDE4D3 and other PDE4 variants (Conti et a l,  
1995b). This region may not be essential for catalysis, instead, it may play a 
role in the regulation of enzyme activity. Indeed, the consensus site for PKA- 
mediated phosphorylation/activation in rat PDE4D3 resides within this region 
(Sette and Conti, 1995). Taken together, these findings suggest the possibility 
that expression of the longer, rapidly activated splice variant is down-regulated 
in favour of the smaller forms under conditions of prolonged hormone 
stimulation. Further investigation seems warranted at both protein and mRNA 
levels in various cell types.
The evidence that the PDE4 subtypes found in P9 cells differ in their 
susceptibility to long-term up-regulation by cAMP offers only a partial 
demonstration of the complexity of their regulation. The present studies are in 
agreement with other work indicating that certain subtypes may function as 
"house keeping" enzymes under basal conditons and play lesser roles in the 
presence of hormone, whereas other subtypes are more strongly induced when 
high levels of cAMP are present. As an example, rat PDE4B mRNA, which is 
readily detectable in unstimulated Sertoli cells (Sette et ai, 1994b), increases no 
more that 5-fold after exposure to follicle-stimulating hormone, forskolin or 
dibutyryl cAMP. Under the same conditions, rat PDE3/4D mRNA increased as 
much as 100-fold, though it is barely detectable in unstimulated Sertoli cells 
(Sette et al, 1994a). Furthermore, Conti e ta l ,  (1995a) reported the partial 
purification and characterization of a cAMP-PDE protein from the rat Sertoli cell 
and the association of the catalytic activity of this form with a 67kDa 
polypeptide derived from the PDE4D gene. These studies suggest that a single 
subtype may be differently regulated in disparate cell types. Although it has
'. ' ï f ï ïS '
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been shown that human PDE4A is up-regulated by cAMP in both monocytes 
and U937 cells (Toiphy et ai,  1995), other investigators have found that rodent 
homologues of this PDE are insensitive to cAMP in FRTL-5 cells and in the 
mouse MA-10 Leydig tumour cell line (Swinnen et a l, 1991a and 199lb). 
These differences, although they are quite possibly species-related, might be 
indicative of different regulatory processes among different cell types. 
Additionally, various N-terminal domains are spliced to the PDE4A unit which 
determine subcellular localisation and activity (Bolger, 1994) and these are also 
differently expressed within different cell types. For example, we have 
observed (Table 4.2) that most of the immunoreactive PDE4A is in the 
membrane fraction in P9 cells. This protein is also detectable only in the 
membrane fraction of human brain homogenates (Torphy unpublished data, 
1996), unlike U937 cells where most of the monocyte PDE4A is found in the 
soluble fraction (Manning et a l,  1996). Our studies using P9 cells (F igure
4.3 and Figure 4.4) have also shown that an increase in total PDE activity is 
associated with significant suppression of both the cells' ability to elevate cAMP 
in response to a hormone stimulus and the ability of the prototypical PDE4 
inhibitor rolipram to elevate cAMP at submicromolar concentratons in the 
presence of hormone. These results are consistent with other findings which 
demonstrated that up-regulation of cAMP-PDE activity plays a major role in 
cellular refractoriness after homnone stimulation (Dwinnen el al, 1989b).
In conclusion, long-term treatment of immortalized hepatocytes with 
agents that activate the c AM P/protein kinase A cascade results in PDE activity 
being up-regulated. The elevation in total cellular PDE4 catalytic activity is an 
increase in steady-state levels of the PDE4B and PDE4D isoforms.
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Chapter 5
Cyclic AMP-Phosphodiesterase expression in normal 
and diabetic hepatocytes
Introduction
Diabetes is a metabolic disease in which in the absence of insulin, 
unbridled catabolism and engergy waste is rampant. Insulin, a powerful 
anabolic hormone, reverses this and restores energy conservation. Diabetes is 
commonly broken down into two types: insulin-dependent diabetes mellitus 
(IDDM) or Type I diabetes and non-insulin-dependent mellitus (NIDDM) or 
Type II diabetes. Type I diabetes occurs in 10% to 15% of diabetic cases in the 
Western world and appears heterogeneous in terms of genetic, autoimmune, 
and environmental factors that bring about the disease (Rimoin and Rotter, 
1981; Rotter and Rimoin, 1981). Most important, Type I diabetes is 
characterized by an eventual absence of endogenous insulin production, as 
measured by circulation C~peptide levels. Insulin resistance (when normal 
insulin levels fail to produce a normal response) is also present, but its 
pathogenesis is not well understood (DeFronzo et a i,  1982). Of individuals 
with diabetes, 90% have Type II diabetes where environmental factors play a 
role in the development of NIDDM because the prevalence rate increases with 
obesity and aging (Fournier et a i ,  1986). NIDDM is characterized by 
diminished insulin secretion relative to serum glucose levels and peripheral 
insulin resistance, individuals with the disease have abnormalities in both 
hepatic glucose production and glucose uptake in the peripheral tissues 
(DeFronzo et a l ,  1982; Kolterman et al., 1881). Three major metabolic 
abnoiTnalities in NIDDM are impairment in pancreatic beta cell insulin secretion 
in response to a glucose stimulus (DdFronzo et al, 1983; Halter et al, 1979); a 
reduced sensitivity to the action of insulin in major organ systems such as 
muscle, liver and adipose tissue (DeFronzo et al, 1979; DeFronzo et al, 1983; 
Olefsky et al, 1982) and excessive hepatic glucose production in the basal state 
(Gerich, 1984; Revers er nV., 1984).
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Besides the insulin secretion abnormalities which can be demonstrated 
in subjects with NIDDM, another disorder associated with NIDDM is hepatic 
overproduction of glucose resulting in progressive hyperglycemia and 
continued reduced insulin sensitivity (DeFronzo et ai, 1982); also lipid and 
lipoprotein abnormalities are present in both Type I and Type II diabetes 
(Stanby, 1968; Swislocki er a/., 1989). Assessment of nucleotide signalling in 
animal models of diabetes and insulin-resistance have identified lesions in the 
control and expression of adenylyl cyclase and specific G-proteins (Griffiths er 
al., 1990; Bushfield et a l,  1990). This may contribute to diabetes-induced 
alterations in the metabolic functions regulated by adenylyl cyclase in certain 
cells (Herberg and Coleman, 1977; Levilliers et al,  1978). Thus analysis of 
streptozotocin-induced diabetes indicated that tissue-specific alterations occuiTed 
in G-protein expression and mRNA levels with hepatocytes (Griffiths et a l,  
1990; Gawler, e ta l ,  1987, Bushfield et al, 1990a;) and adipocytes (Griffiths 
et a l,  1990; Strassheim et a l,  1990) being cell types that are particularly 
affected. In hepatocytes of streptozotocin-induced diabetic rats, levels of tlie G- 
proteins Gg, Gi_2 and Gi-3 were decreased (Bushfield et al, 1990b). Whilst in 
adipocytes, levels of Gi.3 were actually increased (Strassheim et al, 1990). In 
studies done on platelets from type II, non-insulin dependent diabetic male 
subjects markedly lower levels of Gp2 and somewhat reduced levels of Gi-3 
were found compared to normal subjects (Livingstone et a l,  1991). Such 
analyses indicate an abnormality of Gi function in diabetes, which can be 
expected and indeed has been shown, to perturb cAMP metabolism in these 
central metabolically active sites. As we and others have noted that changes in 
cAMP levels can affect PDE expression then it is possible to envisage that an 
altered PDE enzyme complement ensues in diabetes.
Uncontrolled diabetes is believed to be associated with increased levels 
of cAMP in both plasma and tissues (hepatocytes and adipocytes) of the 
affected animals. Intriguingly, adding to this problem has been the observation
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that low Km cAMP PDE activity is apparently decreased in streptozotocin- 
induced diabetic rats (Solomon et al, 1994). This may also be compounded by 
reduced levels of calmodulin in the streptozotocin-induced diabetic rat which 
might attenuate any PDEl activity (Solomon et al., 1994). Such actions, 
however, appear to be fully reversible as when insulin is administered to 
streptozotocin-induced diabetic rats, then cAMP levels fall to normal (Solomon 
et a l ,  1987; Solomon, 1975) (Table 5.1). The underlying mechanisms 
accounting for this are unknown. However, there is evidence that Gi 
expression in hepatocytes may be insulin regulated (Livingston et al, 1991), 
and hence conected by insulin therapy. This may be true for other components 
or may ensue as a consequence of altered G-protein expression.
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Results
Table 5.2 shows that the majority of PDE activity, whether in normal 
or diabetic hepatocytes, is IB MX sensitive. For in the the presence of IGOp-M 
IBMX, a considerable decrease in PDE activity was detected. However, IBMX 
is a reversible inhibitor which, under the conditions used, might be expected to 
inhibit some 95% of the PDE activity of PDEl/2/3/4 isoforms. That inhibition 
was not as great as this suggests the presence of an IBMX-insensitive PDE7 
component. Indeed, in this regard, such a species has been noted in 
hepatocytes (Lavan et al, 1989). Employing selective PDE inhibitors, it can be 
seen that PDE2 and PDE3 are prominent in hepatocytes for both noimal and 
diabetic animals and that levels of these isoforms exceed that of PDE4 (Table 
5.2). Such analyses were made by treating PDE assays of hepatocyte 
homogenates with cilostimide for PDE3, with rolipram for PDE4 and assessing 
the EHNA-inhibited component in the presence of low cGMP eomcentration for 
PDE2. In Table 5.2, we also see the profound decrease in activity of PDE2 
and PDE3 in hepatocytes from diabetic animals compared to those from normal 
animals. In contrast to tliis, there was little significant change in PDE4 activity 
induced upon diabetes (Table 5.2). Also, estimating PDE7 activity, then that 
also appeared unaffected by diabetes.
In this study, I found it hard to detect any Ca^+/CaM-depen dent PDE 
(PDEl) activity in normal hepatocytes. This was done by the addition of 
Ca^+/CaM (50pM; 10unit=10ng/ml) (Table 5.3) to assays. This indicates the 
absence of any PDEl activity in these cells. There is a possibility that sufficient 
endogenous Ca^+ might have been carried over into the assays, from the cell 
homogenates, to stimulate, in full, any PDEl enzyme (Spence et al, 1995). To 
obviate this, I added ImM (or 2mM, 5mM )-EGTA to the assays and then 
determined PDE activity in both the presence and absence of 5mM (or 5mM, 
8 mM) Ca^+ZCaM respectively. However, in such assays no activation was 
elicited by the addition of Ca^+ZCaM (Table 5.3). Using the primers G R18
193
and GR19, which were designed to be specific for PDEl transcripts (Figure 
5,1a), RT-PCR was done using RNA extracted from rat brain, which is 
known to provide a good source of PDEl (Repaske et al,  1992; Bentley et al, 
1992, Sonnenburg et al,  1993), as control. This allowed for the amplification, 
from brain DNA, of a species of -600bp (Figure 5.1b). This indicates that 
such primers are able to allow the amplification of a species of the appropriate 
size. When these primers were used in RT-PCR with RNA extracted from 
normal and diabetic hepatocytes then no such species was amplified (Figure 
5.1b), which confirmed the absence of PDEl activity as suggested by the 
assay (Table 5.3).
PDE4 has recently drawn particular attention as selective inhibitors play 
an important role in pharmacological areas such as the study of asthma, where 
the control of expression of members of the PDE4 gene families involved and 
their multiple splicing, is ill-understood. Because of this, PDE4 enzymes were 
studied in more detail. The PDE4 enzyme distribution between cytosol and 
membrane was assessed for hepatocytes from both normal and diabetic states. 
Cell homogenates were fractionated into a low speed pellet (P i), a high speed 
pellet (P2 ; includes membranes) and a high speed supernatant (cytosol). Table
5.4 demonstrated that, for normal hepatocytes, PDE4 activity predominated 
(72%) in cytosol compared with membrane. This changed dramatically for 
hepatocytes from diabetic animals where the ratio of cytosol and membrane 
distribution was almost equal (43% cytosol). To characterize further the PDE4 
subtypes, cell exti'acts from normal hepatocytes were incubated with antisera for 
PDE4A, PDE4B or PDE4D (see section 2.3.25) which had been pre-adsorbed 
to pansorbin. These specific antisera were generated to rat PDE4A and PDE4B 
species using dodecapeptides representing the extreme C-terminal of these 
enzymes (Shakur et al, 1995, Lobban et al, 1994). The activity of both the 
adsorbed and the supernatant fractions was then determined in the presence or 
absence of lOjiM rolipram  to determ ine PDE4 activity. This
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immunoprécipitation utilised the specificity of the antibody-PDE4 interaction to 
determine which PDE4 subtypes were contributing to the rolipram-sensitive 
activity known to exist here. Results reported in Table 5.5 indicate that PDE4 
activity was quantitatively immunoprecipitated by the antibody specific for 
PDE4A, 4B and 4D. Neither pansorbin alone nor the antibody preadsorbed to 
the synthetic peptide nor the preimmune serum precipitated significant PDE 
activity (data not shown). The particular fraction which has been 
immunoprecipitated by the specific antisera reflected that PDE4A are mostly 
membrane associated, PDE4B are equally distributed between membrane and 
cytosol, whereas, PDE4D are mostly cytosol associated (Table 5.5).
Thus, in order to determine which PDE4 splice variant mRNAs are 
expressed in normal and diabetic hepatocytes, we used generic PCR primer 
pairs specific for PDE4A, B, C and D family members. Using such generic 
primers together with appropriate positive controls, we were able to detect the 
expression of PDE4A (Figure 5.2) in both normal and disease states. Also 
the presence of PDE4B (Figure 5.3) in both normal and diabetic hepatocytes, 
although a weak signal for PDE4B was seen in the latter state. It was a similar 
situation for PDE4D (Figure 5,4) with lower transcript levels being detected 
in the diabetic state. There was no detectable expression of PDE4C in either 
normal or diabetic hepatocytes (Figure 5.5), although tlie primers did amplify 
specific products from testis which provided the positive control.
Whilst, PDE4A mRNA was observed in both diabetic and normal 
hepatocytes, primers designed (Figure 4.5a) for the RD I and rPDE6 splice 
variants of PDE4A, failed to identify transcripts in both cell types (Figure 5.6 
and Figure 5.7 respectively). However, a weak signal for rPDE39 
expression was detected in nonnal hepatocytes but not expressed in the diabetic 
state (Figure 5.8).
Splice valiants PDE4B1(DPD) and PDE4B2 ("pde 4") of the rat PDE4B 
gene which differ at the 5'-end were studied here and results indicated that
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PDE4B1 was expressed in both normal and diabetic hepatocytes (F igure  
5,9), whereas PDE4B2 was only detected in the normal but not in the diabetic 
state (F igure 5.10).
A similar situation exists with PDE4D where complex multiple splice 
variants are known. Using specific primer pairs we were able to detect the 
presence of the PDE4D variants PDE4D1 (F igure  5.11) in diabetic 
hepatocytes and PDE4D3 (F igure 5.12) in both states but with a strong 
signal expressed in normal hepatocytes.
From the results detailed above, it is apparent that induction of diabetes 
causes complex changes in the expression of hepatocyte PDBs and that the 
PDE4 family is no exception to this. We were able to assess changes in the 
PDE4 forms by not only assaying specific activity of the various subfamilies, 
but by detection of the level of changes in the level of their mRNA transcripts 
(Table 5.6 for summary).
..
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Figure 5.1a Design of degererate primers for RT-PCR detection
of PDEl transcripts
Analysis of the complete and partial sequences of PDEl enzymes in GenBank 
(Bilofsky and Burks, 1988) from mouse, rat, human and bovine sources 
revealed substantial homology across a 1252 bp stretch of sequence (labelled 
439-1691 in mouse) which is known to include coding sequence for the 
catalytic unit of this enzyme (Jin etal., 1992). The majority of this sequence is 
also highly homologous to other PDE types (thin horizontal line). Within this 
region three stretches of sequence (hatched boxes) were found to be unique to 
PDEl forms. Degenerate primers were designed to anneal within two of these 
stretches such that they would be predicted to allow for the amplification of a 
601 bp fragment from all known PDEl forms.
Adapted from Spence et al., 1995
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Figure 5.1b RT PCR analyses of PDEl transcripts in normal and
diabetic hepatocytes and P9 cells
This analysis was done as described in methods using degenerate primers 
designed to detect transcrijpts selectively for PD El forms in a species 
independent fashion. Nucleotide sequences of sense and antisense primers ar 
shown in Figure 5.1(a). RT-PCR reaction conditions were as follows: 
Dénaturation: Imin at 94®C, Annealing; Imin 20sec at 50°C and Extension, 
Imin lOsec at72*^C.
The predicted position, from a marker ladder, of the 607bp fragment is shown 
with an aiTow.
Analyses were performed on Marker (M), Brain control (B), P9 cells (P9), 
nonnal (H) and diabetic hepatocytes (D).
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Figure 5.2 RT-PCR analyses of PDE4A ’generic* transcripts in
normal and diabetic hepatocytes.
This analysis was done as described in methods using degenerate primers 
designed to detect transcripts selectively for PDE4A forms in a species 
independent fashion. (Sense; GCGGGACCTRCTGAAGAAATTCC. 
Antisense; CAGGGTGRTCCACATCGTGG). PCR reaction conditions 
employed here were dénaturation; 94®C for Imin, annealing; ST^ ^C for 2min and 
extension; ll'^C  for 3min. 40 cycles of each condition were utilized. The 
predicted position, from a marker ladder, of the 232bp fragment is shown with 
an arrow.
Analyses were performed on Marker (M), Brain control (B), P9 cells (P9), 
normal (H) and diabetic hepatocytes (D).
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506bp
298bp 
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Figure 5.3 RT-PCR analyses o f PDE4B 'generic* transcripts in
normal and diabetic hepatocytes.
This was done as described in methods using degenerate primers designed to 
detect transcripts selectively for PDE4B forms in a species independent fashion. 
(S en se ; C A G C T C A T G A C C C A G A T A A G T G G . A n tise n se ; 
GTCTGCACARTGTACCATGTTGCG). PCR reaction conditions employed 
here were dénaturation; 94®C for Imin, annealing; 55®C for 2min and 
extension; 72‘^ C for 3min. 40 cycles of each condition were utilized. This 
reaction condition allowed the detection of a 786bp fragment.
Analyses were performed on Marker (M), normal (H) and diabetic hepatocytes 
(D).
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Figure 5.4 RT-PCR analyses of PDE4P ^generic' transcrjpls in
normal and diabetic hépatocytes
This was done as described in methods using degenerate primers designed to 
detect transcripts selectively for PDE4D forms in a species independent fashion. 
(S en se ; C C Y Y T G A C T G T T A T C A T G C A C A C C . A n tisen se ; 
GATCYACATCATGTATTGCAGTGGC). PCR reaction conditions employed 
here were dénaturation; 94®C for Imin, annealing; 55®C for 2min and 
extension; 12^C for 3min. 40 cycles of each condition were utilized. This 
reaction condition allowed the detection of a 262bp fragment.
Analyses were performed on Marker (M), normal (H) and diabetic hepatocytes 
(D).
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Figure 5.5 RT-PCR analyses of PDE4C ^generic* transcripts in
normal and diabetic hepatocytes
This was done as described in methods using degenerate primers designed to 
detect transcripts selectively for PDE4C forms in a species independent fashion. 
(S e n s e ;  A C T G  A G T C T G C G C  A G G  A T G G . A n t is e n s e ;
CMTCCTCTTCCTCTGYCTCCTC). PCR reaction conditions employed here 
were dénaturation; 94^C for Imin, annealing; 58°C for 1 min 20sec and 
extension; 72°C for Imin lOsec. 40 cycles of each condition were utilized. 
Thess reaction conditions were optimised for the detection of a 388bp fragment 
as shown with an arrow.
Analyses were performed on Marker (M), testis control (T), normal (H) and 
diabetic hepatocytes (D).
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Figure 5.6 RT-PCR analyses of RDI transcripts in normal
hepatocytes
This was done as described in methods using degenerate primers designed to 
detect transcripts selectively for RDI forms in a species independent fashion. 
(S ense; TT C T T C T G C G A G A C C T G C T C C A A G C . A n tisen se ; 
CAGGCCCCATTTGCTCAAGTTCTCC). PCR reaction conditions employed 
here were dénaturation; 94^C for Imin, annealing; 57°C for 2 min and 
extension; 72®C for 3min. 40 cycles of each condition were utilized. Thess 
reaction conditions were optimised for the detection of a 372bp fragment as 
shown with an arrow.
Analyses were performed on Marker (M), brain control (B), normal hepatocytes 
(H) and P9 cells (P9).
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Figure 5.7 RT-PCR analyses of rPDE6 transcripts in normal and
diabetic hepatocytes
This was done as described in methods using degenerate primers designed to 
detect transcripts selectively for rPDE6 forms in a species independent fashion. 
(S ense; A A G G A G C C T G T C T C T C T C T C T T C C G . A n tisen se ; 
GGTACCGGTGCCGTGG A AGG A). PGR reaction conditions employed here 
were dénaturation; 94°C for Imin, annealing; 62®C for 1 min 20sec and 
extension; 720C for Imin. 40 cycles of each condition were utilized. Tliess 
reaction conditions were optimised for the detection of a 825bp fragment as 
shown with an arrow.
Analyses were peifoimed on Marker (M), brain control (B), normal hepatocytes 
(HI and H2), diabetic hepatocytes (D) and P9 cells (P9).
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Figure 5.8 RT-PCR analyses of rPDE39 transcripts in normal and
diabetic hepatocytes
This was done as described in methods using degenerate primers designed to 
detect transcripts selectively for rPDE39 forms in a species independent 
fashion. (Sense; GCCCAGAGAGGCTTGGTGATTTATCC. Antisense; 
ATATTCGAGGCAGTGTCAGCCTCTTGC), PCR reaction conditions 
employed here were dénaturation; 94®C for Imin, annealing; 62^C for 1 min 
20sec and extension; 72°C for Imin. 40 cycles of each condition were utilized. 
Thess reaction conditions were optimised for the detection of a 215bp fragment 
as shown with an arrow.
Analyses were peifoimed on Marker (M), testis control (T), nonnal hepatocytes 
(H), diabetic hepatocytes (D) and P9 cells (P9).
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Figure 5.9 RT-PCR analyses of PDE4B1 transcripts in normal and
diabetic hepatocytes.
This was done as described in methods using the degenerate primers designed 
to detect transcripts selectively for PDE4B1 forms in a species independent 
fashion. (Sense; AAACCTTCACGGAGCACCGAACAAGAGG. Antisense; 
GCC ACGTTG A AG ATGTTA AGGCCCC ATT). PCR reaction condition 
employed here were dénaturation; 94*^C for Imin, annealing; 58°C for Imin 
20sec and extension; 72®C for Imin lOsec. 40 cycles of each condition were 
utilized. These reaction conditions were optimised for the detection of a 507bp 
fragment.
Analyses were performed on Marker (M), P9 cells (P9), normal hepatocytes 
(H) and diabetic hepatocytes (D1 and D2).
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Figure 5.10 RT-PCR analyses o f PDE4B2 transcripts in normal
and dmbetic hepatocytes
This was done as described in methods using degenerate primers designed to 
detect transcripts selectively for PDE4B2 forms in a species independent 
fashion. (Sense; TTGGTAGATCACTGACACCTCATCCGG. Antisense; 
GCCACGTTGAAGATGTTAAGGCCCCATT). PCR reactions condition 
employed here were dénaturation; 94®C for Imin, annealing; 58°C for Imin 
20sec and extension; 72®C for Imin lOsec. 40 cycles of each condition were 
utilized. These reaction conditions were optimised for the detection of a 667bp 
as shown.
Analyses were performed on Marker (M), P9 cells (P9), normal hepatocytes 
(H) and diabetic hepatocytes (D).
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M H D P9
1078bp
872bp
603bp -----
3%0bp =
198bp
PDE4B2 667bp
Figure 5.11 RT-PCR analyses of PDE4D1 transcripts in normal
and diabetic hepatocytes
This was done as described in methods using degenerate primers designed to 
detect transcripts selectively for PDE4D1 forms in a species independent 
fashion. (Sense; TCCGGTGAAGCGCTTAAGAACTGAGTCC. Antisense; 
CCTGGTTGCCAGACCTACTCAnTCA). PCR reaction condition employed 
here were dénaturation; 94°C for Imin, annealing; 62^C for Imin 20sec and 
extension; 12^C for Imin. 40 cycles of each condition were utilized. These 
reaction conditions were optimised for the detection of a 227bp fragment. 
Analyses were performed on Marker (M), testis control (T), P9 cells (P9), 
nonnal (H) and diabetic hepatocytes (D).
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Figure 5.12 RT-PCR analyses of PPE4D3 transcripts in normal
and diabetic hepatocytes
This was done as described in methods using degenerate primers designed to 
detect transcripts selectively for PDE4D3 forms in a species independent 
fashion. (Sense; CTAATTTGCAAGATCGCGCACCCAGC. Antisense; 
CCTGGTTGCCAGACCGACTCATTTCA). PCR reaction condition 
employed here were dénaturation; 94®C for Imin, annealing; 58°C for Imin 
20sec and extension; 72°C for Imin lOsec. 40 cycles of each condition were 
utilized. This reaction condition allowed the detection of a 255bp fragment. 
Analyses were performed on Marker (M), P9 cells (P9), normal (H) and 
diabetic hepatocytes (D1 and D2).
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Table 5.2 Assessment of cAMP phosphodiesterase activity in
hepatocytes from normal and diabetic animals.
Homogenate PDE activity of hepatocytes from noimal and diabetic animals was 
determined in the absence (regarded as total PDE activity) or presence of either 
10|lM rolipram (regarded as PDE4 activity) or lOpM cilostimide (regarded as 
PDE3 activity), or lOOpM IBMX (regarded as IBMX insensitive component). 
In both normal and diabetic hepatocytes the presence of EHNA (lOjiM), led to a 
decreased activity of cGMP (lOpM) to stimulate activity which was taken as an 
index of PDE2 activity. Data is given with means±S.E. of at least 4 separate 
experiments employing different cell preparations. In each experiment triplicate 
PDE assays were performed and an average value taken. Assays were done in 
the presence of IpM cAMP as substrate (see method section 2.3.11).
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PDE
activity
Nonnal hepatocytes 
(pmols/min/mg)
Diabetic hepatocytes 
(pmols/min/mg)
diabetic xlOO (%) 
normal
Total 23.6+1.8 13.8±2.0 58.5
PDE2 13.9+2.1 7.9+1.2 56.8
PDE3 9.6+2.0 5.4+0.3 56.2
PDE4 4.0+0.4 3.1+0.3 77.5
IBMX
insensitive
3.7+0.8 3.2+0.3 86.5
....
Table 5.3 Assessment of PDEl activity in hepatocytes and P9
cells .
PDEl activity was assessed by determining the effect of adding Ca^+ (50|iM) 
and CaM (lOunits) to the assays. This did not cause any change in PDE activity 
(none; <5%). Also, in order to detect whether endogenous Ca^+ might be 
carried over in this assay, EGTA (at the indicated concentrations) was added in 
the assay. Additional Ca^+ was then added to ensure an excess of free Ca^+ 
was present in the PDE assay. In all cases, CaM was present at lOunits/tube. 
PDE activity assays were done in the presence of l|LtM cAMP as substrate (see 
method section 2.3.11). Data is given as mean±S.E. of at least three separate 
experiments employing different cell preparations. In each experiment triplicate 
PDE assays were performed and an average value taken.
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Table 5.4 Sub-cellular distribution of PDE4 activity in normal
and diabetic hepatocytes.
Preparation of cytosol and membranes from cell homogenates was earned out 
as described by method section 2.3.1. PDE4 activity was detennined as that 
component of homogenate PDE activity which was inhibited by the presence of 
final concentrations of 10p,M rolipram using IjaM cAMP as substrate (for 
details see method section 2.3.11) in the assay. Each point represents the 
mean+S.E. of at least four different experiments, each earned out in triplicate.
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Table 5.5 Immunoprécipitation of PDE4 activity in hépatocytes.
Cytosol and membrane fractions were prepared from cell homogenates as 
described by methods section 2.3.1. Immunoprécipitation with PDE4A, 4B 
and 4D antisera was also carried out as detailed in methods section 2.3.23. 
PDE activity assays were done in the presence of IpiM cAMP as substrate (see 
method section 2.3.11). Data is given as mean±S.E. of at least three separate 
experiments employing different cell preparations. In each experiment triplicate 
PDE assays were performed and an average value taken. Results are shown as 
pmoles/min/mg
2 1 4
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Fractions PDE4A PDE4B PDE4D
Cytosol 0.5±0.2 1.1+0.2 0.7+0.2
Membrane 2.45+0.5 0.8+0.1 0.3+0.1
 : ■ _    ,
Table 5.6. Summary of PDE4 splice variant expression in normal 
and diabetic hepatocytes.
Transcripts analyses were performed in the tissues indicated using primers and 
RT-PCR conditions as detailed previously. See Figures 5.2-5.12 inclusive.
2 1 5
_______________________
Ch
Ch
es
OflCUÜ
w
 : : . ■ •
Discussion
Type 2 diabetes is associated with insulin resistance in peripheral tissues 
with the result that these subjects have supraphysiological levels of glucose 
despite normal or elevated insulin levels. There is extensive evidence that E 
series prostaglandins (PGEl) which, when coupled to its specific receptor 
active intracellular cAMP, elicit a reduced responsiveness in platelets from type 
2 diabetics (Livingstone et al,  1991), implying an effect of diabetes on adenylyl 
cyclase signalling. Indeed, in adipose tissue where the prostanoid receptor 
couples to Gi, a reduction in PGEl responsiveness would tend to enhance 
intracellular cAMP accumulation in response to stimulatory agonists and 
therefore promote lipolysis. A decreased antilipolytic response to PGEl in 
adipocytes from diabetic rats has been proposed to result from a decrease in Gi 
function (Green and Johnson, 1991). Whilst it is becoming increasing clear 
that diabetic states alter the generation of the cAMP signal relatively less is 
known about the effects of this disease state on the termination of this cyclic 
nucleotide message.
Phosphodiesterases (PDEs) act as a terminator of the cAMP signal and 
therefore play an important role in pharmacology. It is thus interesting to 
establish any connection between elevated cAMP levels in the diabetic state and 
their effect on PDE expression and activity. Reports by other groups (eg 
Solomon, 1994) have shown the decreased activity of low-Km cyclic AMP in 
the streptozotocin-induced diabetic rat. Here, our data support this notion and 
demonstrate decreased cAMP-utilizing PDE activity in streptozotocin-induced | |
diabetic rat hepatocytes (Table 5.2) is associated specifically with a reduction 
in PDE2 and 3 and changes in PDE4 activities.
We focused here on an analysis of the PDE4 subtypes, attemping to 
determine the subcellular distribution of these enzymes in normal and diabetic 
hepatocytes and isoform expression. It was shown that total homogenate 
expressed a slightly lower level of PDE4 activity in diabetic hepatocytes
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compared with normal hepatocytes (Table 5,4). However, profound 
differences were noted upon analysis of subcellular distribution. Thus, levels 
of cytosolic PDE4 activity fell profoundly from 72% to 43% in diabetic 
hepatocytes, whilst those for membrane PDE4 were unchanged (Table 5^ 4). 
As splice variants of PDE4 families can show membrane targetting (Shakur et 
a l ,  1995), it is possible that changes in isoform expression underlie these 
differences. To examine this, we used antibodies and PCR. Thus, mRNA 
transcripts encoding PDE4 subtypes were identified through RT-PCR 
methodology using subtype-specific oligonucleotide primers (Table 4.4). 
These results showed that there was a clear preferential decrease in the steady- 
state levels of specific PDE4 splice variant mRNAs, namely PDE4B2 (Figure 
5.10) and rPDE39 (Figure 5.8), arising from the PDE4B and PDE4A genes 
respectively, in diabetic hepatocytes. Meanwhile, even though a reduced signal 
for generic PDE4D (Fig 5.4) was detected in the diabetic hepatocyte, this was 
found not to be due to the reduced expression of PDE4D1 (Figure 5.11) but 
was due, possibly, to changes in the PDE4D3 (Figure 5.12) splice variant. 
However, it could be that changes were due to additional splice variants of 
PDE4D which we were not able to detect. For example, PDE4D4 might be 
expressed in these cells but their sequence for the rat are not known so that no 
specific primer can be designed according to its unique sequence. Thus, RT- 
PCR could not be employed to detect their expression at the mRNA level. 
Also, the primer we designed specifically for PDE4D2 failed to detect transcript 
in these samples, although some reports indicated the existance of PDE4D2 in 
sertoli cells (Swinnen e ta l ,  1989; Sette et ai, 1994b). Due to lack of any other 
"positive" controls, we were therefore unable to detect its expression in the 
other samples.
Antisera raised against the C-terminal region of PDE4B failed to detect 
any change in the nonnal and diabetic hepatocytes. This contrasts with the RT- 
PCR results where lower 4B and 4D levels occurred in the disease state. This
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discrepancy might be due to the proteolysis of these samples so tltat the reduced 
protein synthesis was not able to be detected in diabetic hepatocytes. It is also 
not certain if the reduction in the steady state levels of these transcripts seen in 
the diabetic tissues was caused by impaired transcription or enhanced 
degradation of the target mRNAs. Is the system protecting itself to handle the 
stress of the diabetes, a catabolic state, by shutting down its anabolic 
mechanisms? Examples of such situations are common in nature and are part of 
the explanation of the specialized role of ubiquitin and other heat shock proteins 
in response to severe stress (Lindquist and Craig, 1988).
Soloman with co-workers (1994) have shown levels of CaM and its 
mRNA to be reduced in diabetes and stimulated by insulin. This ability of 
insulin to inhibit the degradation of mRNA suggests a major post-ti’anscriptional 
effect which has been demonstrated in a number of insulin-regulated systems. 
For example, Tewari etal., (1991) proposed that post-transcriptional regulation 
accounts for major differences in insulin receptor mRNA in different tissues.
The pathophysiologic processes involved in diabetic ketoacidosis are 
accompanied by increased levels of cAMP in plasma and tissue (Solomon et al,  
1987). This results from excess counter-regulatory hormones and the 
unavailability of insulin with resultant inability to increase the activity of low- 
Kj*n cAMP PDE. PDE hydrolysis of cAMP is not only stimulated by insulin, 
through specific isofoirns (Pyne et al,  1986, 1988, 1989) but is also modified 
by other regulatory components which are insulin sensitive, eg, CaM (Cheung, 
1971; Solomon et al ,  1987, Solomon et al ,  1986, Smoake et al ,  1981). 
Soloman and co-workers have previously demonstrated that PDE activity is 
reduced in diabetes and restored to nonnal levels with insulin. Insulin-sensitive 
low-Km cAMP PDE appears to be a key regulatory enzyme in insulin's actions 
in tissue, presumably through its ability to regulate levels of the second 
messenger cAMP.
2 1 8 a
These studies illustrate regulation of cAMP-specific PDE enzymes in the 
insulin-independent diabetic state. The biological role of particular PDE 
variants remains to be elucidated. However, the complex changes in cAMP 
signalling incuired in diabetes at the level of synthesis and degradation is likely 
to have profound effects on cellular functioning.
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Chapter 6 
General Discussion
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General discussion
The cAMP signalling system provides adenylyl cyclase and PDE 
isofortns which can couple to signals emanating from evei"y known signalling 
pathway. Thus the cAMP signalling system may actually provide the 'core' 
machinery for integrating signalling with the cell. Far from there being a 
single source of production, degradation and recognition there are now over 8 
isoforms of adenylyl cyclase (Cooper et a l ,  1994; Jacobowitz et al ,  1993, 
Krupinski et al,  1992), over 25 isoforms of cAMP phosphodiesterase (Beavo 
et al ,  1994; Conti et al ,  1991) and multiple forms of PKA-I (Corbin et a l ,  
1977) and PKA-II families (Nigg e ta l ,  1985; Salavatori e ta l ,  1990). This 
vast stock of components allows the cAMP signalling system to be tailored in 
a highly cell-specific fashion.
The complex family of PDEs lends itself to a role in the interactions 
between signalling pathways, due to its ability to be regulated by a number of 
different effectors (Beavo, 1990; Bolger, 1994; Conti e ta l ,  1995b; Houslay 
and Kilgour, 1990; Manganiello et a l ,  1990a) ). This, coupled with the 
enormous capacity for differential regulation of adenylyl cyclase (Chen and 
Iyengar, 1993; Krupinski e ta l ,  1992), demonstrates the immense opportunity 
for dynamic control of a vast network of intracellular signals.
The action of PKC has been shown to regulate a number of elements of 
the cyclic AMP signalling pathway (Houslay, 1991b), leading to an inhibition 
(Beckner and Farrar, 1986; Kelleher et al,  1984) or an enhancement (Cronin 
et al,  1986; Yoshimasa et al ,  1987) of agonist-induced increases in cyclic 
AMP, depending on the cell type. The regulation of cyclic AMP signalling by 
PKC can occur at various different stages of the signalling pathway, such as 
the modification of stimulatory and inhibitory receptors coupled to adenylyl 
cyclase such as the p2-adrenoceptor (Bouvier et a l ,  1987), the a 2 -  
adrenoceptor (Convents et al ,  1989) and the inhibitory Gi protein (Bell and
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Brunton, 1986; Morris et al,  1994; O’Brien et al,  1987) . Adenylyl cyclase 
has been shown to be modulated by PKC phosphorylation in intact cells 
(Jacobowitz and Iyengar, 1994; Kawabe et al ,  1994; Williams et a l ,  1987) , 
as well as in purified cell membranes (Nagshineh ef n/., 1986; Pyne et al ,  
1994). Moreover, differing sensitivities of the cells may occur due to the 
different complement of PKC and adenylyl cyclase/PDE isoforms which are 
expressed within the cell types. In accord with this, Chapter 3 illustrated the 
differences in PMA-mediated inhibition of cholera toxin-stimulated adenylyl 
cyclase in hepatocytes, P9 cells, CHO cells and NIH3T3 cells, These results 
indicated that a particular isoform of adenylyl cyclase (type V) may be 
phosphorylated by PKC, which is expressed in hepatocytes and P9 cells only. 
It has been shown that PKC-Ô and PKC-a selectively activated type-V 
adenylyl cyclase (Kawabe et al ,  1994) and we note here that PKC-a is 
expressed in hepatocytes (Tang et al,  1993).
PDE isoform expression is tissue specific and can be differentially 
regulated by hormones. That individual PDE isoenzymes are regulated In 
both positive and negative manners has highlighted their pivotal role in 
mediating cross-talk between second messenger pathways. It has also 
provided a conceptual basis for understanding many of the distinctive, cell 
type-specific differences in the amplitude and duration of cAMP and cGMP 
signals produced in response to stimulation of adenylyl and guanylyl cyclase. 
In our studies the up-regulation of PDE4 by chronic stimulation of adenylyl 
cyclase, led to an additional mRNA message of PDE4B2, accumulation of 
PDE4D3 transcripts and increased protein expression. These studies provide a 
novel tissue specific model for analysing the functional regulation of PDE4 
genes by cAMP. It has been concluded that increases in PDE-4 activity may 
arise via two mechanisms: one being activation by phosphorylation (rapid) 
and the other probably reflecting constitutive activation (delayed) (Conti et 
al,  1995a; Sette et al ,  1994b). It seems likely that both of these mechanisms
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are imortant contributors to the tachyphylaxis many tissues exhibit with 
continued stimulation of adenylyl cyclase. The situation described here 
differs from that described by Sette et al, (1994b) where PKA has been shown 
to mediate the expression of certain splice variants of PDE4D (PDE4D1 and 
PDE4D2), whilst increasing activity of PDE4D3 by phosphorylation in 
response to thyroid-stimulating hormone. This investigation demonstrated 
that splice variants from the same locus could be differentially regulated on 
stimulation of the cell by a particular hormone. An elevation of cyclic AMP 
has also been shown to cause an increase in ratPDE3 (PDE4D) expression in 
immature Sertoli cells on stimulation with FSH (Monaco et al ,  1994; Sette et 
al,  1994b; Swinnen et al,  1991b) , in cardiac myoblasts (Kovala et al,  1994) 
and in Jurkat cells (Engels et al ,  1994). It would be of interest to see whether 
different PDE4 activities are regulated by different signalling networks.
Although an additional transcript of PDE4B2 has been detected upon 
elevation of cAMP, we have been unable to detect a significant increase in 
enzyme activity under such conditions, which might suggest that this PDE4B 
protein is highly unstable (Alvarez et al ,  1995; Conti et al,  1995a) or that 
transcript levels are not sufficiently high enough to allow for significant 
expression.
The concept of differentially expressed and regulated PDE isozymes 
also implies that individual PDEs are likely to be good targets for therapeutic 
intervention in diseases caused or regulated by cyclic nucleotide-modulated 
transduction mechanisms. Pharmaceutical interest in the area has been further 
sparked by the promise that different PDE isozymes having distinct sequences 
at regulatory and catalytic sites should allow the development of selective 
therapeutic agents that can target a specific cyclic nucleotide pool in a very 
limited number of cell types. As such, an appreciation of the molecular details 
of the enzymes involved and aberrations occurring in disease states may be of 
profound significance. On this basis, the altered PDE4 expression shown in
222
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this study may contribute to our understanding of changes occuring in 
diabetes.
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Appendix
A role for protein kinase C-mediated phosphorylation in 
eliciting glucagon desensitization in rat hepatocytes.
.   . _________
Introduction
Exposure of receptors in intact cells or tissues to agonists often leads to 
a rapid loss of receptor responsivensess. This agonist-induced process is called 
desensitization (Lohse et a l ,  1990). The desensitization processes can be 
subdivided along several lines, most importantly according to the causative 
stimulus ('heterologous' or 'homologous' or receptor-specific); according to the 
time-frame ('rapid' within minutes or 'slow' within hours or days) and, finally, 
depending on the type of mechanism (loss of receptor signalling 'function'- 
called 'uncoupling' or loss of receptor 'number'-called 'down-regulation') 
(Lohse, 1993). These subdivisions are complementary.
Desensitization is a process that occurs in response to a wide variety of 
stimuli and can be found in a multitude of organisms. The widespread 
occurrence of desensitization phenomena points to its importance in biological 
signalling. Desensitization may have two main purposes: it may serve to 
terminate the cellular response to an individual stimulus, or it may cause a 
general reduction in responsiveness without being responsible for the actual 
termination of a single signalling event. Possibly both effects may be achieved 
via the same mechanisms. In either case, the overall effect of desensitization is 
to reduce stimulatory effects and thereby maintain biological equilibria.
Several examples have been studied in detail in order to elucidate the 
mechanisms and biological roles of desensitization. Among them, G-protein- 
coupled receptors is one of the mechanisms which in order to reveal the 
receptor-specific processes of desensitization. Structurally, these receptors are 
characteiized by seven transmembrane a-helices and functionally by their ability 
to transmit signals to effector molecules via GTP-binding regulatory proteins 
(Bourne et a l,  1990; Hepler and Gilman, 1992). Among the Gg-coupled 
receptors, the best studied class of receptors are the ^-adrenoceptors. Three (3- 
adrenergic receptor subtypes have been identified in mammalian tissues and
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their cDNAs cloned; namely pi (Frielle gr a l,  1987), P2  (Dixon et al, 1986) 
and p 3 recepters (Emorine et a i, 1989). The P2-receptor subtype has been 
studied most extensively. It was the first receptor of this class that was pruified 
in significant quantities (Benovic et a l,  1984) and it was the first G-protein- 
coupled receptor whose primary sequence was elucidated (Dixon et a l,  1986). 
In addition, the above hypotheses about desensitization are based on studies of 
this receptor.
. 1
Desensitization of receptor function (receptor un-coupling)
Desensitization via receptor-specific kinases
Phosphorylation of receptors is a critical step in the rapid desensitization 
mechanisms which affect receptor 'function'. The most rapid and quantitatively 
most important desensitization mechanism is triggered by phosphorylation of 
the receptors by the specific ^-adrenergic receptor kinases (Benovic et a l,  
1989; Benovic et a l,  1991). These kinases phosphorylate only agonist- 
occupied, active receptors. Two mechanisms serve to maintain this very strict 
agonist dependence: (i) the cytosolic kinases need to bind to the G-protein py 
subunits in order to bind to the membrane and position themselves for receptor 
phosphorylation (Haga, and Haga, 1992; Pitcher et a l,  1992); and (ii) only 
agonist-occupied receptors are a substrate for the kinases (Benovic et aL, 
1986).
Mechanisms similar to the effects of pARK on p2 receptors have been 
observed in several other sensory and receptors systems. In fact, the visual 
system has served as a prototype in this respect. In this system, activation of 
rhodopsin, the 'light receptor', leads to its multiple C-terminal phosphorylation 
by rhodopsin kinase, followed by binding of the inhibitor protein arrestin 
(Wilden et al, 1986).
Many other receptor systems appear to be regulated by specific receptor 
kinases which may be identical or homologous to PARK and show receptor-
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specific desensitization was observed in isolated cell systems include (jg- 
coupled receptors such as the D 1-dopamine receptor (Balmfort et a/.,. 1990; 
Barton et a l, 1990), the Vz-vasopressin receptor (Birnbaumer et al, 1992), the 
5-TH4"Serotonin receptor (Ansanay et a l,  1992) and parathyroid hormone 
receptors (Pun et al, 1990). A similar homologous pattern of desensitization 
has been obseiwed for several receptors that activate phospholipase C, such as 
5-HT2-serotonin receptors (Ivins and Molinoff, 1991), angiotensin II receptors 
(Abdellatif gr a/., 1991).
The situation is less clear for Gi-coupled receptors, but some reports 
indicated that also in these receptor types a homologous pattern of rapid 
desensitization exists, albeit in many cases to a much smaller extent than for 
corresponding Gg-coupled receptors (Atkinson and Minneman, 1992).
Direct phosphorylation of receptors by pARK or by pARK-like kinases 
has been shown in reconstituted system for the p -2  and a - 2  adrenergic 
receptors (Richardson and Hosey, 1992; Haga and Haga, 1992; Kwatra et al,  
1989). The phosphorylation sites have been shown to reside in the C-terminus 
of the p2-adrenergic receptor, but in the third intracellular loop of the a 2“ 
adrenergic receptor (Liggett et al,  1992; Dohlman et al, 1987). The presence 
of acidic amino acids located 2 or 3 positions N-terminal to a serine or threonine 
seems to be required for phosphorylation by pARK. However, in addition to 
homologous (PARK-like) effects, both PKA and PKC seem to be involved in 
mediating agonist-induced desensitization (Dawson et al., 1993; Boekhoff & 
Breer, 1992; Boekhoff et al., 1992).
Desensitization via the effector kinases
In addition to phosphorylation by their specific kinase, many G-protein- 
coupled receptors are also phosphorylated by their effector kinase, namely 
protein kinases A and C. This type of phosphorylation provides a direct 
negative feedback, whereby the effector enzyme (PKA) shuts off its own 
stimulation. At the same time, this pathway allows a generalized and not
2 6 4
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recep to r  specific form of desensitization, which is termed heterologous 
desensitization. There are two consensus sites for these effector kinase- 
mediated phosphorylations in the pz-adrenergic receptor sequence (Yuan et a l,
1994). One located in the third intracellular loop, RRSSK263 and the other in 
the carbxyl-terminal domain, RRSSSk348, could be involved in PKA and 
PKC-mediated desensitizations. These two domains are essential for coupling 
to Gs and thereby for stimulation of adenylate cyclase activity. Further evidence 
that at least one of the two consensus sites was important for the PKA 
(Hausorff et oL, 1989) and the PKC-mediated desensitization (Bouvier et al., 
1991(a)).
The effector kinase-mediated desensitization has also been observed in 
other G-protein-coupled receptor systems. For example, from characterization 
studies of the epinephrine, prostaglandin E l (PGEl) and PMA-induced 
desensitization pathways in L cells (Yuan et al, 1994).
In summary, two different patterns of rapid, phosphorylation-mediated 
desensitization of G-protein-coupled receptors can be distinguished: one which 
is mediated by specific receptor kinases and which is rapid, strictly homologous 
and possibly confined mainly to synaptic receptors, and a second which is 
mediated by the effector kinases, PKA or PRC, which is somewhat less rapid, 
generalized (heterologous) and much more sensitive to agonist concentrations. 
The degrees to which the two mechanisms will be operative in an individual cell 
and receptor will depend on a multitude of factors: the number of 
phosphorylation sites for the different kinases in an individual receptor, the 
cellular levels of the different kinases and p-arrestins, and the degree of receptor 
stimulation.
Glucagon induced desensitization of adenylyl cvclase in rat hepatocytes through 
protein kinase C-mediated phosphoi-vlation
Glucagon is a 29-amino acid pancreatic hormone that affects the 
production and distribution of glucose by its target organ, ie liver, glucagon
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functions to maintain usual concentrations of glucose and is a key honnone in 
the pathogenesis of diabetes. Glucagon binds to receptors in liver and activates 
two enzymatic pathways, glycogenesis and glyconeogenesis, which result in 
the production of glucose (Unger etal., 1990). It is assumed that these actions 
of glucagon on the liver result when glucagon binds its hepatic receptor and 
activates adenylate cyclase, thereby increasing the intracellular concentration of 
cAMP. However, glucagon may also cause hydrolysis of inositol 
phospholipids (Wakelam e ta l ,  1986; Unson et.al, 1989) and increase in 
intracellular calcium concentratons (Sistare et al, 1985). Two types of hepatic 
glucagon receptor have been proposed and it has been suggested that they signal 
via two different intracellular messengers-cAMP and calcium. However, 
recently a complementaiy cDNA clone for the glucagon receptor (Jelinek et al, 
1993) was isolated by an expression cloning strategy and the receptor protein 
was expressed in several kidney cell lines. The cloned receptor bound glucagon 
and caused an increase in the intracellular concentration of cAMP. The cloned 
glucagon receptor also transduced a signal that led to an increased concentration 
of intracellular calcium. Thus a single receptor can couple to more than one 
transduction system.
The rat hepatic glucagon receptor is coupled to the activation of 
adenylate cyclase through a process that is mediated by the stimulatory guanine 
nucleotide-binding protein Gs and leads to a profound, but transient, increase in 
the intracellular levels of cyclic AMP (Houslay, 1991; Murphy et a l,  1987), 
This is governed by the rapid desensitization of adenylate cyclase to glucagon 
stimulation, which has been attributed to an uncoupling of the glucagon receptor 
from the stimulatory G-protein Gs (Houslay, 1991). This desensitization 
process is however independent of any increase in cyclic AMP concentration 
and it has been suggested that it may result from the action of protein kinase C 
(Murphy et al, 1987). In this regard, the hormone vasopressin which does not 
increase intracellular cyclic AMP levels in hepatocytes but, rather mediate its
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effects through phospholipid metabolism and protein kinase C activation^ can 
also cause the rapid desensitization of glucagon-stimulated adenylate cyclase 
activity (Houslay, 1991).
Here, we have develop a model system, using hepatocytes immobilized 
on collagen plates, which allowed us to demonstrate that the glucagon- 
stimulated elevation of intracellular cyclic AMP levels can be desensitized 
(Savage e ta l ,  1995). However, we also show that desensitization elicited by 
glucagon and vasopressin can be inhibited differentially by protein kinase G- 
selective inhibitors and suggested that the desensitization of glucagon-stimulated 
adenylated cyclase activity involves a role for protein kinase C-mediated 
phosphorylation in rat hepatocytes.
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Results & Discussion
Challenge of hepatocytes with glucagon leads to a transient rise in 
intracellular cyclic AMP concentrations (Houslay, 1991). It has suggested that 
this is primarily governed by the rapid desensitization of adenylate cyclase with 
the subsequent degradation of cyclic AMP through phosphodiesterase action 
(Houslay and Kilgour, 1990; Houslay, 1990). The criterion for desensitization 
was that in membranes isolated from cells which had been challenged with 
glucagon for various periods of time, a rapid attenuation in the ability of 
subsequent glucagon treatment to stimulate adenylate cyclase activity (by 
approx. 50%-60% (Housaiy, 1991).) was observed. However, results here 
show for the first time that treatment of intact hepatocytes with glucagon can 
desensitize the ability of a subsequent challenge with hormone to elevate 
intracellular cyclic AMP levels (Figure A .l). This has done using 
hepatocytes attached to collagen plates such that they could first be challenged 
with glucagon (lOnM; 6 min) then washed, both to remove the hormone and to 
allow intracellular cyclic AMP levels to re-attain those seen under basal (resting 
conditions) conditions, before re-challenge with glucagon. Thus the intact-cell 
cyclic AMP response to glucagon itself became desensitized (Figure A.l). 
As with studies peifonned to observe the desensitization of glucagon-stimulated 
adenylate cyclase activity in membranes (Murphy e ta l ,  1987), desensitization 
assessed using the intact-cell cyclic AMP response could also be elicited by 
pretreating intact hepatocytes with the hormone vasopressin. This occuned in a 
manner that was just as effective as that elicited by glucagon in achieving the 
desensitization of the intact-cell cyclic AMP response (Figure A.2). 
Vasopressin does not, however, increase intracellular cyclic AMP level in 
hepatocytes (Houslay, 1991; Crebe et al., 1983). That it can elicit the 
desensitization of glucagon-stimulated adenylate cyclase activity (Figure 
A .2), as can angiotensin, tumour-promoting phorbol esters and synthetic
ill
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diacylglycerols (Houslay, 1991) supports the concept that the desensitization of 
glucagon-stimulated adenylate cyclase is a cyclic AMP-independent process 
(Houslay, 1991; Muiphy etal., 1987; Refnes et al., 1989) which can be elicited 
through the activation of protein kinase C in rat hepatocytes (Houslay, 1994).
Both glucagon and vasopressin (Mauger et al, 1985; Mine and Ogata, 
1988; Bygrave and Benedetti, 1993) elicit major increases in intracellular Ca^+ 
levels. It is possible that such changes could be sufficient to trigger 
desensitization by stimulating the activity of either Ca^+Zcalmodulin-dependent 
protein kinase activity or protein kinase C. But neither an increase in 
intracellular Ca^+ nor a flux of this bivalent cation across the plasma membrane 
is pivotal in mediating the desensitization of glucagon-stimulated adenylate 
cyclase that can be elicited by both vasopressin and by glucagon (Savage et al, 
1995).
It has been suggested (Housaly, 1991) that protein kinase C may play a 
pivotal role in mediating the desensitization of glucagon-stimulated adenylate 
cyclase. This was based upon observations which showed that not only did 
desensitization occur apparently independently of any increase in cyclic AMP 
but that it could be triggered by both phorbol esters (Murphy et al, 1987) and 
synthetic diacylglycerols (Newlands and Houslay, 1991). In addition, the 
hormones vasopressin and angiotensin, which are known to stimulate inositol 
pospholipid metabolism and produce diaeylglycerol in hepatocytes (Creba al, 
1983; Bocckino et a l,  1985) elicited a similar uncoupling of the glucagon 
receptor from adenylate cyclase (Murphy et al, 1987). Indeed, glucagon is 
regarded as utilizing such a mechanism, in that it too can elicit the production of 
diaeylglycerol in hepatocytes (Bocckino e ta l ,  1985) with the stimulation of 
phosphatidylcholine metabolism which is believed (Pittner and Fain, 1991) 
have demonstrated that both vasopressin and glucagon can cause a transient 
activation of hepatocyte protein kinase C activity, die kinetics of which parallel 
those seen for desensitization.
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In hepatocytes, under resting conditions, the level of cyclic AMP is well 
below tlie threshold for activation of protein kinase A that remains in its inactive 
tetrameric state (Houslay, 1991). In contrast to this, however, it would seem 
that in hepatocytes, under resting conditions, a residual protein kinase C activity 
can be observed which is able to act on the a-subunit of the inhibitory G- 
protein Gi-2, leading to a small fracton of this protein being phosphorylated 
(Bushfield et a l, 1990a; Bushfield et a l,  1991; Morris et a l,  1994). This G- 
protein appears to be the focus of an active phosphorylation/dephosphorylation 
cycle, in that its phosphorylation can be rapidly elicited by either activation of 
protein kinase C or inhibition of protein phosphatase activity (Bushfield et al, 
1990a; Bushfield et a l,  1991; Morris et al,  1994). This latter action can be 
demonstrated by treatment of intact hepatocytes with the protein phosphatase 
inhibitor okadaic acid (Bushfield e ta l ,  1991). Treatment of hepatocytes, under 
basal conditions, with okadaic acid was able to mimic the degree of 
desensitization achieved by both glucagon and vasopressin (Savage et al,
1995), Heance, desensitization can be achieved not only through the activation 
of protein kinase C (as with phorbol myristate acetate and diacylglycerols), but 
can also result as a consequence of protein phosphatase inhibition. This 
indicates that, in hepatocytes, tlie control of coupling of the glucagon receptor to 
ad eny la te  cyclase  is also  a t the cen tre  o f an ac tiv e  
phosphoiylation/dephosphoi'ylation cycle which is determined by protein kinase 
C and protein phosphatase activity.
In order to explore further the possible role of protein kinase C in 
glucagon desensitization, the process was investigated using chosen selective 
protein kinase C inhibitors. One such compound is chelerythrine, which has 
been shown to exhibit some selectivity for inhibition of protein kinase C at low 
concentrations (Herbert et al,  1990). Indeed, I found that a concentration of 
l|iM  chelerythrine was sufficient to obliterate completely the ability of 
vasopressin to cause desensitization (Table A.l). However, intriguingly,
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such a concentration of chelerythrine had no effect upon the ability of glucagon 
to cause desensitization; with a higher concentration of 5p.M causing half 
maximal blockade (Table A.l), This differential sensitivity to the action of a 
protein kinase C inhibitor was not limited to chelerythrine, however, we also 
analysed the action of two other selective protein kinase C inhibitors, namely 
staurosporine (Herbert eta l., 1990) and calphostin C (Hidaka etal., 1984; 
Kobayashi et a i ,  1989). Using these compounds I also noted that they 
expressed a greater susceptibility to block the vasopressin-compared with the 
glucagon-induced desensitization of adenylate cyclase (Table A .l). One 
possible explanation for these observations is that vasopressin and glucagon 
show very different abilities to stimulate lipid signalling pathways in 
hepatocytes and can thus be expected to produce diaeylglycerol species with 
different spectra of acyl chains. This might well give rise to a different profile 
of activation of the various isoforms of protein kinase C that are found in 
hepatocytes. Consistent with such a hypothesis are the analyses showing 
marked differences (Tang and Houslay, 1992) in the ability of both glucagon 
and vasopressin to increase protein kinase C activity in hepatocyte membrane 
and cytosolic compartments. If the spectrum of protein kinase C isoforms 
activated by these two hormones exhibited slightly different sensitivities to 
inhibition by chelerythrine then this might provide a basis for our observations. 
It is also possible, however, that additional regulatoiy effects may complicate 
the situation when glucagon is used to effect desensitiztion. For example, 
glucagon challenge will also lead to the activation of protein kinase A, which 
might affect the functioning of protein kinase C isoforms and of protein 
phosphatases. It is also possible, however, that in a similar fashion to that seen 
for the p-adrenoceptor (Lohse, 1993), glucagon may elicit additional 
desensitizing contributions by activating a receptor-specific kinase which shows 
a susceptibility to inhibition by these protein kinase C inhibitors, albeit at 
slightly reduced sensitivity.
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On the assumption that a component of the glucagon-stimulated 
adenylate cyclase system becomes phosphorylated during desensitization, the 
process can be reversed by alkaline phosphatase treatrnent in rnembranes frOm 
cells that had been pretreated with either glucagon or vasopressin to achieve 
desensitization (Savage et a l ,  1995). These results suggest that the 
phosphoiylation of a membrane protein is pivotal to the desensitization process.
By analysing various adenylate cyclase ligand-stimulated activities I 
have been able to show that the desensitization lesion takes the form of an 
inability of tlie glucagon receptor to couple functionally to Gg It does not occur 
as a result of the phosphorylation of Gg as this G-protein can be 
immunoprecipitated from desensitized hepatocytes in a non-phosphorylated 
form (Tang and Houslay, 1992; Pyne et a l, 1989). On such a basis it is 
believed that the glucagon receptor itself becomes phosphorylated in the 
desensitization process through the action of protein kinase C. Desensitization 
of glucagon-stimulated adenylate cyclase can be achieved in both a homologous 
fashion by glucagon and also in a heterologous fashion by vasopressin, with 
protein kinase C-selective inhibitors identifying subtle differences in the 
processes utilized by these two honnones.
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Figure A .l Desensitization o f  glücagon-stiniulated cyclic AMP
accumulation in intact hepatocytes
Desensitization of glucagon (lOnM, 6 min)-stimulated cyclic AMP accumulation 
was studied in intact hepatocytes, attached to collagen plates, as described in the 
methods section 2.3.2 and 2.3.3. ImM of IBMX was also present during the 
glucagon challange of intact cells. Intracellular cAMP was 0.3±0.2pmol/10^ 
cells. When preteated with glucagon, cAMP levels were allow to return to the 
resting/basal state over the recovery period; the value of the glucagon-stimulated 
increase in the intracellular concentration of cyclic AMP following preti'eatment 
was 11.7±0.5pmols/10^ cells. In experimental sets the appropriate control 
value was taken as the native stimulation of pmol intracellular cAMP 
accumulation/10^ cells (100%). Results are means+S.E. with similar results 
found in one other experiment.
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Figure A,2 Desensitization of g lucagon-stim ulated  adenylyl
cyclase in hepatocyte membranes
Intact hepatocytes were treated with either glucagon (lOnM) or vasopressin 
(lOnM) or were untreated (control) for 6 rain. After this time cells were 
harvested, washed, disrupted and a washed membrane fraction obtained as 
described by methods section (2.3.1). Data shown is from a typical experiment 
with glucagon-stimulated adenylyl cyclase activity expressed in pmol of cyclic 
AMP produced/min/|ig of membrane protein with means±S.E.for three 
deteiTninations of activity.
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Table A J  Protein kinase C involvement in the desensitization
of glucagon-stim ulated cyclic AMP accumulation in intact 
hepatocytes
In these experiments desensitization of glucagon-stimulated cyclic AMP 
accumulation was studied in intact hepatocytes attached to collagen plates^ as 
described in the methods section (2.3.3). Protein kinase C inhibitors were 
added at the attachment stage so that a 40 min pre-incubation with these ligands 
was achieved. In experimental sets the appropriate control (100%) value was 
taken as the native stimulation of intracellular cAMP accumulation/10^ cells. 
This was approximately lO.bpmols, with comparisons done using various 
ligands in the pre-incubation. The experiments described show data for n=3 
with ±S.E.
-  ■ ■_________________________
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Pre-incubation conditions
Control
Glucagon(lOnM) 
Vasopressin 
Chelerythrine (IjiM) 
Chelerythrine (5|iM) 
Staurosporine (lOnM) 
Calphostin C (lOnM) 
Calphostin C (lOOnM)
Cyclic AMP production by glucagon 
challenge (% of control response seen 
with no ligand pre-incubaton)
100
45+3
51+3
109+7
91+3
98+6
98+4
96±5
Vasopressin (10mM)+chelei-ythrine (IpM) 106±5 
Glucagon (10nM)+cheleiythiine (IpM) 45+5
Glucagon (10nM)+chelerythnne (5|iM) 73±4
Vasopressin (10iiM)+staurosporine (lOnM) 94+2 
Glucagon ( 1 OnM)+staurosporine (lOnM) 58+7 
Vasopressin (lOnM)-fcalphostin C (lOnM) 7 1±5 
Vasopressin (10nM)+calphostin C (lOOnM) 103+5 
Glucagon ( 10mM)+calphostin C (lOnM) 59±5
Glucagon (10nM)+calphostin C (lOOnM) 101+6
